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Abstract 
 
Myostatin, a Transforming Growth Factor-beta (TGF-β) superfamily member, has 
been well characterised as a negative regulator of muscle growth and 
development.  In support, inactivation or mutation of the myostatin gene results in 
a dramatic increase in skeletal muscle mass, however excess myostatin inhibits 
myogenesis.  Recently, myostatin has also been shown to have a role in post-natal 
muscle growth.  Myostatin regulates activation, proliferation and self-renewal of 
the muscle satellite cell pool.  Moreover, loss of myostatin results in enhanced 
skeletal muscle regeneration in response to injury, whereas increased post-natal 
myostatin expression is associated with many skeletal muscle wasting conditions.  
Furthermore, myostatin has been shown to directly induce cachexia following 
subcutaneous injection of Myostatin over-expressing cells into mice.  Despite 
studies implicating myostatin in the regulation of post-natal skeletal muscle 
growth, little is known about the processes through which myostatin activity is 
regulated or the mechanisms through which myostatin functions.  Thus this thesis 
examines regulation of myostatin activity through proteolytic processing, and 
signaling mechanisms through which myostatin acts to regulate the satellite cell 
pool and to promote skeletal muscle proteolysis.   
In this thesis it is demonstrated that processing and secretion of Myostatin is 
relatively reduced in differentiated myotubes as compared to proliferating 
myoblasts.  Furthermore, processing of Myostatin is developmentally regulated, 
with decreased Myostatin processing occurring during foetal muscle development 
when compared to post-natal adult muscle.  It is also demonstrated that mature 
Myostatin negatively regulates furin promoter activity.  Furin protease is critical 
for the processing of several members of the TGF-β superfamily, thus a 
mechanism is proposed whereby myostatin negatively auto-regulates its 
proteolytic processing during development to facilitate the process of myoblast 
differentiation.   
It was further demonstrated that over-expression of Pax7 in C3H10T1/2 
multipotent cells enhances myogenic conversion in these cells.  However, over-
expression of Pax7 in C2C12 myoblasts delays the onset of differentiation, 
concomitant with an increase in the population of quiescent, satellite cell-like 
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reserve cells.  Furthermore, treatment with Myostatin down-regulates Pax7 
expression, while Pax7 expression was higher in myostatin-null myoblasts as 
compared to wild-type myoblast cultures.  Furthermore, absence of myostatin 
alters cell heterogeneity, whereby an increase in Pax7+/MyoD- reserve cell 
populations is observed.  Pax7 expression persists longer through differentiation 
in cultured primary myoblasts from myostatin-null animals when compared to 
wild-type counterparts.  Reserve cell populations were also measured, and 
consistent with increased expression of Pax7, there is an increased pool of 
quiescent “self-renewed” reserve cells in differentiated cultures from myostatin-
null mice as compared with wild-type cultures.  Taken together, these results 
suggest that increased expression of Pax7 regulates the self-renewal process of 
satellite cells, and furthermore, growth factors such as myostatin signal through 
Pax7 to regulate the self-renewed pool of satellite cells.  
In this thesis it is shown that myostatin induces cachexia through a mechanism 
independent of NF-κB.  Myostatin treatment results in a cachexia phenotype with 
a reduction in myotube number and size in vitro, as well as a loss of body mass in 
vivo.  Furthermore, the expression of the myogenic genes myoD and pax3 are 
reduced, while NF-κB localisation and expression remains unchanged.  
Expression of the ubiquitin-associated genes Atrogin-1, MuRF-1 and E214k are 
shown to be up-regulated following Myostatin treatment.  The mechanism behind 
myostatin-mediated cachexia was further investigated.  It is shown that myostatin 
antagonises the IGF-1/PI3-K/AKT hypertrophy pathway by inhibiting AKT 
phosphorylation, thereby increasing the levels of active FoxO1, allowing for 
increased expression of atrophy-related genes.   
In addition, microarray analysis resulted in the identification of a potentially 
interesting downstream target gene of myostatin during the induction of cachexia.  
Initial characterisation of CXXC5, or MM1 as it was renamed, was also 
performed.  Over-expression of MM1 in vitro results in the up-regulation of 
components of the ubiquitin-proteasome pathway including Atrogin-1, E214k, 
E220k and RC2.  It was further demonstrated that increased expression of MM1 
enhances the level of protein ubiquitin-conjugation.  Furthermore, over-expression 
of MM1 results in myotube collapse and the formation of multinucleated 
myosacs.  It was also demonstrated that the MM1-induced myotube collapse 
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results in disruption of the typical myotube microtubule structure.  Therefore, 
these data suggest that MM1 is a muscle wasting-inducing gene which functions 
in the regulation of myostatin-mediated cachexia.   
Therefore data presented in this thesis highlights a mechanism through which 
myostatin is regulated, and further delineates the role of myostatin in controlling 
several key processes during post-natal myogenesis, namely satellite cell 
replenishment and skeletal muscle wasting.   
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Chapter 1  Literature review 
 
1.1  Muscle and embryonic myogenesis 
 
Three distinct classes of muscle exist in vertebrates: smooth, cardiac and skeletal.  
Skeletal muscle, is primarily involved with the production of active force, 
resulting in voluntary movement of the skeletal system.  The following section 
reviews literature on the structure of skeletal muscle and the process of embryonic 
myogenesis. 
 
1.1.1  Skeletal muscle structure 
Skeletal muscle is a highly structured tissue consisting of several distinct 
compartments.  Skeletal muscle is enclosed by a connective tissue sheath termed 
the epimysium.  A layer of connective tissue, termed the perimysium, further 
divides the muscle into a number of compartments called fascicles.  Each fascicle 
contains a bundle of skeletal muscle fibres, which are themselves enclosed within 
a third layer of connective tissue, the endomysium (Figure 1.1A) (Martini 2001).  
Skeletal muscle fibres, or myofibres, are composed of myofibrils (Figure 1.1B); 
myofibrils contain bundles of myofilaments, which comprise both thick and thin 
filaments, consisting of myosin and actin respectively.  The myofilaments are 
organised into parallel, longitudinally repeated units called sarcomeres.  The 
sarcomeres are the basic functional unit for force production and fibre contraction 
in the muscle (Figure 1.1C) (Fung 1981; Bagshaw 1993; Martini 2001).  The 
sarcomere can be separated into two distinct regions (Figure 1.1C): the A-band, 
which corresponds to the central region where thick filaments overlap with thin 
filaments, and the I-band, which is comprised of thin filaments only and is the 
region between the A-bands of adjacent sarcomeres.  In the middle of the A-band 
is an area termed the H-zone, composed only of thick myosin filaments (Martini 
2001)   
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Figure 1.1  Skeletal muscle structure 
A) The epimysium, a connective tissue sheath, encloses the entire muscle. The 
perimysium, a further connective tissue, separates the muscle into compartments 
called fascicles.  Fascicles enclose the myofibres, which are surrounded by a fine 
layer of connective tissue termed the endomysium.  B) The myofibre is further 
divided into myofibrils.  C) Myofibrils are composed of sarcomeres, the basic unit 
of contraction in the muscle. Sarcomeres are themselves comprised of an ordered 
alignment of thick and thin filaments.  Modified from Martini (Martini 2001). 
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The M-line, a network of proteins located at the centre of the H-zone, is 
responsible for connecting thick filaments together and maintaining their 
orientation.  Finally, the Z-line defines the boundaries of the sarcomere and is 
responsible for binding thin filaments of adjacent sarcomeres (Fung 1981; Martini 
2001).  The “sliding filament theory” describes the mode of action during skeletal 
muscle contraction.  During contraction, actin filaments are actively pulled 
between the thick myosin filaments.  The sliding of the actin filaments results in 
shortening of the muscle towards the centre of the sarcomere.  With regard to the 
sarcomere, contraction results in a change in length of the I-band and H-zone, 
whereas the length of the A-band remains constant (Fung 1981; Martini 2001). 
 
1.1.2  Embryonic myogenesis  
The majority of vertebrate skeletal muscles, with the exception of craniofacial 
muscles, are derived from somites (Figure 1.2) (Buckingham 1992; Cossu et al. 
1996).  Somites are transient structures consisting of mesenchymal cells which 
arise from segmentation of the paraxial mesoderm on either side of the neural tube 
and notochord (Christ and Ordahl 1995).  Somites quickly become 
compartmentalised, whereby the ventral region forms the sclerotome, giving rise 
to vertebrae and ribs (Cossu et al. 1996; Buckingham et al. 2003; Hollway and 
Currie 2005); while the dorsal somite region forms the dermomyotome, and is 
responsible for the formation of the dermis and the body and limb musculature 
(Buckingham et al. 2003; Hollway and Currie 2005).  Myogenic precursor cells 
delaminate from the dermomytome to form the myotome (Hollway and Currie 
2005).  The dorsal myotome gives rise to the deep back and intercostal muscles, 
or what is termed epaxial muscle (Christ and Ordahl 1995; Brand-Saberi et al. 
1996).  In contrast cells derived from the lateral myotome and the lateral region of 
the dermomyotome give rise to myogenic precursor cells which migrate to limb 
buds to form hypaxial muscles, such as those of the body wall and the limb 
(Cossu et al. 1996; Brand-Saberi and Christ 1999).  Skeletal muscle precursor 
cells give rise to skeletal muscle cells, termed myoblasts, which subsequently 
differentiate into multinucleated primary myotubes (Harris et al. 1989).  
Following this period of primary myogenesis, secondary myogenesis ensues 
whereby primary myotubes act as a template for a wave of secondary myoblasts.  
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Here the secondary myoblasts line up on the primary myotubes, fuse and form 
secondary myotubes.  The resulting differentiated myotubes further fuse, forming 
myofibres which then align to produce the functional muscle (Gullberg et al. 
1998).   
 
 
 
 
 
 
 
 
 
Figure 1.2  Somitogenesis 
Somites specify dorsally into the dermomyotome and ventrally into the 
sclerotome. The dermomyotome gives rise to a second layer of cells termed the 
myotome.  Myogenic precursor cells from the dorsal medial lip (DML) contribute 
to the medial (epaxial) region of the myotome and will give rise to back 
musculature; while myogenic precursor cells produced from the ventral lateral lip 
(VLL) will contribute to the lateral (hypaxial) region of the myotome, forming 
limb and body wall musculature.  Modified from (Pownall et al. 2002).   
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Members of the Myogenic Regulatory Factor (MRF) family are critical for the 
timely progression of skeletal muscle myogenesis.  The MRFs, consisting of Myf-
5 (Braun et al. 1989), MyoD (Davis et al. 1987), myogenin (Edmondson and 
Olson 1989) and MRF4 (Rhodes and Konieczny 1989), are a family of basic 
helix-loop-helix (bHLH) transcription factors.  Myf-5 expression is initially 
detected at day 8 in the developing somite (Ott et al. 1991), and has recently been 
shown to function together with MRF4 to specify commitment of progenitor cells 
to the myogenic lineage (Kassar-Duchossoy et al. 2004).  MyoD expression is 
also detected early in the somite at about day 10.5 (Sassoon et al. 1989).  MyoD 
may also specify progenitor cells to the myogenic lineage in the absence of myf-5.  
In agreement with this, mice lacking either myoD (Rudnicki et al. 1992) or myf-5 
(Braun et al. 1992) are still able to generate skeletal muscle, while mice lacking 
both myoD and myf-5 are not (Rudnicki et al. 1993), thus suggesting a 
compensatory role for MyoD and Myf-5 during myogenic specification.  Once 
specified, progenitor cells form myoblasts which differentiate into multinucleated 
myotubes.  Myogenin and MRF4 are important for myogenic differentiation; 
indeed mice containing a mutated form of myogenin die peri-natally due to a 
severe deficiency in differentiated myofibres, however, myoblast cell number 
remains unaffected (Hasty et al. 1993; Nabeshima et al. 1993).  Furthermore, 
MRF4-null embryos have been shown to be devoid of any differentiated skeletal 
muscle (Olson et al. 1996).   
The paired-box transcription factors Pax3 and Pax7 also have an important role in 
regulation of skeletal muscle myogenesis.  Pax3 expression is detected throughout 
the somite, with progressive restriction to the dermomyotome and further 
concentration at the epaxial and hypaxial edges of the dermomyotome (Goulding 
et al. 1991; Tajbakhsh and Buckingham 2000).  Pax3 is critical in cell 
delamination and migration of myogenic precursor cells to the limb buds.  In 
support, progenitor cells do not delaminate from the hypaxial dermomyotome in 
pax3-null “Splotch” mice, and furthermore pax3-null mice are deficient in limb 
musculature (Franz et al. 1993; Tajbakhsh et al. 1997; Tremblay et al. 1998).  In 
contrast to pax3-null, pax7-null mice have no discernable skeletal muscle defects 
during embryonic myogenesis (Mansouri et al. 1996).  However, recently 
identified populations of myogenic progenitor cells, which express both Pax3 and 
Pax7, have been detected in the myotome region of the somite (Kassar-Duchossoy 
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et al. 2005; Relaix et al. 2005).  These populations of Pax3+/Pax7+ cells have been 
shown to activate both Myf-5 and MyoD and give rise to myoblasts, which 
subsequently contribute to skeletal muscle formation (Relaix et al. 2005).  The 
populations of Pax3+/Pax7+ cells appear to persist through to late foetal stages of 
growth and are further suggested to contribute to the skeletal muscle stem cell or 
satellite cell pool in adult muscle (Kassar-Duchossoy et al. 2005; Relaix et al. 
2005). 
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1.2  Post-natal myogenesis 
 
Adult skeletal muscle has the intrinsic ability to repair itself in response to injury.  
This repair process has been attributed to the satellite cell population present 
within skeletal muscle, making this population of cells especially important for 
post-natal myogenesis.  Thus several aspects of satellite cell biology will be 
reviewed in the following section. 
 
1.2.1  Satellite cells 
Satellite cells, which are also referred to as muscle stem cells, were initially 
discovered in 1961 (Katz 1961; Mauro 1961).  The term satellite cell was coined 
based on their peripheral location on skeletal muscle fibres (Katz 1961; Mauro 
1961); specifically, satellite cells reside between the basal lamina and sarcolemma 
of muscle fibres (Grounds and Yablonka-Reuveni 1993; Bischoff and Heintz 
1994).  Satellite cells are located throughout skeletal muscle tissue, however, 
heterogeneity exists in the distribution of satellite cells with oxidative muscle 
fibres containing a greater population of satellite cells as compared to glycolytic 
fibres (Gibson and Schultz 1982; Holterman and Rudnicki 2005).  At birth 
satellite cells account for 30% of the sub-laminar muscle nuclei in mice, however, 
in adult mice the number rapidly declines to only about 5% (Bischoff 1994a), 
presumably due to the contribution of satellite cells to post-natal muscle 
development (Gibson and Schultz 1983; Seale and Rudnicki 2000).  Post-natal 
skeletal muscle growth, repair and maintenance are attributed to the myogenic 
precursor satellite cell population (Seale and Rudnicki 2000).  Satellite cells are 
typically maintained in a quiescent state until induced to activate in response to 
such stimuli as stretching, exercise and injury (Rosenblatt et al. 1994; Grounds 
1998; Hawke et al. 2003; Yan et al. 2003).  The signals responsible for satellite 
cell activation are yet to be fully elucidated.  However, studies have highlighted a 
role for Hepatocyte Growth Factor (HGF) in mediating satellite cell activation.  
Exogenous addition of HGF has been shown to induce activation; while antibody-
mediated neutralisation of HGF inhibits satellite cell activation (Tatsumi et al. 
1998).  Moreover, Nitric Oxide Synthase (NOS) has been implicated in HGF-
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mediated satellite cell activation.  Inhibition of NOS reduces satellite cell 
activation and reduces the levels of HGF released following muscle stretching 
(Anderson 2000; Tatsumi et al. 2002); furthermore, it has been recently shown 
that HGF is released in a NOS-dependent manner during passive skeletal muscle 
stretch (Tatsumi et al. 2006).  In addition, Fibroblast Growth Factor 2 (FGF2) has 
been demonstrated to promote recruitment of quiescent satellite cells towards 
proliferation (Yablonka-Reuveni et al. 1999).  However, growth factors such as 
Insulin-like Growth Factor-1 (IGF-1), Endothelial Growth Factor (EGF), and 
Platelet-Derived Growth Factor (PDGF) appear to enhance satellite cell 
proliferation rather than promoting activation (Bischoff 1986; Johnson and Allen 
1995).  Once activated, satellite cells re-enter the cell cycle, proliferate and 
differentiate and then fuse to repair or replace damaged muscle fibres (Grounds 
and Yablonka-Reuveni 1993; Bischoff 1994b; Seale and Rudnicki 2000).   
 
1.2.1.1  Satellite cell origin  
There have been many articles published debating the specific origin of skeletal 
muscle satellite cells.  However, it is commonly accepted that satellite cells are 
originally derived from the somites, as evidenced by several recent articles.  
Populations of cells that express both Pax3 and Pax7 but lack expression of 
muscle specific-markers have been detected within the mouse somite (Kassar-
Duchossoy et al. 2005; Relaix et al. 2005).  These cells form a pool of muscle 
progenitor cells which are able to become myogenic and give rise to skeletal 
muscle during development.  These progenitor cells are further shown to adopt a 
satellite cell position later in foetal development (Kassar-Duchossoy et al. 2005; 
Relaix et al. 2005).  Similar populations of muscle progenitor cells, initially 
detected in the dermomyotome compartment of chicken somites, are also 
suggested to be the origin of satellite cells (Gros et al. 2005).  More recently, a 
study has traced the origins of satellite cells back to the hypaxial domain of the 
somite.  It was further shown that these somitically-derived progenitor cells 
contribute to the satellite cell pool in post-natal musculature (Schienda et al. 
2006). 
In contrast, multipotent cells of non-somitic origin may also contribute to the 
satellite cell pool.  For example, myogenic cells have been isolated from the 
 9
embryonic dorsal aorta which display a similar morphology and have comparable 
gene expression to that of adult satellite cells (De Angelis et al. 1999).  Moreover, 
the aorta-derived myogenic cells were able to contribute to skeletal muscle growth 
and regeneration following transplantation.  Therefore, it is possible that 
endothelial cells may in part give rise to satellite cells (De Angelis et al. 1999), or 
alternatively, endothelial cells and satellite cells may have a common origin; 
indeed it has been shown that endothelial and myogenic cells share a common 
somitic precursor (Kardon et al. 2002). 
 
1.2.1.2  Molecular markers of satellite cells 
Several studies have highlighted a number of molecular markers that identify the 
satellite cell lineage (Figure 1.3).  Quiescent satellite cells have been shown to 
express a range of proteins, including a truncated form of the endothelial marker 
CD34 (Beauchamp et al. 2000), the hepatocyte growth factor receptor c-Met 
(Cornelison and Wold 1997), M-cadherin (Irintchev et al. 1994), myocyte nuclear 
factor (MNF) (Garry et al. 1997), syndecan-3/syndecan-4 (Cornelison et al. 2001) 
and Pax7 (Seale et al. 2000).  M-cadherin, a cell adhesion molecule, is thought to 
play a role in the adhesion of satellite cells to the basal lamina of the muscle fibre 
(Hawke and Garry 2001).  In addition, it may also play a role in the migratory 
response of these cells in response to stimuli (Hawke and Garry 2001).  Syndecan-
3 and syndecan-4 are cell surface proteoglycans which are reportedly expressed 
by satellite cells; indeed, expression of syndecan-3/syndecan-4 is detected under 
the basal lamina within the satellite cell compartment (Cornelison et al. 2001).  
The paired-box transcription factor Pax7 is a commonly used marker for satellite 
cells and is present in both quiescent and proliferating satellite cells (Seale et al. 
2000; Zammit et al. 2004).  Moreover, it has been recently demonstrated that 
Pax7 is transcriptionally active within quiescent satellite cells (Zammit et al. 
2006b).  Using Myf5nlacZ/+ mice it has been established that the Myf5 locus is 
active in quiescent satellite cells (Beauchamp et al. 2000; Shefer et al. 2006).   
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Figure 1.3  Molecular markers of satellite cell growth 
Satellite cells normally exist in a quiescent state, but in response to several 
stimuli, including muscle injury, they activate and proliferate prior to 
differentiation and eventual fusing to form myotubes.  Quiescent satellite cells 
express CD34, Pax7 and Myf-5/β-gal.  Following activation, satellite cells express 
MyoD and maintain expression of Pax7, while myogenin expression is detected 
during the onset of differentiation.  Modified from Zammit et al. (Zammit et al. 
2006a).   
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Although the Myf-5 locus is active, no published accounts have demonstrated 
Myf-5 mRNA or protein expression in quiescent satellite cells.  Recent markers 
include the monoclonal antibody SM/C-2.6, which reacts with an epitope 
expressed on quiescent satellite cells (Fukada et al. 2004).  Furthermore, caveolin-
1 (Volonte et al. 2005) and lysenin (Nagata et al. 2006) have been recently 
identified as markers of quiescent satellite cells.  To mediate skeletal muscle 
regeneration, satellite cells must activate, proliferate and terminally differentiate.  
Upon activation satellite cells begin expressing MyoD and desmin, along with 
continuing expression of Pax7, Myf-5, and M-cadherin (Yablonka-Reuveni and 
Rivera 1994; Cornelison and Wold 1997; Yablonka-Reuveni et al. 1999; Olguin 
and Olwin 2004; Zammit et al. 2004).  Interestingly, activated satellite cells, 
unlike quiescent satellite cells, no longer express the truncated form of CD34; 
instead, expression of the full length isoform is detected (Beauchamp et al. 2000).  
During the progression of terminal differentiation, myogenin expression is up-
regulated, while the expression of Pax7 is rapidly down-regulated during the 
induction of differentiation .(Cornelison and Wold 1997; Yablonka-Reuveni et al. 
1999; Zammit et al. 2004).   
 
1.2.1.3  Satellite cell self-renewal 
The hallmark features of stem cells include the capacity to form differentiated 
tissue and the ability to self-renew their population (Weissman et al. 2001).  
Satellite cells, also referred to as skeletal muscle stem cells, have been shown to 
differentiate to form myotubes (Yablonka-Reuveni and Rivera 1994; Rosenblatt et 
al. 1995; Beauchamp et al. 2000).  Furthermore, evidence is mounting to support 
the ability of satellite cells to self-renew their population, thus supporting their 
purported role as muscle stem cells.  Satellite cell number remains constant 
through repeated cycles of skeletal muscle injury and regeneration, thus 
supporting the presence of mechanisms that replenish the satellite cell pool 
(Schultz and McCormick 1994).  Evidence for satellite cell self-renewal has been 
obtained through several studies that analyse the function of transplanted 
myoblast populations in vivo.  Skeletal muscle myoblasts have been shown to 
differentiate and contribute to muscle following injection into nude (immune-
deficient) mdx mice (Morgan et al. 1994; Gross and Morgan 1999).  Moreover, 
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injected muscle precursor cells were able to contribute to muscle formation 
following successive rounds of muscle injury due to notexin injection (Gross and 
Morgan 1999), thus providing evidence for the formation of a quiescent pool of 
cells capable of contributing to muscle repair.  Furthermore, Montarras et al. 
demonstrated that injected Pax3GFP/+ satellite cells contributed to muscle repair 
and were also located within the satellite cell compartment in nude mdx mice.  
The Pax3GFP/+ cells were further shown to express the myogenic markers MyoD 
and Pax7 upon isolation from injected muscle (Montarras et al. 2005).  A further 
study utilising the Myf5nlacZ/+ mouse, whereby β-galactosidase (β-gal) activity was 
used to mark quiescent satellite cells, has yielded evidence to support satellite cell 
self-renewal (Heslop et al. 2001).  Specifically, β-gal positive myoblasts were 
incorporated into muscles of recipient mice following injection.  Heslop et al. 
further demonstrated that the β-gal positive cells occupied the satellite cell niche 
beneath the basal lamina and when isolated and cultured in vitro gave rise to 
myogenic cells.  An elegant study by Collins et al. has provided direct evidence of 
satellite cell self-renewal in vivo.  In that study they injected intact Myf5nlacZ/+ 
muscle fibres into irradiated immune compromised mdx mice.  Injection of muscle 
fibres, containing as few as seven satellite cells, produced more than one hundred 
new fibres.  Furthermore, the transplanted satellite cells self-renewed to expand 
the population of new satellite cells, as determined by their location beneath the 
basal lamina and by expression of the satellite cell marker Pax7.  In addition, 
following further injury these transplanted satellite cells were able to contribute to 
skeletal muscle regeneration (Collins et al. 2005). 
Several cell culture models have provided further evidence for the ability of 
satellite cells to self-renew their population.  C2C12 myoblast cultures proliferate 
until a decision is made to exit the cell cycle and differentiate to form 
multinucleated myotubes.  During the induction of differentiation, through serum 
withdrawal, it has been shown that a subset of cells exit the cell cycle but fail to 
up-regulate the differentiation marker myogenin, and as a consequence do not 
commit to differentiation (Kitzmann et al. 1998; Yoshida et al. 1998).  These 
“reserve cells” remain in a quiescent state until stimulated to activate, proliferate 
and contribute to further differentiation in culture (Kitzmann et al. 1998; Yoshida 
et al. 1998).  Studies of satellite cell cultures have yielded more evidence for self-
renewal.  Heterogeneity in the expression of several key satellite cell markers is 
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observed in cultured single fibres (Olguin and Olwin 2004; Zammit et al. 2004).  
It has been shown that once activated, satellite cells express Pax7 and MyoD, 
proliferate, then down-regulate Pax7 prior to differentiation.  However, sub-
populations of satellite cells maintain expression of Pax7 but lose MyoD; these 
cells exit the cell cycle, fail to differentiate, and adopt a quiescent phenotype 
(Olguin and Olwin 2004; Zammit et al. 2004).  Similarly, satellite cell populations 
from chickens, which are positive for Pax7 but lack MyoD, are phenotypically 
similar to quiescent reserve cells (Halevy et al. 2004).  Further evidence for the 
role of Pax7 in self-renewal is obtained from studies of pax7-null mice.  Pax7-null 
mice appear normal at birth but die between 2-3 weeks of age (Mansouri et al. 
1996).  Although pax7-null mice are born with satellite cells, the number quickly 
decreases with age, resulting in impaired regeneration (Oustanina et al. 2004; 
Relaix et al. 2006).  While evidence points towards Pax7 as a key regulator of 
self-renewal, the unequivocal involvement and moreover the mode of action of 
Pax7 during self-renewal, remain matters of contention; indeed, loss of pax7 has 
recently been shown to result in aberrant apoptosis (Relaix et al. 2006).  
Furthermore, Zammit et al. have recently demonstrated that constitutive 
expression of Pax7 is unable to induce quiescence or block myogenic 
differentiation in satellite cell cultures (Zammit et al. 2006b), thus Pax7 may 
mediate satellite cell survival, rather than self-renewal, to maintain the satellite 
cell pool.   
The exact mechanism of satellite cell self-renewal is currently unknown, however, 
two alternative models have been proposed.  The stochastic model, whereby 
satellite cells activate and proliferate until, by a yet undefined signal, one or more 
cells returns to quiescence (Dhawan and Rando 2005).  Secondly, the asymmetric 
model has also been proposed.  In this model, asymmetric division occurs 
immediately after satellite cell activation, at which point one daughter cell returns 
to quiescence, while the other daughter continues proliferating to contribute to the 
pool of myoblasts (Dhawan and Rando 2005).  These myoblasts may also divide 
asymmetrically, thus further replenishing the satellite cell pool (Dhawan and 
Rando 2005).  Support for the asymmetric hypothesis in seen in populations of 
actively growing satellite cells; sub-populations of satellite cells have been shown 
to undergo asymmetric division during mitosis resulting in selective sorting of 
DNA strands (Shinin et al. 2006).  It is suggested that this selective DNA sorting 
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may provide a mechanism through which template DNA is protected from 
replication-induced errors (Shinin et al. 2006).  Furthermore, the notch inhibitor 
numb is asymmetrically distributed in dividing satellite cells (Conboy and Rando 
2002).  It is suggested that segregation of numb may be critical in cell fate 
determination and in the decision to continue proliferating or to exit the cell cycle 
and differentiate (Conboy and Rando 2002).   
 
1.2.2  Muscle stem cells 
 
Self-renewal may not be the only method of satellite cell replenishment.  Recent 
evidence has highlighted the possible contribution of other cell types in 
maintaining satellite cell number, including bone-marrow derived cells and multi-
potent progenitor cells.  The blood vessel-associated mesoangioblast stem cells 
have been detected at the periphery of muscle fibres following injection into mice, 
where they expressed the satellite cell markers M-cadherin and c-Met (Sampaolesi 
et al. 2003).  In addition, transplantation of mesoangioblasts into the alpha-
sarcoglycan-null mouse (α-SG-/-), a model of limb girdle muscular dystrophy, 
results in the formation of new alpha-sarcoglycan expressing muscle fibres 
(Guttinger et al. 2006).  Furthermore, Galvez et al. demonstrated that pre-
treatment of mesoangioblasts with Stromal Derived Factor-1 (SDF-1) and Tumor 
Necrosis Factor-alpha (TNF-α), with increased expression α4-integrin enhanced 
the regenerative capacity of the mesoangioblasts, resulting in complete repair of 
skeletal muscle in the α-SG-/- mouse (Galvez et al. 2006).  Populations of 
interstitial cells have been identified in skeletal muscle tissue and may contribute 
to post-natal skeletal muscle myogenesis.  Tamaki et al. identified populations of 
CD45-/CD34+/Sca-1+ cells which are able to differentiate into adipocytes, 
endothelial and myogenic cells (Tamaki et al. 2002).  More recently, a rare 
population of Pax3+ cells have been identified in the interstitial space of adult 
muscle.  These cells were shown to have myogenic potential and co-express 
MyoD during regeneration (Kuang et al. 2006).  Side population (SP) cells were 
initially identified by fluorescence-activated cell sorting (FACS) through their 
ability to efflux the vital dye Hoechst 33342.(Goodell et al. 1996; Gussoni et al. 
1999; Seale et al. 2000).  The majority of muscle SP cells express the early 
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haematopoietic stem cell marker Sca-1 but not CD45 (Buckingham 2001; 
Montanaro et al. 2004).  Transplanted muscle-derived SP cells participate in 
muscle regeneration in mdx mice and appear capable of contributing to the 
satellite cell compartment (Gussoni et al. 1999).  Recently it has been identified 
that, like satellite cells, a large proportion of limb muscle SP cells are derived 
from the hypaxial somite (Schienda et al. 2006).  Further resident populations of 
CD45+ and Sca-1+ stem cells exist in skeletal muscle.  However, these cells only 
commit to a myogenic fate after muscle injury, a process which seems to be 
controlled by Wnt signalling and the transcription factor Pax7 (Polesskaya et al. 
2003; Seale et al. 2004).  Bone marrow may also play an important role in 
satellite cell replenishment.  Indeed, injected bone marrow-derived cells are able 
to contribute to skeletal muscle fibres and are able locate within the satellite cell 
compartment (LaBarge and Blau 2002; Dreyfus et al. 2004).  However, a recent 
report demonstrates that a high proportion of bone marrow-derived cells injected 
into mdx mice fail to adopt a myogenic program (Wernig et al. 2005).  
Furthermore, Sherwood et al. have shown that, although bone marrow-derived 
cells are able to occupy the satellite cell niche and express several satellite cell 
markers, they are unable to contribute to the myogenic program (Sherwood et al. 
2004).  Therefore, the contribution of bone marrow-derived cells to replenishing 
the satellite cell population remains a matter of contention. 
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1.3  Skeletal muscle wasting 
 
Muscle wasting, or atrophy, is an important process which afflicts post-natal 
musculature and is almost certainly responsible for the high morbidity and 
mortality associated with many diseases.  Therefore, skeletal muscle wasting will 
be reviewed in the subsequent sections with emphasis on cachexia, proteolytic 
systems and molecular mechanisms responsible for the progression of skeletal 
muscle wasting.  
 
1.3.1  Muscle atrophy 
Skeletal muscle atrophy is the progressive change that occurs in post-natal 
musculature in response to circumstances of disuse (immobilisation, denervation 
and muscle unloading), starvation, ageing (sarcopenia) and disease states 
(cachexia; see Section 1.3.2).  A number of characteristic changes define the 
progression of skeletal muscle atrophy, including an increase in protein 
degradation, a reduction in protein synthesis, a decrease in muscle fibre cross 
sectional area and a loss of muscle nuclei content (Mitchell and Pavlath 2001; 
Edgerton et al. 2002; Hudson and Franklin 2003; Jackman and Kandarian 2004; 
Sandri et al. 2004).  These pathological changes most certainly contribute to the 
reduction in muscle force production and decreased resistance to fatigue that is 
associated with skeletal muscle atrophy.   
 
1.3.2  Cachexia 
The term cachexia is derived from the Greek words kakos (bad) and hexis 
(condition) and defines a condition of severe skeletal muscle loss as a result of 
chronic disease.  Several common symptoms are associated with the progression 
of cachexia, including anorexia, anaemia, muscle loss and atrophy with associated 
asthenia (loss of muscle strength), loss of body fat and changes in lipid, 
carbohydrate and protein metabolism (Argiles et al. 1997; Argiles et al. 2005).  
Cachexia is associated with many diseases including cancer, acquired 
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immunodeficiency syndrome (AIDS), sepsis, congestive heart failure, diabetes 
and renal failure (Mitch and Goldberg 1996; Jackman and Kandarian 2004; 
Lecker et al. 2004; Boonyarom and Inui 2006).  Cancer-associated cachexia often 
leads to a poor prognosis, with greater than half of all cancer patients experiencing 
some degree of cachexia (Argiles et al. 2003).  Moreover, one third of cancer-
related deaths can be attributed to the development of the cachexia syndrome 
rather than the disease itself (Acharyya et al. 2004).  Early cachectic events 
include the release of amino acids from skeletal muscle tissue, which provides the 
liver with a source of amino acids for acute-phase protein synthesis and 
gluconeogenesis (Rosenblatt et al. 1983; Hasselgren and Fischer 2001; Argiles et 
al. 2006a).  Both humoral (immune system released) and tumoral (tumour 
released) factors promote the severe muscle and fat loss observed during cachexia.  
Cytokines are the major humoral factors which regulate cancer-associated 
cachexia.  Cytokines including Tumor Necrosis Factor-α (TNF-α), interleukin-1 
(IL-1), interleukin-6 (IL-6) and interferon-γ (IFN-γ) have been shown to play a 
role in the cachectic response (Argiles et al. 2005; Argiles et al. 2006b) (reviewed 
in Section 1.3.4.1).  In addition, the tumoral factors toxohormone-L, anaemia-
inducing substance, lipid-mobilising factor and proteolysis-inducing factor (PIF) 
(reviewed in Section 1.3.4.2) are released by the tumour during the progression of 
cachexia (Argiles et al. 2005).   
 
1.3.3  Skeletal muscle proteolytic systems 
Skeletal muscle is a dynamic tissue undergoing constant cycles of degradation and 
subsequent regeneration.  The degradation of skeletal muscle proteins is 
controlled by three major proteolytic systems, the ATP-dependent ubiquitin-
proteasome pathway, the calcium-dependent calpain pathway and the lysosomal 
protease system.  These three major proteolytic pathways are discussed in the 
subsequent sections. 
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1.3.3.1  Lysosomal protease system  
Lysosomes play an important role in skeletal muscle proteolysis with a primary 
role in the degradation of membrane lipids and membrane proteins including 
receptors and ion channels (Bechet et al. 2005; Tisdale 2005).  Lysosomes are 
membrane-bound vesicles which contain various acid hydrolases including 
proteases, glycosidases, lipases, nucleases and phosphatases (Bechet et al. 2005).  
The ubiquitously expressed cathepsins, L, B, D and H form the major component 
of lysosomal proteases (Bechet et al. 2005), and indeed have been shown to be 
associated with several forms of muscle wasting.  In particular, cathepsin B 
mRNA expression is shown to increase in muscle tissue from patients with lung 
cancer (Jagoe et al. 2002).  Increased mRNA expression of both cathepsin B and 
cathepsin D has also been reported during glucocorticoid-induced muscle wasting 
and disuse atrophy (Dardevet et al. 1995; Taillandier et al. 1996).  Furthermore, 
Deval et al. have demonstrated that cathepsin L mRNA and protein levels were 
elevated in a rat model of sepsis, and that cathepsin L mRNA expression was 
increased following glucocorticoid (dexamethasone; Dex) treatment and in rats 
bearing the AH-130 tumour (Deval et al. 2001).  In addition, microarray analysis 
has identified enhanced expression of cathepsin L in rat models of muscle wasting 
induced by fasting, uraemia (chronic renal failure), diabetes mellitus and tumour 
growth (Lecker et al. 2004).  Conversely, IGF-1 mediated inhibition of burn-
induced skeletal muscle wasting is associated with a decrease in Cathepsin B and 
Cathepsin L activity (Fang et al. 2002).   
 
1.3.3.2  Calcium-dependent pathway 
Calcium-dependent proteolysis is mediated through the action of calcium-
activated cysteine proteases termed calpains (Costelli et al. 2005).  Calpain-1 (µ-
calpain), calpain-2 (m-calpain) and calpain-3 are all highly expressed in skeletal 
muscle tissue, however, in contrast to the ubiquitously expressed calpains 1 and 2, 
calpain-3 is reported to be expressed specifically in muscle tissue (Bartoli and 
Richard 2005; Kramerova et al. 2005).  Calpains normally exist in a dormant state 
in the cytosol however, in response to increasing levels of intracellular calcium, 
calpains translocate to the plasma membrane to become activated by Ca2+ and 
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phospholipids (Goll et al. 2003; Costelli et al. 2005).  Calpains appear to be 
critical for initiating the degradation of myofibrillar proteins, including the Z-disc 
associated proteins filamin, nebulin, titin, troponin-T and desmin (Solomon and 
Goldberg 1996; Huang and Forsberg 1998; Williams et al. 1999b; Bartoli and 
Richard 2005).  In contrast, calpains are unable to degrade actin and myosin; 
instead calpains facilitate the release of these proteins from the sarcomere 
allowing for their subsequent degradation through the ubiquitin-proteasome 
pathway (Solomon and Goldberg 1996; Huang and Forsberg 1998; Williams et al. 
1999b; Bartoli and Richard 2005).  The calcium-dependent calpain pathway has 
been associated with several forms of muscle wasting.  Calpains may have a role 
in the severe pathology associated with muscular dystrophy.  Duchenne muscular 
dystrophy (DMD) is characterised by mutations in the dystrophin gene which 
results in the complete absence of Dystrophin.  Dystrophin, a large cytoskeletal 
protein, associates with several sarcolemmal proteins and glycoproteins to form 
the dystrophin-glycoprotein complex, which is critical for interactions between 
the cytoskeleton and the extracellular matrix (Porter et al. 2002).  Absence of 
dystrophin weakens the sarcolemma allowing influx of extracellular calcium into 
the myofibril (Costelli et al. 2005).  Indeed, elevated levels of intracellular 
calcium are observed in mdx mice, a model of DMD, with an associated increase 
in calpain expression (Spencer et al. 1995; Hopf et al. 1996).  Furthermore, it has 
been demonstrated that treatment of mdx mice with the calpain inhibitor 
Calpastatin alleviates the muscle wasting associated with this disease (Spencer 
and Mellgren 2002).  Calpains may also play an important role in muscle wasting 
associated with sepsis.  In fact, it has been recently shown that treatment with the 
calpain inhibitors calpeptin and BN82270 blocks sepsis-induced protein 
degradation in the rat (Fareed et al. 2006).  In addition, transgenic mice over-
expressing calpastatin demonstrate greatly reduced skeletal muscle atrophy 
following hindlimb unloading (Tidball and Spencer 2002).  Calpains may also 
regulate protein degradation during cancer cachexia.  Increased m-calpain has 
been observed in skeletal muscle tissue from rats containing the Yoshida AH-130 
tumour (Temparis et al. 1994; Costelli et al. 2005); furthermore, increased 
calpain-dependent proteolytic activity is observed in AH-130 tumour-bearing rats 
(Costelli et al. 2002).   
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1.3.3.3  Ubiquitin-proteasome pathway  
Ubiquitin-mediated degradation is an ordered process which results in the 
eventual poly-ubiquitination of substrate proteins and degradation by the 26S 
proteasome (Figure 1.4A and Figure 1.4B).  Firstly, ubiquitin must be activated by 
an ubiquitin-activating enzyme (E1), an ATP-dependent 2-step process which 
results in the formation of an ubiquitin-E1 thiol ester product (Tisdale 2005; Wing 
2005; Nandi et al. 2006) (Figure 1.4A).  The activated ubiquitin is then transferred 
to an ubiquitin-conjugating enzyme (E2), also termed the ubiquitin carrier protein.  
These E2 enzymes associate with a third class of enzyme, E3 ubiquitin protein 
ligases (Figure 1.4A).  The E3 enzymes are responsible for the transfer of the 
ubiquitin from the E2 to a specific target substrate or protein, with subsequent 
rounds of E3-mediated ubiquitin ligation resulting in poly-ubiquitination of target 
proteins (Figure 1.4A and Figure 1.4B).  In some circumstances a fourth enzyme 
(E4) functions to lengthen the ubiquitin chains on target proteins (Tisdale 2005; 
Nandi et al. 2006).  Ubiquitin-tagged proteins are marked for degradation by the 
26S proteasome.  The 26S proteasome complex is formed when two 19S cap 
particles associate, in an ATP-dependent manner, with each end of the 20S 
proteasome (Nandi et al. 2006) (Figure 1.4B).  The 19S cap is responsible for 
unfolding proteins and facilitating their entry into the 20S proteasome.  The 20S 
proteasome, comprised of two outer α rings and two inner β rings (Figure 1.4B), 
contains the proteolytic core and is responsible for degrading target proteins in an 
ATP-independent manner (Tisdale 2005; Nandi et al. 2006).  The ubiquitin-
proteasome pathway typically functions to degrade damaged or defective proteins 
within the cell.  However, ubiquitin-mediated proteolysis is also involved in 
degradation of tumour-suppressor proteins, oncoproteins and cell cycle regulators 
including cyclins and cyclin-dependent kinases.  In addition to degrading aberrant 
proteins, the ubiquitin-proteasome pathway is further implicated in transcriptional 
activation (Yu et al. 1998; Lipford and Deshaies 2003; Tisdale 2005; Wang et al. 
2005).  The ubiquitin-proteasome pathway plays a major role in protein 
degradation during muscle wasting with the majority of myofibrillar proteins 
targeted for degradation through this ATP-dependent mechanism (Solomon and 
Goldberg 1996).  It has been shown that myosin, actin, troponin and tropomyosin 
are targeted for degradation by the ubiquitin-proteasome pathway (Solomon and 
Goldberg 1996).   
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However, it is noteworthy to mention that the ubiquitin-proteasome pathway is 
unable to degrade these proteins while the myofibrils remain intact (Solomon and 
Goldberg 1996), suggesting the involvement of more than one proteolytic 
pathway in the process of skeletal muscle degradation (see Section 1.3.3.2).  
Enhanced expression of ubiquitin-proteasome pathway components is linked with 
several forms of skeletal muscle wasting.  Increased mRNA expression of both 
polyubiquitin and proteasome subunits (C-1, C-3, C-5, C-8 and C-9) has been 
observed in models of starvation and denervation-induced muscle atrophy 
(Medina et al. 1995).  In addition, enhanced levels of ubiquitin-conjugated 
proteins were observed during hindlimb unloading experiments in the rat 
(Vermaelen et al. 2005).  Furthermore, higher mRNA expression of proteasome 
subunits, ubiquitin and the ubiquitin-conjugating enzyme E214k were detected in 
rat models of diabetes and glucocorticoid-induced muscle proteolysis (Auclair et 
al. 1997; Mitch et al. 1999).  Muscle degradation during cancer is also associated 
with enhanced ubiquitin-proteasome activity.  Indeed, rats bearing the Yoshida 
ascites hepatoma-130 (AH-130) have enhanced expression of ubiquitin (Costelli 
et al. 2006) and ubiquitin-proteasome subunits, with an associated increase in the 
levels of ubiquitin-conjugated proteins (Baracos et al. 1995).  Furthermore, 
several studies on cancer patients have identified an associated increase in the 
expression of ubiquitin-proteasome pathway genes, including ubiquitin, several 
proteasome subunits and the conjugating enzyme E214k (Williams et al. 1999a; 
Bossola et al. 2001; Khal et al. 2005).  Therefore, ubiquitin-mediated degradation 
may play a major role in the severe muscle loss associated with cancer. 
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Figure 1.4  The ubiquitin-proteasome pathway 
A)  An ordered series of events results in the poly-ubiquitination of target proteins 
for their eventual degradation through the 26S proteasome.  Firstly, ubiquitin is 
activated by an E1 enzyme and subsequently transferred to a conjugating enzyme 
(E2).  The E3 enzymes transfer ubiquitin from the E2 enzyme to a target protein.  
Multiple rounds of E3-mediated ubiquitin ligation results in a poly-ubiquitinated 
protein ready for degradation.  B)  Poly-ubiquitinated proteins are targeted by the 
26S proteasome for degradation in an ATP-dependent manner resulting in the 
breakdown of target proteins and the release of amino acids.  Modified from 
Mitch and Goldberg (Mitch and Goldberg 1996).   
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The muscle-specific ubiquitin E3 ligases Atrogin-1 (MAFbx) and MuRF-1 
(Bodine et al. 2001; Gomes et al. 2001) are gaining recognition as two important 
markers of muscle atrophy.  The expression of both Atrogin-1 and MuRF-1 are 
consistently up-regulated in several forms of skeletal muscle wasting.  Expression 
of atrogin-1 and MuRF-1 is shown to be dramatically increased in muscle atrophy 
associated with immobilisation, denervation, hindlimb suspension, glucocorticoid 
(Dex) treatment and addition of the cachectic cytokine, interleukin-1 (Bodine et 
al. 2001; Krawiec et al. 2005).  Bodine et al. also demonstrated that mice 
deficient in atrogin-1 or MuRF-1 were more resistant to the effects of 
denervation-induced muscle atrophy (Bodine et al. 2001).  Additional studies 
have identified increased expression of atrogin-1 and MuRF-1 in muscle wasting 
associated with fasting, diabetes, renal failure and cancer conditions (Gomes et al. 
2001; Lecker et al. 2004; Costelli et al. 2006).  Furthermore, in a recent study 
addressing age-associated muscle loss (sarcopenia), the levels of both atrogin-1 
and MuRF-1 were significantly increased in an aged rat model (Clavel et al. 
2006).  However, in contrast, no differences were observed in the expression of 
both atrogin-1 and MuRF-1 in young versus old human patients, a phenomenon 
attributed to the physical inactivity of both groups (Whitman et al. 2005).  
Recently, Lang et al. have shown that burn-induced injury in rats results in an 
increase in the mRNA expression of both atrogin-1 and MuRF-1, concomitant 
with a reduction in M. gastrocnemius muscle weight.  Thus Atrogin-1 and MuRF-
1 appear to be useful molecular markers for measuring the incidence of skeletal 
muscle atrophy associated with various causes (Lang et al. 2006). 
Recently, Atrogin-1 has been shown to degrade the myogenic regulatory factor 
MyoD, and in fact over-expression of Atrogin-1 is demonstrated to antagonise 
MyoD-mediated myogenic differentiation with a subsequent loss in myotube 
formation (Tintignac et al. 2005).  Thus Atrogin-1 may be important in timely 
regulation of skeletal muscle differentiation through regulation of MyoD 
expression (Tintignac et al. 2005).  The Nuclear Factor-kappa B (NF-κB) pathway 
has been implicated in skeletal muscle wasting.  Indeed, transgenic mice which 
have enhanced NF-κB activity show a dramatic muscle wasting phenotype.  
Furthermore, the profound muscle wasting in these mice was associated with an 
increase in the expression of MuRF-1 (Cai et al. 2004).  Interestingly, activation 
of the NF-κB pathway requires ubiquitin-mediated degradation of Inhibitor of 
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kappa B (IκB) protein, which binds to, and represses NF-κB nuclear import and 
thus transcriptional activity.  Furthermore, the NF-κB sub-units p50 and p52 are 
generated through proteasome-mediated degradation of p105 and p100 
respectively (Chen 2005), highlighting a role for the ubiquitin-proteasome 
pathway in regulation of NF-κB activity. 
 
1.3.4  Factors associated with muscle wasting 
 
1.3.4.1  Cytokines - Tumor Necrosis Factor and Interleukins 
Tumor necrosis factor-α (TNF-α), formerly cachectin, is a pro-inflammatory 
cytokine which is involved in many aspects of cachexia.  TNF-α is associated 
with many forms of muscle wasting including that associated with disease.  
Elevated levels of TNF-α are seen in patients with cachexia associated with 
prostate cancer, chronic obstructive pulmonary disease and chronic heart failure 
(Di Francia et al. 1994; Zhao and Zeng 1997; Nakashima et al. 1998).  
Furthermore, the levels of TNF-α as well as the pro-inflammatory cytokines 
interleukin-1β (IL-1β), and interleukin-6 (IL-6), are elevated during the 
progression of human immunodeficiency virus (HIV) in women (Belec et al. 
1995).  In addition, TNF-α is also detected in serum samples of patients with 
pancreatic cancer (Karayiannakis et al. 2001).  Karayiannakis et al. also reported 
that elevated levels of TNF-α were associated with reduced body weight and body 
mass index and a greatly reduced serum protein level (Karayiannakis et al. 2001).  
Over-expression of TNF-α has also been shown to promote skeletal muscle 
wasting.  Two studies have analysed the effect of injecting TNF-α-secreting 
Chinese hamster ovary (CHO) cells into nude mice.  Results indicated that 
continual release of TNF-α into the nude mice promoted the development of 
severe cachexia (Oliff et al. 1987; Tracey et al. 1990).   
Several in vitro studies have provided insights into the possible mechanism 
through which cytokines function.  Over-expression of TNF-α in the C2C12 
system enhanced cell proliferation, however the increased levels of TNF-α 
reduced the expression of MyoD and myogenin and prevented the appearance of 
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myogenic differentiation markers such as myosin heavy chain (MHC) (Szalay et 
al. 1997).  Guttridge et al. have further studied the role of TNF-α in regulation of 
MyoD and skeletal muscle differentiation.  TNF-α-mediated NF-κB activation 
resulted in inhibition of MyoD, with subsequent inhibition of differentiation.  
Furthermore, it was reported that TNF-α, in conjunction with interferon-γ (IFN-γ), 
was required for down-regulation of MyoD in differentiated myotubes (Guttridge 
et al. 2000).  TNF-α is a potent activator of NF-κB.  Indeed, TNF-α has been 
shown to promote ubiquitin-mediated degradation of the NF-κB inhibitor IκBα, 
resulting in enhanced NF-κB binding to its target sequence (Li et al. 1998).  
Furthermore, Li and Reid generated C2C12 stable cell lines transfected with 
constructs expressing a mutated form of IκBα, which is resistant to ubiquitin-
mediated degradation and thus functions to selectively inhibit NF-κB signalling.  
In control cells, treatment with TNF-α resulted in a reduction in protein content 
and myosin expression, while in mutant cell lines no effect on protein or myosin 
levels were detected.  Thus it was suggested that NF-κB is required for TNF-α-
mediated proteolysis (Li and Reid 2000).  TNF-α has been demonstrated to result 
in enhancement of the ubiquitin-proteasome pathway.  Indeed, administration of 
TNF-α was shown to increase the levels of ubiquitin-conjugated proteins (Garcia-
Martinez et al. 1993).  Conversely, inhibition of TNF-α, through injection of anti-
TNF antibodies, inhibited TNF-α-mediated up-regulation of ubiquitin and the 
proteasome subunit C-8 in AH-130 tumour-bearing rats (Llovera et al. 1996).  
More recently it has been demonstrated that in vitro and in vivo addition of TNF-
α, resulted in an up-regulation of atrogin-1 mRNA expression (Li et al. 2005a).  
Li et al. further demonstrated that the TNF-α-induced up-regulation of atrogin-1 
is mediated through the p38 mitogen-activated protein kinase (MAPK) signalling 
pathway.  Treatment of C2C12 myoblasts with TNF-α has been shown to induce 
apoptosis (Stewart et al. 2004).  Furthermore, Tolosa et al. have demonstrated that 
treatment with IFN-γ prevented TNF-α-mediated apoptosis in C2C12 cells, 
through targeted down-regulation of the subtype 2 TNF-α receptor (TNF-R2) 
(Tolosa et al. 2005). 
Recently, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) has 
been shown to regulate myoblast differentiation (Dogra et al. 2006).  Treatment 
with TWEAK resulted in activation of the NF-κB signalling cascade and 
inhibition of differentiation in C2C12 and primary myoblasts.  Furthermore, 
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TWEAK inhibited the expression of MyoD and myogenin and also promoted 
MyoD degradation.  Therefore, Dogra et al suggested that TWEAK negatively 
regulates myogenesis through preceding activation of NF-κB and degradation of 
MyoD. 
In addition to TNF-α, the interleukin family of cytokines play important roles in 
the progression of skeletal muscle wasting.  The anorectic cytokine interleukin-1 
(IL-1) has been associated with diminished food intake and subsequent induction 
of anorexia (Hellerstein et al. 1989; Laviano et al. 1999).  However, the role of 
IL-1 in cachexia is a matter of contention.  Indeed, injection of an IL-1 receptor 
antagonist failed to ameliorate the symptoms of cancer-induced cachexia (Argiles 
et al. 2005).  Interleukin-1β (IL-1β) has been shown to impair IGF-1-dependent 
C2C12 myoblast differentiation, resulting in the inhibition of protein synthesis 
and a reduction in the expression of myogenin and myosin (Broussard et al. 
2004).  Interleukin-6 (IL-6) has been implicated in the progression of cachexia.  
Increased serum levels of IL-6 are detected in patients with Hodgkin’s lymphoma 
(Kurzrock et al. 1993).  Furthermore, increased circulating levels of IL-6 were 
detected in non-small-cell lung cancer patients with associated weight loss (Scott 
et al. 1996).  Conversely, treatment of colon-26 tumour-bearing mice with the IL-
6 specific antagonist, 20S, 21-epoxy-resibufogenin-3-acetate (ERBA), greatly 
reduced the body weight loss associated with this model of cancer cachexia 
(Enomoto et al. 2004). In addition, antibody-mediated inhibition of IL-6, inhibits 
the severe cachexia associated with injection of human melanoma and prostate 
cells into nude mice (Zaki et al. 2004).  Subcutaneous injection of IL-6 has also 
been shown to induce myocardial dysfunction with associated skeletal muscle 
atrophy (Janssen et al. 2005).  Furthermore, Haddad et al. demonstrated that 
administration of IL-6 to rats resulted in skeletal muscle atrophy concomitant with 
a reduction of myofibrillar protein (Haddad et al. 2005).  
Another cytokine of particular interest with respect to cachexia is interferon-γ 
(IFN-γ).  IFN-γ is produced by activated T and natural killer cells and shares 
common functions to those of TNF-α (Argiles et al. 2005).  Matthys et al. 
demonstrated that injection of IFN-γ-specific monoclonal antibodies into a 
tumour-bearing (Lewis lung carcinoma; LLC) mouse model alleviated the muscle 
loss associated with the presence of this tumour (Matthys et al. 1991).  In 
addition, severe cachexia develops in nude mice following injection of CHO cells 
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constitutively expressing IFN-γ (Matthys et al. 1991).  More recently, a study by 
Acharyya et al. has demonstrated a dual requirement for TNF-α and IFN-γ in 
suppression of the myofibrillar protein myosin (Acharyya et al. 2004).  
 
1.3.4.2  Proteolysis-inducing factor (PIF) 
The sulfated glycoprotein proteolysis-inducing factor (PIF) was initially purified 
from the cachexia-inducing MAC16 colon adenocarcinoma (McDevitt et al. 
1995).  PIF is detected in urine samples of cancer patients who have experienced 
weight loss, while in contrast, PIF is absent in urine from cancer patients with no 
associated weight loss, suggesting a role for PIF in the cachectic state associated 
with cancer (Cariuk et al. 1997).  Injection of PIF into mice has been shown to 
result in 10% body weight loss, which was accounted for in equal amounts by 
increased protein degradation and decreased protein synthesis (Lorite et al. 1997).  
Furthermore, Smith et al. have demonstrated that treatment of C2C12 myoblasts 
with PIF resulted in a dose-dependent decrease in protein synthesis, concomitant 
with an increased rate of protein degradation through a mechanism involving 
increased production of 15-hydroxyeicosatetraenoic acid (15-HETE) (Smith et al. 
1999).  The ATP-dependent ubiquitin-proteasome pathway appears to be the 
major mechanism through which PIF induces skeletal muscle proteolysis.  Indeed 
exposure of MAC16 tumour-bearing mice to PIF results in enhanced levels of 
ubiquitin-conjugated proteins and increased mRNA expression of E214k and the C-
9 proteasome subunit (Lorite et al. 1998).  Similarly, injection of PIF into normal 
mice resulted in an increase in mRNA expression of ubiquitin, E214k, and the C-9 
proteasome sub-unit.  Furthermore, enhanced protein expression of the 20S and 
19S proteasome components was observed following injection of PIF (Lorite et 
al. 2001).  More recently, addition of PIF to C2C12 myotubes has been shown to 
result in enhanced protein degradation with an associated increase in the mRNA 
expression of proteasome C-2 and C-5 subunits (Wyke et al. 2005).  PIF has also 
been shown to interact with the NF-κB signalling pathway.  Whitehouse and 
Tisdale demonstrated that addition of PIF to C2C12 myotubes reduced the levels 
of the NF-κB inhibitor IκBα and also enhanced the nuclear entry of NF-κB 
(Whitehouse and Tisdale 2003).  More recently, Wyke and Tisdale have studied 
the involvement of the NF-κB in PIF-mediated proteolysis.  In this study C2C12 
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cells were transfected with a construct harboring a mutant form of the NF-κB 
inhibitor IκBα, which is resistant to ubiquitin-proteasome degradation, and thus 
acts as a potent inhibitor of NF-κB mediated transcription.  In the presence of 
mutant IκBα, administration of PIF was unable to induce protein degradation and 
loss of myosin in the C2C12 cell line.  Furthermore, PIF-mediated up-regulation 
of the 20S and 19S proteasome sub-units and the E214k conjugating enzyme was 
abolished in the presence of mutated IκBα (Wyke and Tisdale 2005).  Therefore, 
it is suggested that functional NF-κB signalling is critical for the ability of PIF to 
induce protein degradation and the expression of members of the ubiquitin-
proteasome pathway (Wyke and Tisdale 2005). 
 
1.3.4.3  Insulin-like growth factor-1 (IGF-1) 
Insulin-like growth factor-1 (IGF-1) is a positive regulator of skeletal muscle 
mass and has critical functions in regulating growth, repair and maintenance of 
skeletal muscle (Heszele and Price 2004; Glass 2005).  Furthermore, IGF-1 
appears to play a major role in regulating increases in skeletal muscle mass or 
hypertrophy.  Indeed, skeletal muscle hypertrophy is accompanied by an increase 
in the expression of IGF-1 (DeVol et al. 1990).  Furthermore, muscle-specific 
over-expression of IGF-1 in mice results in a dramatic increase in skeletal muscle 
hypertrophy, while mice over-expressing a muscle-specific dominant-negative 
form of the IGF-1 receptor exhibit reduced skeletal muscle mass and hypoplasia 
(Musaro et al. 2001; Fernandez et al. 2002).  In contrast, treatment of C2C12 
myotubes with IGF-1 results in myotube hypertrophy (Rommel et al. 2001).  
Rommel et al. have further highlighted a potential mechanism through which 
IGF-1 regulates skeletal muscle hypertrophy, specifically, IGF-1 was shown to 
induce hypertrophy through the phosphatidylinositol 3-kinase (PI3-K)-AKT 
pathway.  Briefly, IGF-1 receptor binding initiates activation of PI3-K; once 
activated, PI3-K facilitates binding of AKT to the cell membrane, where it is 
subsequently phosphorylated and activated by the 3-phosphoinositide-dependent 
protein kinase PDK-1.  AKT is the downstream mediator of IGF-1 signalling and 
affects several downstream targets, including mTOR and GSK3 which are both 
implicated in IGF-1-mediated skeletal muscle hypertrophy (Rommel et al. 2001; 
Vivanco and Sawyers 2002). 
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Several studies have highlighted a critical role for IGF-1 in the prevention of 
skeletal muscle atrophy.  Muscle-specific over-expression of IGF-1 in the mdx 
mouse model of DMD alleviates the dramatic muscle loss associated with this 
disease (Barton et al. 2002).  Specifically, increased IGF-1 expression resulted in 
a 40% increase in M. extensor digitorum longus (EDL) muscle mass with an 
associated improvement in muscle force production (Barton et al. 2002).  
Furthermore, Sacheck et al. have demonstrated that treatment of C2C12 myotube 
cultures with IGF-1 prevents Dex-mediated proteolysis, concomitant with a rapid 
down-regulation of atrogin-1 mRNA expression (Sacheck et al. 2004).  In 
addition, transgenic mice over-expressing skeletal muscle specific IGF-1 were 
shown to be resistant to angiotensin-II-mediated skeletal muscle loss (Song et al. 
2005).  Song et al further demonstrated that over-expression of IGF-1 blocked 
angiotensin-II-induced expression of the ubiquitin E3 ligases Atrogin-1 and 
MuRF-1.  Thus IGF-1-mediated inhibition of skeletal muscle proteolysis may be 
due to regulation of the ubiquitin-proteasome pathway.   
The Forkhead box O (FoxO) class of transcription factors, consisting of FoxO1 
(FKHR), FoxO3 (FKHRL1) and FoxO4 (AFX) (Barthel et al. 2005), are reported 
targets of the IGF-1/PI3-K/AKT pathway.  Indeed, activation of the PI3-K/AKT 
pathway results in the phosphorylation of FoxO proteins.  The phosphorylated 
FoxO proteins are subsequently excluded from the nucleus, resulting in an 
inhibition of FoxO-mediated transcription (Brunet et al. 1999).  In support, AKT 
has been shown to block FoxO1-mediated transcription through specific 
phosphorylation of FoxO1 at three different phospho-acceptor sites (Tang et al. 
1999).  Interestingly, deactivation of the IGF-1/PI3-K/AKT pathway highlights a 
connection between FoxO activation and the transcriptional regulation of 
ubiquitin components during atrophy.  Indeed, angiotensin-II-induced muscle 
wasting is associated with dephosphorylation of AKT, FoxO1, and FoxO3 with a 
subsequent increase in the mRNA expression of atrogin-1 and MuRF-1 (Song et 
al. 2005).  A similar pattern of gene regulation is observed in starvation and 
dexamethasone-induced myotube atrophy in vitro (Sandri et al. 2004).  
Furthermore FoxO3 has been shown to directly activate the atrogin-1 promoter in 
a mouse model of starvation; conversely, siRNA-mediated knock-down of FoxO 
proteins prevented atrogin-1 promoter up-regulation.  Thus it is suggested that 
FoxO transcription factors play a critical role in the progression of skeletal muscle 
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atrophy (Sandri et al. 2004).  Therefore it is apparent that the IGF-1/PI3-K/AKT 
pathway is critical in regulating FoxO protein function; moreover it is suggested 
that the IGF-1/PI3-K/AKT pathway prevents the induction of the ubiquitin E3 
ligases Atrogin-1 and MuRF-1 through AKT-mediated phosphorylation and 
inactivation of FoxO1 (Stitt et al. 2004).   
 
1.3.4.4  Myostatin 
The secreted growth factor myostatin is involved in the negative regulation of 
skeletal muscle mass.  A number of studies have implicated myostatin in the 
regulation of skeletal muscle wasting, and recent data has highlighted an 
involvement of myostatin in ubiquitin-mediated degradation (see Section 1.4.5.4).  
A detailed review of myostatin biology and physiological effects is discussed in 
the following section (see Section 1.4). 
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1.4  Myostatin 
 
1.4.1  The myostatin gene, structure and processing 
Myostatin, or growth and differentiation factor-8 (GDF-8), is a TGF-β 
superfamily member that was initially characterised in 1997 as a specific regulator 
of skeletal muscle mass in mice (McPherron et al. 1997).  Targeted disruption of 
the myostatin gene in mice (Figure 1.5A and Figure 1.5B) resulted in a 
generalised increase in skeletal muscle mass (double-muscling); in particular a 2-
3-fold increase in muscle weight was observed with no corresponding increase in 
adipose tissue (Figure 1.5A and Figure 1.5B).  The enhanced muscle phenotype in 
the myostatin-null mice was determined to result from a combination of both 
muscle hyperplasia and hypertrophy (McPherron et al. 1997).   
 
 
 
Figure 1.5  Double-muscling in myostatin-null mice 
A)  Photograph showing the difference between the forelimbs of wild-type and 
myostatin-null mice.  A dramatic increase in skeletal muscle mass is observed in 
the myostatin-null mice compared to wild-type mice (adapted from McPherron et 
al. 1997).  B)  Photograph showing the size difference between wild-type and 
myostatin-null mice at the same age.  Myostatin-null mice were generated by 
McPherron et al. (1997).  
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Myostatin has a number of characteristics common to the TGF-β superfamily 
(Figure 1.6).  In particular, the precursor Myostatin molecule contains an N-
terminal (NH2) core of hydrophobic amino acids that functions as a signal 
sequence for secretion (McPherron et al. 1997).  In addition, the C-terminal 
(COOH) region of Myostatin contains nine conserved cysteine residues which are 
critical for homodimerisation and for the formation of the “cysteine knot” 
structure, a characteristic feature of the TGF-β superfamily (McPherron and Lee 
1996; McPherron et al. 1997).  Furthermore, Myostatin is synthesised as a 376 
amino acid precursor protein which, like other members of the TGF-β 
superfamily, is proteolytically cleaved at the RSRR site (Figure 1.6), a process 
which may occur within the Golgi apparatus under the control of the serine 
protease furin or other members of the proprotein convertase family (McPherron 
et al. 1997; Sharma et al. 1999; Lee and McPherron 2001).  The importance of 
proteolytic processing is clear, as generation of a dominant-negative form of 
Myostatin, through mutation of the RSRR site to the amino acids GLDG, results 
in widespread skeletal muscle hypertrophy (Zhu et al. 2000).  Cleavage of the 52 
kDa precursor protein at the RSRR site has been reported to result in the 
formation of a 36/40 kDa Latency-Associated Peptide (LAP) and a 12.5/26 kDa 
mature portion, which is suggested to correspond to a C-terminal monomer or 
dimer respectively (Thomas et al. 2000; Lee and McPherron 2001; McFarlane et 
al. 2005).   
 
 
 
 
 
 
Figure 1.6  The structure of myostatin 
Schematic representation of the structure of Myostatin.  Myostatin shares 
characteristics common to the TGF-β superfamily, including a signal peptide (SP) 
for secretion and a RSRR proteolytic processing site.  Proteolytic processing of 
Myostatin gives rise to LAP and mature Myostatin regions.  Adapted from Joulia-
Ekaza and Cabello (Joulia-Ekaza and Cabello 2006).   
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1.4.2  Expression of myostatin 
Myostatin is first detected in mice embryos at day 9.5 post-coitum, where it is 
specifically located within the most rostral somites (McPherron et al. 1997).  By 
day 10.5 post-coitum, myostatin is expressed in the majority of the somites, 
specifically located in the myotome layer of developing somites (McPherron et al. 
1997).  In cattle, low levels of myostatin mRNA are detected in day 15 to day 29 
embryos with increasing expression detected from day 31 onwards (Kambadur et 
al. 1997; Bass et al. 1999; Oldham et al. 2001).  Furthermore, in the pig foetus 
myostatin mRNA expression is abundant at days 21 and 35 of gestation, with an 
increase in expression by day 49 (Ji et al. 1998).  In the chicken myostatin 
expression is first detected as early as embryonic day 0 (the blastoderm stage) 
with relatively low levels detected through to embryonic day 6.  From day 7, 
myostatin mRNA levels rapidly increase and level off through to day 16 (Kocamis 
et al. 1999).  Post-natal skeletal muscle continues to express myostatin, although 
variation in myostatin expression is observed between individual muscles 
(Kambadur et al. 1997; McPherron et al. 1997).  The expression of myostatin is 
primarily restricted to skeletal muscle (Kambadur et al. 1997; McPherron et al. 
1997; Ji et al. 1998; Bass et al. 1999; Carlson et al. 1999; Kocamis et al. 1999; 
Sazanov et al. 1999; Jeanplong et al. 2001; Oldham et al. 2001), however, low 
levels of myostatin expression have been detected in various other tissues; in 
particular in the secretory lobules of lactating mammary glands (Ji et al. 1998), in 
adipose tissue (McPherron et al. 1997), and in cardiomyocytes and Purkinje fibres 
of the heart (Sharma et al. 1999).  More recently it has been shown that both 
myostatin mRNA and protein are expressed in human placental tissue.  The 
presence of myostatin in the placenta is suggested to be involved with uptake of 
glucose (Mitchell et al. 2006). 
Myostatin expression may also be associated with specific fibre types in skeletal 
muscle.  Carlson et al. have shown that higher amounts of myostatin mRNA and 
protein are detected in fast-twitch muscle (type-II fibres) as compared to slow-
twitch muscle (type-I fibres) (Carlson et al. 1999).  Furthermore, it has been 
shown that in myostatin-null mice there is an increase in fast fibres (type-II) in the 
typically slow fibre-dominated M. soleus muscle, and a switch from oxidative 
(type-IIA) to glycolytic fibres (type-IIB) in the predominantly fast-twitch EDL 
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muscle (Girgenrath et al. 2005).  Therefore, suggesting a fibre type-specific role 
for Myostatin in regulation of muscle physiology. 
 
1.4.3  Regulation of myostatin 
Myostatin is synthesised as a precursor protein, proteolytically processed and 
secreted to elicit its biological function.  Studies have highlighted the importance 
of several proteins that interact with myostatin to regulate its action.  Myostatin 
has been shown to interact with the sarcomeric protein Titin-cap (Nicholas et al. 
2002); specifically, titin-cap interacts with the C-terminal mature portion of 
Myostatin (Nicholas et al. 2002).  Over-expression of titin-cap had no effect on 
Myostatin synthesis and processing, however, increased titin-cap expression 
results in enhanced cell proliferation and accumulation of processed Myostatin 
within myoblasts.  Thus titin-cap appears to function by regulating the secretion 
of mature Myostatin (Nicholas et al. 2002).  In addition, human small glutamine-
rich tetratricopeptide repeat-containing protein (hSGT) has been shown to 
associate with intracellular myostatin (Wang et al. 2003).  The C-terminal region 
of hSGT and the N-terminal signal peptide region of Myostatin were shown to be 
critical for this interaction.  It is suggested that hSGT likely plays a role in 
mediating Myostatin secretion and activation (Wang et al. 2003).  Latent TGF-β 
binding proteins (LTBPs) are extracellular matrix proteins which have been 
previously identified to interact with the TGF-β superfamily (Saharinen et al. 
1999).  LTBPs associate with TGF-β superfamily members to allow for secretion; 
once secreted, removal of LTBPs from the latent complex is essential for TGF-β 
activation (Saharinen et al. 1999).  Although LTBPs play an essential role in the 
secretion and activation of TGF-β superfamily members, published results from 
this thesis suggest that LTBPs do not play a role in the regulation of myostatin 
(McFarlane et al. 2005).  Following secretion, the majority of Myostatin (>70%), 
like TGF-β, has been shown to exist in an inactive latent complex both in vitro 
and in vivo, whereby the mature processed portion of Myostatin is bound non-
covalently to the propeptide (LAP) region of Myostatin (Lee and McPherron 
2001; Thies et al. 2001; Yang et al. 2001).  Recently it has been demonstrated that 
members of the bone morphogenetic protein-1/tolloid (BMP-1/TLD) family can 
cleave the Myostatin LAP region from the latent Myostatin complex, thus 
 35
resulting in activation of mature Myostatin (Wolfman et al. 2003).  Furthermore, 
Wolfman et al. demonstrated that a mutation of LAP to confer resistance to 
cleavage by BMP/TLD resulted in enhanced muscle mass in vivo.  Previous 
studies have demonstrated that follistatin is capable of binding and inhibiting 
various members of the TGF-β superfamily (Michel et al. 1993; Hemmati-
Brivanlou et al. 1994; Fainsod et al. 1997).  Follistatin has been shown to bind 
directly to the mature portion of Myostatin blocking the ability of Myostatin to 
bind with the ActRIIB receptor (Lee and McPherron 2001).  Furthermore, 
interaction with follistatin interferes with the intrinsic ability of myostatin to 
inhibit muscle differentiation (Amthor et al. 2004) (reviewed in Section 1.4.5.2).  
In support, mice over-expressing follistatin show a drastic increase in muscle 
mass, significantly greater than that of myostatin-null animals (Lee and 
McPherron 2001).  Additionally, follistatin-null mice demonstrate reduced muscle 
mass at birth (Matzuk et al. 1995), consistent with increased myostatin activity.  
Follistatin-related gene (FLRG), like follistatin, is able to bind and inhibit 
members of the TGF-β superfamily (Tsuchida et al. 2000; Schneyer et al. 2001; 
Tsuchida et al. 2001).  In addition, FLRG has been shown to interact directly with 
the mature portion of Myostatin, resulting in a dose-dependent reduction in the 
activity of myostatin, as assessed through reporter gene assay analysis (Hill et al. 
2002).  Growth and differentiation factor-associated serum protein-1 (GASP-1) 
has been shown to associate with Myostatin in circulation; specifically associating 
with both mature and LAP regions of Myostatin.  Functionally GASP-1 has been 
shown to interfere with the activity of myostatin as determined by reporter gene 
analysis (Hill et al. 2003).  More recently, decorin, a leucine-rich repeat 
extracellular proteoglycan, has been shown to interact with the mature region of 
Myostatin, in a Zn2+-dependent manner (Miura et al. 2006).  This interaction was 
demonstrated to relieve the inhibitory effect of myostatin on myoblast 
proliferation in vitro.  One of the intrinsic features of myostatin is its ability to 
negatively auto-regulate its expression.  In particular, exogenous addition of 
recombinant Myostatin protein results in both a decrease in myostatin mRNA and 
repression of myostatin promoter activity (Forbes et al. 2006).  Furthermore, 
myostatin appears to signal through Smad7 to regulate its own activity (Zhu et al. 
2004; Forbes et al. 2006).  In support, addition of Myostatin resulted in enhanced 
Smad7 expression, while over-expression of Smad7 resulted in repression of 
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myostatin promoter activity and mRNA, an effect abolished through incubation 
with siRNA specific for Smad7 (Zhu et al. 2004; Forbes et al. 2006).   
 
1.4.4  Mutations in myostatin 
In addition to the targeted disruption of myostatin in mice, several naturally 
occurring mutations have been identified in various double-muscled cattle breeds 
including Belgian Blue (Figure 1.7A) and Piedmontese (Kambadur et al. 1997; 
McPherron and Lee 1997; Grobet et al. 1998).  Specifically two separate 
mutations in the coding region of the myostatin gene have been reported to result 
in a non-functional Myostatin product.  The phenotype seen in Belgian Blue cattle 
(Figure 1.7A) is caused by an 11-nucleotide deletion, which ultimately results in 
expression of a non-functional truncated protein product (Kambadur et al. 1997).  
Conversely, the Piedmontese cattle express a non-functional Myostatin protein 
through a missense mutation in the gene sequence, resulting in a G to A transition 
and substitution of cysteine for tyrosine (Kambadur et al. 1997; Berry et al. 2002).  
Furthermore, a mutation in the myostatin gene has been reported to result in the 
hyper-muscularity observed in compact (Cmpt) mice (Szabo et al. 1998).  More 
recently, the heavy muscled phenotype of the Texel sheep breed has been traced 
to a mutation in the myostatin gene resulting in a G to A transition in the 3’ 
untranslated region (UTR) (Clop et al. 2006).  This mutation creates a target site 
for two microRNAs abundant in skeletal muscle, namely mir1 and mir206 (Clop 
et al. 2006).  MicroRNAs are short non-coding RNAs which diminish gene 
activity post-transcriptionally by binding to target genes, resulting in 
destabilisation of mRNA and/or inhibition of protein translation (Tsuchiya et al. 
2006). 
A mutation in the myostatin gene has recently been shown to result in dramatic 
hypertrophy in a human child (Schuelke et al. 2004) (Figure 1.7B).  Cross-
sectional measurements determined that the M. quadriceps muscle was more than 
two-fold larger than age- and sex-matched controls, while the thickness of the 
sub-cutaneous fat pad was significantly lower than controls.  The mutation was 
shown to result from a G to A transition within intron 1 of the myostatin gene.  
This transition resulted in mis-splicing of the precursor mRNA and insertion of 
the first 108 base pairs of intron 1 (Schuelke et al. 2004).   
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Figure 1.7  Natural mutations in myostatin 
A)  Photograph showing the heavy muscling observed in the Belgian Blue cattle 
breed (reproduced from Haliba ’96 Catalogue).  B)  Photograph of a human child 
at 7 months of age possessing a G to A transition mutation in the myostatin gene, 
resulting in a non functional Myostatin protein product.  Arrows highlight 
protruding muscles from the boy’s calf and thigh regions.  Modified from 
Schuelke et al. (Schuelke et al. 2004).   
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1.4.5  Physiological actions of myostatin 
 
1.4.5.1  Myostatin signaling 
Members of the TGF-β superfamily elicit biological functions by binding to 
specific type-I and type-II serine/threonine kinase receptors.  Studies have shown 
that Myostatin specifically binds to the activin type-IIB (ActRIIB) receptor (Lee 
and McPherron 2001; Rebbapragada et al. 2003).  Indeed, transgenic mice that 
over-express a dominant-negative form of the ActRIIB show a drastic increase in 
muscle weights, similar to that seen in myostatin-null mice (Lee and McPherron 
2001).  Myostatin-mediated type-II receptor activation results in the 
phosphorylation of the type-I receptor, either activin receptor-like kinase 4 
(ALK4) or ALK5, which in turn initiates downstream signaling events 
(Rebbapragada et al. 2003). 
TGF-β superfamily signalling is primarily mediated through substrates known as 
Smads (Piek et al. 1999).  Smad proteins can be separated into three sub-groups: 
the receptor Smads (R-Smads; Smads 1, 2, 3, 5 and 8), the common Smad (Co-
Smad; Smad 4) and the inhibitory Smads (I-Smads; Smads 6 and 7) (Piek et al. 
1999).  Phosphorylation of the R-Smads occurs at the type-I receptor, the now 
active R-Smad heterodimerises with the Co-Smad and translocates to the nucleus 
to regulate transcription (Nakao et al. 1997b; Souchelnytskyi et al. 1997; Zhang et 
al. 1997).  Inhibitory Smads can compete with R-Smads for receptor binding and 
Co-Smad heterodimerisation, thus blocking Smad-mediated signaling (Hayashi et 
al. 1997; Nakao et al. 1997a; Hata et al. 1998).  Consistent with other members of 
the TGF-β superfamily, myostatin has been shown to signal specifically through 
Smads 2/3 with the involvement of Smad 4 (Zhu et al. 2004).  In addition, it 
appears that myostatin-mediated Smad signaling is negatively regulated by Smad 
7 but not Smad 6 (Zhu et al. 2004).  Furthermore, myostatin has also been shown 
to induce the expression of Smad 7.  Interestingly, this induction of Smad 7 
appears to provide an auto-regulatory mechanism through which myostatin 
negatively regulates its own activity (Zhu et al. 2004; Forbes et al. 2006).   
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1.4.5.2  Regulation of proliferation and differentiation 
It has been previously shown that myostatin is a negative regulator of skeletal 
muscle growth, in support, naturally occurring mutations or targeted disruption of 
the myostatin gene result in increased muscle mass (Kambadur et al. 1997; 
McPherron et al. 1997).  Several cell culture based studies have analysed the role 
of myostatin in the regulation of cell proliferation.  Myostatin has been shown to 
negatively regulate skeletal muscle growth through inhibiting the proliferation of 
myoblast cell lines in a dose-dependent, reversible manner (Thomas et al. 2000).  
In support, primary myoblasts isolated from myostatin-null mice proliferate 
significantly faster than myoblast cultures from wild-type mice (McCroskery et 
al. 2003).  More recently, myostatin has been demonstrated to reversibly inhibit 
the proliferation of Pax7-positive myogenic precursor cells in embryos injected 
with Myostatin-coated beads (Amthor et al. 2006).  Mechanistically, myostatin 
appears to interact with the cell cycle machinery, resulting in cell cycle exit during 
the gap phases (G1 and G2) (Thomas et al. 2000).  Specifically, treatment with 
Myostatin results in up-regulation of the cyclin-dependent kinase inhibitor (CKI), 
p21 (Thomas et al. 2000).  p21 is a member of the Cip/Kip family of CKIs which, 
as their name suggests, block the action of cyclin-dependent kinases and their 
cyclin partners (Harper et al. 1993; Xiong et al. 1993).  Consistent with this, 
treatment with recombinant Myostatin protein has been shown to decrease the 
expression and activity of cyclin-dependent kinase 2 (cdk2) (Thomas et al. 2000).  
The myostatin-mediated loss in cdk2 activity resulted in accumulation of 
hypophosphorylated retinoblastoma (Rb), which in turn induces cell cycle arrest 
in the G1 phase.  A recent report has highlighted a role for the p38 mitogen-
activated protein kinase (MAPK) signaling pathway in myostatin regulation of 
myogenesis (Philip et al. 2005).  In particular, myostatin has been shown to 
activate p38 MAPK; moreover this activation was shown to augment myostatin-
mediated transcription.  Furthermore, p38 MAPK was shown to play an important 
role in myostatin-mediated up-regulation of p21 and subsequent inhibition of cell 
proliferation (Philip et al. 2005).  More recently, myostatin has been shown to 
inhibit the proliferation of the rhabdomyosarcoma cell line, RD (Langley et al. 
2004).  However, unlike normal myoblasts, treatment with Myostatin did not up-
regulate the expression of p21 or alter the phosphorylation or activity of Rb.  
Langley et al. demonstrated that treatment with Myostatin resulted in a reduction 
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in expression and activity of cdk2 and cyclin E.  NPAT is a substrate of 
cdk2/cyclinE and is critical for the continuation of the cell cycle at the G1/S 
checkpoint.  Thus treatment of the RD cell line with Myostatin also reduced the 
phosphorylation of NPAT, concomitant with a reduction in the expression of the 
NPAT target histone-H4 (Langley et al. 2004).   
In addition to the intrinsic ability of myostatin to regulate myoblast proliferation, 
myostatin has been shown to negatively regulate myogenic differentiation.  
(Langley et al. 2002; Rios et al. 2002).  In particular, treatment of myoblasts with 
recombinant Myostatin protein resulted in a dose-dependent reversible inhibition 
of differentiation (Langley et al. 2002).  Furthermore, treatment of differentiating 
myoblasts with Myostatin inhibited the mRNA and protein expression of MyoD, 
Myf5, myogenin and MHC (Langley et al. 2002; Rios et al. 2002).  Langley et al. 
further demonstrated that during differentiation, treatment with Myostatin 
increased the phosphorylation of Smad 3 and enhanced Smad 3•MyoD 
interaction.  MyoD is critical for the successful commitment to myogenic 
differentiation, and furthermore MyoD has been shown to induce cell cycle arrest 
and induce differentiation through up-regulation of p21.  Thus, Langley et al 
proposed that myostatin blocked myogenic differentiation by inhibiting the 
expression and activity of MyoD in a Smad 3-dependent manner.  Recently a role 
for the extracellular signal-regulated kinase 1/2 (Erk1/2) MAPK signaling 
pathway has been identified in myostatin regulation of myogenesis (Yang et al. 
2006).  Indeed, inhibition of the Erk1/2 pathway suppressed myostatin-mediated 
inhibition of myoblast proliferation and differentiation and further interfered with 
the ability of myostatin to inhibit the expression of genes critical to myogenic 
differentiation, including MyoD, myogenin and MHC (Yang et al. 2006).   
 
1.4.5.3  Post-natal muscle growth and repair 
Myostatin expression is detected during embryonic and foetal growth and is 
maintained through into adult muscle tissue, thus myostatin may be an important 
mediator of skeletal muscle mass throughout myogenesis.  Indeed myostatin 
appears to play a critical role in the regulation of post-natal muscle growth and 
repair.  Several studies have analysed the effect of post-natal modification of 
myostatin on skeletal muscle mass.  Over-expression of a dominant-negative 
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Myostatin, whereby the RSRR processing site was mutated to GLDG, resulted in 
a 25-30% increase in skeletal muscle mass in mice; specifically resulting from 
increased hypertrophy rather than hyperplasia (Zhu et al. 2000).  In contrast, 
recapitulation of the Piedmontese cattle C313Y mis-sense mutation in mice results 
in skeletal muscle hyperplasia without muscle hypertrophy (Nishi et al. 2002).  
Furthermore, injection of the JA16 monoclonal Myostatin-neutralising antibody 
into mice resulted in an increase in skeletal muscle mass (Whittemore et al. 2003).  
It was determined that incubation with the JA16 antibody for 2-4 weeks was 
sufficient to induce an increase in muscle mass as compared to control mice.  
Concomitant to an effect on muscle mass, injection of the neutralising antibody 
increased the grip strength of treated mice, specifically a 10% increase in peak 
force was observed (Whittemore et al. 2003).  Another study focussed on the 
effect of conditionally targeting myostatin for inactivation using the cre-lox 
system.  Subsequent inactivation of myostatin resulted in skeletal muscle 
hypertrophy phenotypically similar to that observed in myostatin-null mice 
(Grobet et al. 2003).  More recently, an increase in muscle mass was observed 
following injection of a myostatin-specific short interfering RNA (siRNA) 
directly into the M. tibialis anterior (TA) muscle of rats (Magee et al. 2006).  The 
siRNA-mediated knock-down resulted in a 27% drop in myostatin mRNA and a 
48% drop in Myostatin protein expression.  Furthermore, myostatin inhibition 
resulted in an increase in TA muscle weight and myofibre area.  Satellite cell 
number was also increased 2-fold, as quantified by the number of Pax7-positive 
cells (Magee et al. 2006).  Thus inhibitors directed against myostatin may have 
therapeutic benefit in circumstances where skeletal muscle wasting enhances the 
morbidity or mortality of a disease.   
Myostatin has been demonstrated to be involved in the regulation of skeletal 
muscle regeneration.  A recent study has compared the regeneration process of 
skeletal muscle in myostatin-null mice versus wild-type controls following 
injection of the myotoxin, notexin (McCroskery et al. 2005).  Following injury, 
satellite cell-derived myoblasts migrate to the site of injury to help repair the 
damage (Watt et al. 1987; Watt et al. 1994). Muscle damage is closely followed 
by a localised inflammatory response resulting in the influx of macrophages to the 
site of injury (Tidball 1995).  Interestingly, McCroskery et al. found that lack of 
myostatin increased the rate of myogenic cell migration and the rate of 
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macrophage infiltration to the site of injury, resulting in enhanced numbers of 
both.  Furthermore, presence of recombinant Myostatin protein in vitro 
significantly reduced the migration of both myoblasts and macrophages in 
chemotaxis chambers (McCroskery et al. 2005).  The formation of scar tissue is a 
prominent feature of skeletal muscle injury.  However, during the process of 
regeneration the presence of scar tissue was greatly reduced in regenerated muscle 
from myostatin-null as compared with muscle from wild-type mice.  Thus, in 
addition to regulating the involvement of satellite cells and macrophages in 
muscle regeneration, myostatin may also contribute to skeletal muscle fibrosis 
(McCroskery et al. 2005).   
Satellite cells are responsible for maintaining and repairing skeletal muscle mass 
following injury (reviewed in Section 1.2).  Recently myostatin has been shown to 
play a role in regulating satellite cell activation, growth and self-renewal 
(McCroskery et al. 2003).  Myostatin is expressed within muscle satellite cells 
and satellite cell-derived primary myoblasts.  Specifically, satellite cells, 
characterised through positive Pax7 staining, were also positive for Myostatin by 
immunocytochemistry.  Furthermore, in situ hybridisation confirmed high 
expression of both pax7 and myostatin mRNA in satellite cells (McCroskery et al. 
2003).  In addition, McCroskery et al. also demonstrated that abundant expression 
of myostatin could be detected by both RT-PCR and Western Blot analysis in 
isolated satellite cells and satellite cell-derived myoblasts.  Functionally, 
myostatin appears to negatively regulate the activation and proliferation of 
satellite cells.  In particular, increased satellite cell activation, quantified by 
percentage of BrdU positive cells, is observed in satellite cells isolated from 
myostatin-null mice as compared to wild-type controls (McCroskery et al. 2003; 
Siriett et al. 2006).  In support, treatment of isolated single fibres with 
recombinant Myostatin protein results in a dose-dependent decrease in BrdU-
positive satellite cells, concomitant with a decrease in satellite cell migration 
(McCroskery et al. 2003; McCroskery et al. 2005).  Furthermore, treatment of 
satellite cell-derived myoblasts with Myostatin results in inhibition of 
proliferation (Thomas et al. 2000; McCroskery et al. 2003; McFarland et al. 
2006).  Conversely, primary myoblasts isolated from myostatin-null mice 
proliferate at a faster rate compared with cultures isolated from wild-type mice 
(McCroskery et al. 2003).   
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Satellite cells, consistent with the term muscle stem cell, are able to self-renew 
their population (reviewed in Section 1.2.1.3).  Myostatin has been implicated in 
regulation of satellite cell self-renewal; in fact, single fibres isolated from 
myostatin-null mice contain a greater proportion of satellite cells as compared 
with wild-type controls (McCroskery et al. 2003).  In addition, a recent report has 
demonstrated that injection of myostatin-specific short hairpin interfering RNA 
(shRNA) into the TA muscle of rats results in an increase in satellite cell number, 
as assessed by Pax7 immunostaining (Magee et al. 2006).  McCroskery et al. 
suggested that increased proliferation and increased satellite cell number per 
muscle fibre, in the myostatin-null mice, is indicative of increased self-renewal.  
Recently presented results from this thesis further highlight the mechanism behind 
myostatin regulation of satellite cell self-renewal (McFarlane et al. 2006a).  Pax7 
is thought to play a role in the induction of satellite cell self-renewal.  Treatment 
of primary myoblasts with recombinant Myostatin protein resulted in a significant 
down-regulation of Pax7, while expression of Pax7 was induced in primary 
cultures from myostatin-null mice as compared to wild-type controls (McFarlane 
et al. 2006a).  Furthermore, absence of myostatin increased the pool of quiescent 
reserve cells, a group of cells which share several characteristics with self-
renewed satellite cells.  It is thus suggested that myostatin may regulate satellite 
self-renewal through negatively regulating Pax7 (McFarlane et al. 2006a). 
 
1.4.5.4  Myostatin and muscle wasting 
In addition to the inhibitory role of myostatin on skeletal muscle myogenesis, a 
plethora of evidence now exists to implicate myostatin in the induction of skeletal 
muscle wasting.  Myostatin has been associated with the induction of cachexia, a 
severe form of muscle wasting that manifests as a result of disease.  HIV-infected 
men undergoing muscle wasting have increased intramuscular and serum 
concentrations of Myostatin protein as compared with healthy controls (Gonzalez-
Cadavid et al. 1998).  Thus myostatin may contribute to the muscle wasting 
pathology observed as a result of HIV-infection.  Myostatin has also been 
associated with muscle wasting resulting from liver cirrhosis; Dasarathey et al. 
used the portacaval anastamosis rat, a model of human liver cirrhosis, to study the 
involvement of myostatin in the muscle wasting associated with this disease.  
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Gene expression analysis demonstrated an increase in the mRNA and protein 
levels of myostatin and the myostatin receptor, activin type-IIb (Dasarathy et al. 
2004).  Patients suffering from Addison’s disease (adrenal insufficiency) 
commonly experience skeletal muscle atrophy. Recently it was shown that active 
Myostatin serum levels increased over time in adrenalectomised rats, a model of 
Addison’s disease (Hosoyama et al. 2005).  This increase in serum Myostatin 
correlated with a decrease in muscle weights as compared with controls 
(Hosoyama et al. 2005).  Cushing’s syndrome is associated with an excessive 
increase in glucocorticoid production resulting in skeletal muscle wasting (Shibli-
Rahhal et al. 2006).  Ma et al. has demonstrated that injection of the 
glucocorticoid dexamethasone into rats induces skeletal muscle atrophy, 
concomitant with a dose-dependent up-regulation of myostatin mRNA and 
protein.  The dexamethasone-induced up-regulation of myostatin was inhibited in 
the presence of glucocorticoid antagonist RU-486 (Ma et al. 2003).  A separate 
study has demonstrated that, in addition to mRNA and protein, myostatin 
promoter activity is induced following Dex-induced muscle wasting (Salehian et 
al. 2006).  The amino acid glutamine has been previously shown to antagonise 
glucocorticoid-induced skeletal muscle atrophy (Hickson et al. 1995; Hickson et 
al. 1996).  Consistent with this, injection of glutamine in conjunction with Dex 
into rats significantly reduced the muscle atrophy phenotype, concomitant with a 
down-regulation of myostatin expression (Salehian et al. 2006).  In addition to an 
associative role in cachexia, myostatin has been shown to induce cachexia 
following administration to mice, specifically injection of CHO-control cells and 
CHO cells over-expressing myostatin (CHO-myostatin) resulted in the formation 
of tumours.  However, in contrast to the gain in body weight observed in CHO-
control mice, injection of CHO-myostatin cells resulted in a 33% reduction in 
total body weight within 16 days (Zimmers et al. 2002).  This severe body mass 
reduction was ameliorated by injection of CHO cells expressing the Myostatin 
propeptide (LAP) region or follistatin, two identified antagonists of myostatin 
function.  Furthermore, injection of CHO-myostatin cells resulted in a significant 
reduction in fat pad mass, consistent with cachexia (Zimmers et al. 2002).  
Published work from this thesis further delineates the mechanism behind 
myostatin-mediated induction of cachexia.  Specifically over-expression of 
myostatin in vitro and in vivo resulted in the up-regulation of genes involved with 
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the ubiquitin-proteasome proteolytic pathway including atrogin-1, MuRF-1 and 
E214k (McFarlane et al. 2006b).  Treatment of C2C12 myotubes with recombinant 
Myostatin antagonised the IGF-1/PI3-K/AKT pathway, resulting in enhanced 
activation of the transcription factor FoxO1 and subsequent activation of atrophy-
related genes (McFarlane et al. 2006b).  It was further shown that myostatin 
signals independently of NF-κB during the induction of cachexia.  In support, 
myostatin and NF-κB have been previously shown to signal through separate 
pathways to regulate myogenesis (Bakkar et al. 2005).  Recently it has been 
demonstrated that FoxO1 can regulate the expression of myostatin; in particular, 
over-expression of constitutively active FoxO1 increased the expression of 
myostatin mRNA and promoter reporter activity.  Allen and Unterman suggest 
that FoxO1 up-regulation of myostatin may contribute to skeletal muscle atrophy 
(Allen and Unterman 2006). 
Muscle disuse or inactivity, such as that experienced during periods of prolonged 
bed rest, also contributes to skeletal muscle atrophy.  Several studies have 
implicated myostatin in the muscle atrophy associated with disuse.  The 
expression of myostatin was measured in a mouse model of hindlimb unloading.  
Carlson et al. showed that myostatin mRNA was significantly increased following 
1 day of hindlimb unloading, however, no detectable difference in myostatin 
expression was observed at days 3 and 7 of unloading, as compared with controls 
(Carlson et al. 1999).  In a separate study, hindlimb unloading in the rat resulted 
in a 16% decrease in M. plantaris muscle weight, concomitant with a 110% 
increase in myostatin mRNA and a 35% increase in Myostatin protein (Wehling et 
al. 2000).  A dramatic 30-fold increase in myostatin mRNA was observed in 
patients suffering from disuse atrophy as a result of chronic osteoarthritis of the 
hip (Reardon et al. 2001).  In addition, a significant negative correlation was 
observed between expression of myostatin and type-IIA and type-IIB fibre area, 
suggesting that myostatin may target type-IIA and IIB fibres during disuse 
atrophy (Reardon et al. 2001).  Furthermore, a 25 day period of bedrest increased 
the levels of serum Myostatin-immunoreactive protein to 12% above that 
observed in baseline measurements (Zachwieja et al. 1999).  In addition, 
myostatin has been associated with skeletal muscle loss during space flight 
(Lalani et al. 2000).  In particular, exposing rats to the microgravity environment 
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of space resulted in muscle weight loss, with an associated increase in both 
myostatin mRNA and protein (Lalani et al. 2000). 
Sarcopenia is the skeletal muscle atrophy observed as a result of the normal 
ageing process (Marzetti and Leeuwenburgh 2006).  There are several conflicting 
reports on the expression pattern of myostatin during age-related muscle atrophy.  
myostatin mRNA expression has been shown to be unaltered during ageing in 
human males (Marcell et al. 2001; Welle et al. 2002); in contrast, studies have 
shown that myostatin mRNA decreases in aged rats (Baumann et al. 2003; 
Haddad and Adams 2006).  Furthermore, Myostatin protein serum levels in 
humans, and intramuscular protein expression of Myostatin in rats, have been 
shown to increase during atrophy associated with old age (Schulte and Yarasheski 
2001; Yarasheski et al. 2002; Baumann et al. 2003).  However, Kawada et al. 
measured myostatin expression in muscle during ageing in mice and observed no 
increase in Myostatin protein (Kawada et al. 2001).  To further delineate the role 
of myostatin in old age muscle wasting a recent study has analysed the 
phenomenon of sarcopenia between myostatin-null and wild-type mice (Siriett et 
al. 2006).  During the ageing process muscle fibres tend to switch to an oxidative 
state (Alnaqeeb and Goldspink 1987; Allen and Unterman 2006).  Interestingly, 
comparison of fibre-type in young and old myostatin-null mice revealed that no 
fibre switching occurred, whereas muscle fibres from wild-type controls became 
progressively more oxidative with age (Siriett et al. 2006).  Although satellite cell 
activation declined dramatically in both wild-type and myostatin-null mice during 
ageing, satellite cell number remained steady.  However, satellite cell number was 
consistently higher in myostatin-null mice as compared with wild-type controls 
irrespective of age.  Furthermore, the ensuing skeletal muscle regeneration, 
subsequent to notexin-induced muscle injury, was greatly enhanced in old age 
(24-month) myostatin-null mice as compared with wild-type controls (Siriett et al. 
2006).  Thus, myostatin appears to play a critical role in sarcopenia.  Therefore 
methods to target and antagonise the action of myostatin may prove beneficial in 
reducing the effects of muscle wasting during age.   
The most common forms of muscular dystrophy are Duchenne muscular 
dystrophy (DMD) and Becker muscular dystrophy (BMD) (Zhou et al. 2006).  
Both DMD and BMD are X-linked recessive disorders which can be traced back 
to mutations in the dystrophin gene (DMD) (Flanigan et al. 2003; Sironi et al. 
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2003).  BMD results from in-frame mutations in the DMD gene, resulting in a 
partially functional protein product (Hoffman et al. 1988; Koenig et al. 1989), 
however in DMD patients, frame-shift mutations result in very low levels or 
complete absence of the dystrophin (Hoffman et al. 1987; Koenig et al. 1987).  
DMD and BMD afflict about 1 in every 3500 and 1 in 18500 newborn males 
respectively (Emery 1991; Peterlin et al. 1997; Siciliano et al. 1999; Darin and 
Tulinius 2000; Zhou et al. 2006).  Myostatin is a well characterised negative 
regulator of skeletal muscle mass: as such, several studies have been performed 
looking at the role of myostatin in the severe muscular dystrophy phenotype.  The 
expression of myostatin has been shown to decrease by 4-fold in regenerated mdx 
muscle (Tseng et al. 2002).  It is suggested that a reduction in myostatin may be 
an adaptive response to aid in the maintenance and rescue of mdx skeletal muscle.  
Antibody-mediated blockade of Myostatin results in both enhanced body mass 
and skeletal muscle hypertrophy in the mdx mouse model of DMD (Bogdanovich 
et al. 2002).  Furthermore, antagonising myostatin resulted in increased muscle 
strength, as measured through grip strength experiments.  Bogdanovich et al. 
further demonstrated that blocking Myostatin, through injection of an Fc-fusion 
stabilised Myostatin propeptide region (LAP), resulted in improvement of the mdx 
DMD phenotype.  Consistent with antibody-mediated Myostatin blockade, 
propeptide injection resulted in enhanced growth, increased muscle mass and grip 
strength (Bogdanovich et al. 2005).  They further showed that this blockade 
resulted in enhanced muscle specific force, over and above that shown by 
antibody-mediated inhibition of Myostatin.  Recently, transgenic mdx mice 
containing a dominant negative activin type-IIB receptor gene (ActRIIB) showed 
phenotypic improvement over wild-type mdx mice (Benabdallah et al. 2005).  
Indeed, increased skeletal muscle mass was observed in conjunction with 
increased resistance to exercise-induced muscle damage.  More recently, Minetti 
et al. have examined the effect of deacetylase inhibitors on the mdx phenotype.  
Treatment of mdx mice with deacetylase inhibitors resulted in an improvement in 
muscle quality and function with an increase in myofibre size (Minetti et al. 
2006).  Interestingly, addition of the deacetylase inhibitors TSA or MS 27-275 
resulted in enhanced expression of the myostatin antagonist follistatin (Minetti et 
al. 2006).  In addition to disruption in dystrophin, muscular dystrophy can result 
from mutations in several genes involved in the formation of the dystrophin-
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associated protein complex, including laminin-II.  Crossing of the myostatin-null 
mice with the dy mice, a model of laminin-II-associated dystrophy, resulted in 
increased muscle mass and enhanced regeneration (Li et al. 2005b).  However, 
elimination of myostatin in the dy mice was unable to correct the severe 
dystrophic pathology associated with loss of laminin-II, moreover, loss of 
myostatin resulted in an increase in post-natal mortality (Li et al. 2005b).  Thus, 
the validity of myostatin as a target for treatment of all forms of dystrophy 
remains a matter of contention.   
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1.5  Aims and objectives 
 
Myostatin, a member of the TGF-β superfamily, is now widely accepted as a 
potent and specific inhibitor of skeletal muscle growth.  In support, naturally 
occurring mutations or targeted inactivation of the myostatin gene results in a 
dramatic increase in skeletal muscle mass.  Mechanistically myostatin functions 
by inhibiting myoblast proliferation and differentiation, which is indeed true with 
respect to satellite cells and satellite cell-derived myoblast cultures.  Satellite 
cells, which are occasionally referred to as skeletal muscle stem cells, form the 
basis of the regenerative capacity of skeletal muscle.  With the innate ability to 
inhibit satellite cell activation, proliferation and self-renewal, myostatin may have 
a negative effect on the ability of skeletal muscle to regenerate.  Indeed, it has 
been recently shown that in the absence of myostatin the process of skeletal 
muscle regeneration is enhanced.  The potent inhibitory effect of myostatin begs 
the question whether or not myostatin functions as a skeletal muscle wasting-
inducing factor.  Most certainly, elevated myostatin expression is associated with 
a plethora of skeletal muscle wasting inducing conditions including AIDS, 
diabetes and liver cirrhosis.  Moreover, systemic over-expression of Myostatin 
results in a severe form of muscle wasting, termed cachexia.  Although a role for 
myostatin is now established in regulation of post-natal muscle growth much of 
the mechanism behind this regulation remains to be elucidated.  Thus the overall 
aim of this thesis is to enhance the current knowledge of myostatin in the 
regulation of post-natal muscle growth and repair, with emphasis on satellite cell 
functionality and skeletal muscle proteolysis.  With such a potent negative 
regulator of skeletal muscle mass, therapies aimed at neutralising active Myostatin 
may help to alleviate the severe symptoms of skeletal muscle loss associated with 
disease.  The aims of this thesis were studied with the following objectives. 
 
Objective 1: To study regulation of myostatin through proteolytic processing.   
Objective 2: To delineate the role of myostatin in satellite cell self-renewal to 
enable the characterisation of a mechanism through which 
myostatin acts to regulate this process. 
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Objective 3: To characterise in detail the functional role of myostatin in skeletal 
muscle wasting and delineate a potential mechanism through which 
myostatin signals to promote muscle degradation. 
Objective 4: To study and characterise the function of a novel myostatin 
downstream target gene during the induction of cachexia. 
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Chapter 2  Materials and Methods 
 
This Chapter reviews the relevant materials and methods utilised throughout this 
project, including all reagents, chemicals and solutions.  Also it includes an 
overview of all the general methods, with the specific methods being detailed in 
the relevant results chapters. 
2.1  Materials 
 
This section outlines general materials used in this thesis.  Specific laboratory 
equipment required and the relevant commercially-available kits used during this 
study will be outlined in Section 2.2 of this Chapter.   
 
2.1.1  Enzymes 
All restriction endonuclease enzymes were acquired from either Invitrogen 
(Invitrogen, Carlsbad, CA) or Roche (Roche Diagnostics Corporation, 
Indianapolis, IN).  Restriction enzyme buffers are supplied with all restriction 
enzymes.  The remaining enzymes used in this study are listed in Table 2.1 
 
Table 2.1  Enzymes 
Enzyme Source 
DNase1 Invitrogen 
Proteinase K Roche 
RNase H Invitrogen 
Superscript II Reverse Transcriptase Invitrogen 
T4 DNA ligase Invitrogen 
Taq DNA Polymerase Roche 
ThermalAce DNA Polymerase Invitrogen 
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2.1.2  Radioactive isotopes 
dCTP [α-32P] with a specific activity of 3000 Ci/mM was used for labelling cDNA 
probes.  This isotope was purchased from GE Healthcare Bio-Sciences. 
 
2.1.3  Antibodies 
Antibodies used in this thesis were purchased from the following companies:  BD 
Pharmingen (BD Pharmingen, San Diego, CA), Boston Biochem (Boston 
Biochem, Cambridge, MA), DSHB (Developmental Studies Hybridoma Bank , 
Iowa City, IA), Santa Cruz Biotechology Inc. (Santa Cruz Biotechnology Inc, 
Santa Cruz, CA), Dako (Dako, Glostrup, Denmark), Sigma (Sigma, St Louis, 
MO), GE Healthcare Bio-Sciences (GE Healthcare Bio-Sciences Corp. 
Piscataway, NJ) and Research Diagnostics (Research Diagnostics, Concord, MA).  
All antibodies and associated information including dilution and incubation times 
are outlined in the Material and Methods sections of the results Chapters 3, 4, 5 
and 6 where they were used. 
Rabbit anti-Myostatin antibodies were produced by Dr Ravi Kambadur and Dr 
Mridula Sharma, Functional Muscle Genomics, AgResearch, Hamilton, New 
Zealand. 
The Atrogin-1 antibody was a gift from Dr Cam Patterson, Department of 
Medicine, Division of Cardiology, University of North Carolina, School of 
Medicine, NC, USA. 
 
2.1.4  Plasmid DNA 
Plasmid DNA and their sources are listed in Table 2.2, commercial plasmids are 
listed in Table 2.3  The DNA was stored at -20ºC or 4ºC in TE buffer or MQ 
water. 
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Table 2.2  Plasmid DNA 
 
1Functional Muscle Genomics, AgResearch, Hamilton, New Zealand. 
2Department of Biological Sciences, University of Waikato, Hamilton, New 
Zealand. 
3University of Pennsylvania School of Medicine, University of Pennsylvania, PA, 
USA. 
4Department of Biochemistry, McMaster University, Hamilton, Ontario L8N 3Z5, 
Canada.   
5Immunology Division, Faculty of Medicine, Université de Sherbrooke, 
Sherbrooke QC, Canada. 
6Molecular Medicine Program and Center for Stem Cell and Gene Therapy, 
Ottawa Health Research Institute, Ottawa, ON, Canada. 
7BACPAC Resources, Children’s Hospital Oakland, Oakland, CA, USA. 
 
Name Species Size (bp) Approx Source 
CXXC5 (MM1)  Mouse 1000 Bridgette Wilson1,2 
(Wilson 2006) 
Pax3 Promoter Mouse 1600 Dr J.A. Epstein3 
(Li et al. 1999) 
MyoD Enhancer Human 6500 Dr J.P. Capone4 
(Hunter et al. 2001) 
P1 Furin promoter Human 3700 Dr Claire Dubois5 
(Blanchette et al. 
2001) 
Pax7 Mouse 3000 Dr Michael Rudnicki6 
 
RP23-48C24 Mouse >100,000 BACPAC Resources7 
RP24-337A16 Mouse >100,000 BACPAC Resources7 
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Table 2.3  Commercial plasmids 
Name Description Source 
pcDNA3 5.446 bp, Ampr, Neor, CMV, T7 and Sp6 
RNA pol initiation sites, bGH p(A)  
Invitrogen 
pGEM-T Easy 3018 bp, Ampr, T3 and T7 RNA pol 
initiation sites, LacZ 
Promega 
pGL3b 4818 bp, Ampr, Luciferase gene-SV40 late 
p(A)  
Promega 
pCH110 7128 bp, Ampr, SV40 Early promoter-lacZ  GE Healthcare 
Bio-Sciences 
pBACe3.6 11612 bp, CMr, T7 and SP6, SacB gene 
promoter, loxP 
BACPAC 
Resources 
 
2.1.5  Common solutions 
Common solutions were made using the recipes described by Ausubel (Ausubel 
1988) or Sambrook et al. (Sambrook et al. 1989) unless otherwise stated.  
Common solutions and their composition are listed in Table 2.4. 
 
Table 2.4  Common solutions 
Solution Composition 
Apoptosis lysis buffer 10 mM Tris-HCL (pH ) 
10nM EDTA 
0.5% Triton X-100 
0.1 mg/mL RNase A 
 
Chicken embryo extract see Section 2.2.8.4 
 
Church and Gilbert hybridisation 
buffer 
0.5 M Na2HPO4 (pH 7.2) 
7% SDS 
1 mM EDTA 
 
DEPC treated water Add 2 mL DEPC (0.1%) to 2 L of MQ 
water 
Autoclave  
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DNA loading dye 15% ficoll 
0.25% bromophenol blue 
0.25% xylene cyanol 
1% SDS 
1 mM EDTA (pH 8.0) 
 
LB broth (with ampicillin) 20g/L Lennox LB broth base 
(Invitrogen) 
Add 1g/L of glucose 
MilliQ water to 1 L 
Autoclave.  When cool add 1ml/litre of 
50 mg/mL ampicillin. 
 
LB agar (with ampicillin) 32 g/L Lennox LB agar base 
(Invitrogen) 
Add 1 g/L of glucose 
MilliQ water to 1 L 
Autoclave.  When cool add 1ml/litre of 
50 mg/mL ampicillin. 
Pour onto Petri dish 
 
Lysis Buffer (protein extraction 
buffer) 
50 mM Tris (pH 7.5) 
250 mM NaCl 
5 mM EDTA 
0.1% NP-40 
1x Protease inhibitor (Complete; Roche) 
 
MOPS (10x) 41.8% MOPS 
50 mM NaOAc 
10 mM EDTA 
 
PBS 1 Phosphate Buffered Saline tablet 
(Oxoid) 
100 mL H2O 
 
Protein Sample buffer (2x)  1.5 M Tris (pH 6.8) 
30% glycerol 
20 % SDS 
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2 M β-mercaptoethanol 
0.0018% bromophenol blue 
 
RNA loading dye 10% MOPS (10x) 
20% deionised formaldehyde 
50% deionised formamide 
0.02% bromophenol blue 
5% glycerol 
1 mM EDTA (pH 8.0) 
40 µg/mL ethidium bromide 
 
Running buffer  
(DNA Agarose) 
 
1x TAE diluted in MilliQ water 
Running buffer  
(RNA Agarose) 
 
1x MOPS diluted in DEPC treated water 
Running buffer   
(SDS-PAGE; Western Blot)  
25 mM Tris 
190 mM glycine 
1% SDS 
 
Scott’s tapwater 2 g Sodium Bicarbonate 
20 g Magnesium Sulphate 
1L MQ water 
1 Crystal of Thymol 
SSC (20x) 3 M NaCl 
0.3 M sodium citrate (pH 7.0) 
 
TAE 40 mM Tris-acetate 
2 mM EDTA (pH 8.0) 
 
TBS (Tris-buffered saline) 50 mM Tris (pH 7.5) 
150 mM NaCl  
 
TBST  50 mM Tris (pH 7.5) 
150 mM NaCl 
0.1% Tween 20 
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TE 10 mM Tris-Cl (at desired pH) 
1 mM EDTA (pH 8.0) 
 
Transfer buffer  
(Western transfer) 
25 mM Tris 
190 mM Glycine 
20% methanol 
 
Western Blocking Solution (Milk) 5% solution of low fat milk in TBST 
 
Western Blocking Solution (BSA) 1% PVP 10,000, 1% PEG  4000 and 
0.3% BSA in TBST 
 
10x Trypsin 2.5% Trypsin in PBS 
 
 
2.1.6  Common laboratory chemicals and reagents 
All common laboratory chemicals and reagents are specified in Table 2.5.  All 
chemicals and reagents are Analar grade unless otherwise stated. 
 
Table 2.5  Chemicals and reagents 
Chemical or Reagent Source 
Hybond-N+ membrane; radiographic 
cassettes 
 
GE Healthcare Bio-Sciences 
 
Ethanol; formaldehyde; glycerol; 
hydrochloric acid; methanol; sodium 
chloride; Tween-20; EDTA; sodium 
hydroxide (pelleted); chloroform; 
isopropanol; glucose 
 
BDH Ltd 
Bradford protein assay Bio-Rad 
 
Ultrapure agarose; low melting point Invitrogen (Gibco BRL) 
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agarose (LMP); ethidium bromide; 
formamide; sodium dodecyl sulphate 
(SDS); dNTPs; TRIZOL reagent; tris; 
Benchmark prestained protein ladder; 
glycine; LB broth base; LB agar base; 
IPTG (isopropyl thio-β-galactoside); 
urea;  NuPAGE 4-12% Bis Tris precast 
protein gels; phenol; DMEM 
(Dulbeccos Modified Eagle Medium); 
geneticin 
 
Kodak imaging film (XOMAT XAR) Radiographic Supplies 
 
DEPC (Diethyl pyrocarbonate); βMe 
(Beta-mercaptoethanol); Trizma base; 
MOPs (3-[N-Morpholino] 
propanesulfonic acid); ampicillin; 
phenol red. 
Sigma-Aldrich 
 
2.1.7  Bacterial strains 
The bacterial strains used in this project are outlined in Table 2.6.  The bacterial 
strains were kept at -80ºC in a 50% glycerol, 50% LB solution. 
 
Table 2.6  Bacterial strains 
Species Strain Source 
E. coli DH5α  Invitrogen 
E. coli JM109 Promega 
 
 92
2.1.8  Oligonucleotides 
All oligonucleotides used during the course of this study were synthesised by 
Invitrogen.  All oligonucleotides were stored at -20ºC and resuspended in TE at a 
concentration of 100 µM.  Primers were further diluted in MQ water to generate 
working concentrations of 10 µM for each primer.  While primers used for 
specific work will be documented in the relevant results chapters, Table 2.7 
contains a list of primers, their associated annealing temperatures and product 
sizes. 
 
Table 2.7  Oligonucleotides 
Gene 
name 
Primer sequence (5' - 3') Temp 
(°C) 
Size 
(bp) 
Myostatin Fwd: GGTATTTGGCAGAGTATTGATGTG 52 514 
 Rev: GTCTACTACCATGGCTGGAAT   
MyoD Fwd: GGATCCTAAGACGACTCTCAC 52 1047 
 Rev: GGATCCAGTGCCTACGGTGG   
Pax3 Fwd: GCAAGATGGAGGAAACAAGC 60 676 
 Rev: CGTTCTCAAGCAAGAGGTG   
NF-κB Fwd: GGATCCATGGACGATCTGTTTCCCCT 55 1651 
 Rev: GGATCCTTAGGAGCTGATCTGACTC   
FoxO1 Fwd: TTCAAGGATAAGGGCGACAG 60 300 
 Rev: ACTCGCAGGCCACTTAGAAA   
CXXC5 Fwd: AACATGTGGGTGTATCGG 60 954 
 Rev: TCTTGAGGGGAAAGTGAG   
Atrogin-1  Fwd: AACATGTGGGTGTATCGG 52 465 
 Rev: TCTTGAGGGGAAAGTGAG   
MuRF-1 Fwd: GTTAAACCAGAGGTTCGAG 52 343 
 Rev: ATGGTTCGCAACATTTCGG   
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E214k Fwd: ATGTCGCCCCGGCCCGGAGGCTCATG 45 453 
 Rev: ATGAATCATTCCAGCTTTGTTCAAC   
E220k Fwd: GGCGACACCATGTCATC 52 552 
 Rev: ATGTCCTGGGCCTCATC   
RC2 Fwd: TCCAAACCTGCCCATCTGCTAACT 45 305 
 Rev: AGGCTGTGCTTTTCTCTGTGGTCT   
Atrogin-1 
promoter Fwd: GGGGTACCCTTCTCCAGGCCAGTAGGTG 60 3500 
 Rev: GGAAGATCTTGGTACAGAGCGCGGACGC   
FoxO1 
promoter Fwd: GGTACCAGTGCCCATGAAGTTTGGAG 60 4000 
 Rev: GCTAGCCCCACCAGCAGAGAAGTACC   
GAPDH Fwd: GTGGCAAAGTGGAGATTGTTGCC 60 289 
 Rev: GATGATGACCCGTTTGGCTCC   
 
2.1.9  Mammalian cell lines 
The established mammalian cell lines used in this thesis are listed below in Table 
2.8.  Mammalian cell stocks were stored in DMEM 10% Foetal bovine serum 
(FBS) medium with 10% DMSO in liquid Nitrogen. 
 
Table 2.8  Mammalian cell lines 
Line Species Cell type Source 
C2C12 Mouse Myoblast ATCC (Yaffe and Saxel 1977) 
C3H10T1/2 Mouse Fibroblast ATCC (Reznikoff et al. 1973) 
CHO  Hamster Ovary Dr Se-Jin Lee1 
(Zimmers et al. 2002) 
IκBα SR C2C12 Mouse Myoblasts Dr Denis Guttridge2 
(Guttridge et al. 1999) 
 94
 
1Dr Se-Jin Lee, Johns Hopkins University School of Medicine, Baltimore, MD, 
USA. 
2Dr Denis C. Guttridge, Ohio State University, OH, USA. 
 
2.1.10  Bovine skeletal muscle 
The bovine skeletal muscle used in this study had been collected previously by Dr 
Sonnie Kirk, Dr Julie Martyn and Mr Mark Thomas; myoblast extraction and 
tissue culture by Mr Mark Thomas, Animal Genomics, AgResearch, Hamilton, 
New Zealand. 
The AgResearch Ruakura Animal Ethics Committee gave prior approval to the 
animal manipulations.  Standard superovulation and embryo transfer techniques 
were used to generate bovine foetuses (Kambadur et al. 1997)  Foetuses were 
Hereford/Friesian crossbreeds.  The M. semitendinosus and M. vastus lateralis 
muscles were excised from the foetus and stored at -80°C or were cut into small 
pieces, placed in Minimal Essential Medium (MEM) containing 20% FBS and 
10% DMSO, and frozen in liquid nitrogen for subsequent myoblast culture 
generation. 
 
2.1.11  Recombinant myostatin protein 
The recombinant Myostatin protein (Mstn) used in all the experiments was 
generated and purified by Mrs Carole Berry, Animal Genomics, AgResearch, 
Hamilton, New Zealand. 
The generation of recombinant Myostatin is overviewed below, the pET protein 
expression system (Novagen) was used to express and purify recombinant 
myostatin.  Bovine myostatin cDNA (amino acids 267-375) was PCR amplified 
and cloned into the pGEM-T easy vector (Promega).  After BamH1 digestion, the 
myostatin cDNA was sub-cloned into the pET 16-B vector (Novagen) in-frame 
with the 10-histidine residues.  An overnight BL21 E. coli culture transformed 
with the recombinant myostatin expression vector was diluted and grown to an 
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OD of 0.8 (600 nm) in 1 L of Lennox Luria Broth (LB) medium plus ampicillin 
(50 mg/L).  Expression of the Myostatin fusion protein was then induced by 0.5 
mM isopropyl thio-β-galactoside (IPTG) for 2-3 hr.  The bacteria were then 
harvested by centrifugation and resuspended in 40 mL of lysis buffer (6 M 
guanidine hydrochloride; 20 mM Tris pH 8.0; 5 mM β-mercaptoethanol), 
sonicated and centrifuged at 10,000 x g for 30 min.  Myostatin was purified from 
the supernatant by Ni-Agarose affinity chromatography (Qiagen), according to the 
manufacturer’s protocol.  Soluble fractions containing myostatin were pooled and 
dialysed at 4ºC against two changes of 50 mM Tris-HCl (pH 8.0) containing 500 
mM NaCl and 10% glycerol for 6 hr.  Coommassie Blue stained SDS-PAGE gels 
and Western Blot analyses were performed using specific anti-Myostatin 
antibodies to verify purification. 
 
2.2  Methods 
 
Standard molecular biology techniques utilised in this study can be found in 
Ausubel (Ausubel 1988) or Sambrook et al. (Sambrook et al. 1989).  Experiments 
were all performed with MQ purified water.  DEPC-treated solutions, including 
water, were used for any work involving RNA.  Unless otherwise stated, 
experimental reactions were carried out at room temperature.  All cell culture 
work performed was carried out in PC1 laminar flow hoods located in a tissue 
culture suit. 
 
2.2.1  Electrophoresis 
2.2.1.1  DNA gel electrophoresis 
Agarose gels ranged from 0.8-2% agarose (Invitrogen), depending on the size of 
the fragments to be separated.  DNA gels were made up in 1 x TAE, with 
ethidium bromide added for visualisation of the DNA bands at a concentration of 
300 ng/mL.  The DNA gels were cast and run in specific gel boxes (either Owl 
[Biolab Scientific] or Horizon [Invitrogen] boxes) containing 1 x TAE as the 
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running buffer.  DNA samples were mixed with a 10 x concentrated DNA loading 
dye before loading.  DNA molecular markers were run beside the DNA samples.  
Electrophoresis was carried out between 30-100 V until the desired separation of 
bands was obtained.  The separated DNA was then visualised under ultraviolet 
(UV) light (312 nm) using the Gel Doc system (Bio-Rad Laboratories, Hercules, 
CA) and photos were printed as a record. 
 
2.2.1.2  RNA gel electrophoresis 
Formaldehyde/Agarose gels contained between 1-2% agarose, 1 x MOPS and 
0.66 M Formaldehyde.  Total RNA was quantified using the NanoDrop 
spectrophotometer (ND-1000; NanoDrop Technologies Inc., Wilmington, DE, 
USA) to ensure accurate amounts for Northern analysis and RT-PCR reactions.  
Total RNA (10-15 µg) was mixed with an equal volume of RNA loading dye and 
incubated at 65oC for 5 min prior to loading.  Electrophoresis of RNA was 
between 40-80 V until the desired separation was achieved.  The RNA loading 
dye contained ethidium bromide and allowed the visualisation of the RNA by UV 
illumination.  A Gel Doc system (Bio-Rad) was used to photograph gels.  The 
integrity of the RNA was monitored by observing the state of the 28S and 18S 
ribosomal bands. 
 
2.2.1.3  SDS polyacrylamide gel electrophoresis 
Total protein was estimated for Western Blot analysis using Bradford’s protein 
assay reagent (Bio-Rad) analysed against BSA standards read at 595 nm.  
Samples were boiled for 5 min in the presence of loading dye and β-
mercaptoethanol (βMe) before loading.  Samples were run with the SeeBlue Plus 
2 Pre-Stained Standard (Invitrogen) to give a guide to the size of the proteins on 
the gel.  Separation of proteins was achieved using SDS-PAGE gels.  SDS-PAGE 
gels were run in the XCell Surelock Electrophoresis cell (Invitrogen).  NuPage 4-
12% gradient Bis-Tris pre cast polyacrylamide gels (Invitrogen) were used for 
protein separation.  4 x NuPage sample buffer (Invitrogen) and a 1 x NuPage 
MES SDS running buffer were used with this system.   
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2.2.2  Nucleic acid purification 
2.2.2.1  Purification after enzymatic manipulation 
Infrequently, plasmid DNA and DNA resulting from PCR amplification needed to 
be purified after enzymatic reactions; removing protein and contaminants by 
phenol-chloroform extraction.  DNA was extracted two times with a mix of 
Buffer-saturated phenol:chloroform at a ratio of 1:1, followed by a single 
extraction with chloroform alone.  Purified DNA was then precipitated in 1 µL of 
Glycogen, 1/10 volume of 0.3 M NaOAc and three volumes of 100% ethanol at –
20oC for at least 30 min.  The DNA was pelleted by centrifugation (>10,000 x g 
for 10-15 min).  The DNA pellet was washed two times in 70% ethanol, dried and 
resuspended in an appropriate volume of TE or MQ-H2O. 
 
2.2.2.2  The Wizard DNA purification system (Promega) for recovery of DNA 
DNA was initially separated by DNA gel electrophoresis (see 2.2.1.1) using low 
melting point (LMP) agarose (Invitrogen).  The DNA band of interest was excised 
from the gel using a razor blade, placed in an eppendorf tube and then incubated 
at 65ºC until the agarose was melted (5 min).  Purification resin (1 mL) was added 
to the melted gel slice and mixed by inverting the tube.  The resin/DNA mix was 
then passed through a wizard minicolumn using a syringe, followed by a wash 
with 80% isopropanol (2 mL).  The minicolumns were removed from the syringes 
and centrifuged (10,000 x g for 2 min).  DNA was then eluted from the column 
with 30 µL of TE buffer (1 min incubation) and centrifugation (10,000 x g for 20 
s). 
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2.2.3  Enzymatic reactions 
2.2.3.1  Restriction endonuclease digestions 
Restriction endonuclease digests were performed with 5-10 U of required enzyme 
per µg of DNA with the amount of enzyme not exceeding 10% of the total 
reaction volume.  The digests were performed with the appropriate restriction 
endonuclease buffers supplied at an initial 10 x concentration.  Digests were 
performed at 37ºC (unless manufacturer guidelines specified otherwise) for 1-2 hr.  
Restriction digests were then either visualised using gel electrophoresis (see 
Section 2.2.1.1) or purified using the Wizard kit (see Section 2.2.2.2) for further 
manipulations. 
 
2.2.3.2  Ligation of DNA 
Separate restriction endonuclease digestions were performed on DNA inserts and 
vector DNA to generate complementary 3’ or 5’ extensions for cloning.  The 
digested DNA was separated by gel electrophoresis (see Section 2.2.1.1) on LMP 
agarose gels and purified (see Section 2.2.2.2), with the desired vector or insert 
DNA excised from the gel.  Ligation reactions contained 25-50 ng of vector DNA 
with a 3-fold molar excess of insert DNA, 1 µL of 10 x ligation buffer 
(Invitrogen) and 1 U T4 DNA ligase.  The ligation reactions were performed at 
16ºC for 18 hr. 
 
2.2.4  Transformation and growth of bacteria 
2.2.4.1  Transformation of competent cells 
Transformation of DH5α or JM109 competent cells was achieved by addition of 
1-20 ng of either vector DNA or ligation mixture to 50 µL of the cells.  The 
DNA/competent cell mixture was incubated on ice for 20 min, followed by a heat 
shock at 42ºC for 48 s, then a further 2 min incubation on ice.  Following this, 950 
µL of room temperature LB broth (without antibiotic) was added to the mixture 
and the transformed cells were incubated at 37ºC for 90 min with gentle shaking 
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(~150 rpm).  The culture was spread over LB agar plates, which contain 
ampicillin (50 µg/mL), and grown overnight for 16-24 hr at 37ºC. 
 
2.2.4.2  Culturing of bacteria 
Single colonies, from LB agar plates grown overnight or from frozen bacterial 
strains in the form of glycerol stocks, were seeded in 4 mL (miniprep) or 100 mL 
(maxiprep) of LB broth with ampicillin (50 µg/mL).  Miniprep cultures were 
grown in 50 mL plastic tubes (Nalge Nunc International, Rochester, NY) and 
maxiprep cultures were grown in 1 L plastic flasks (Nalge Nunc).  The cultures 
were grown at 37ºC with shaking (~250 rpm) for 12-18 hr. 
 
2.2.5  Isolation of plasmid DNA from bacteria 
2.2.5.1  Miniprep (Small scale plasmid isolation) 
Plasmid DNA from miniprep cultures was extracted and purified using the 
QIAprep spin miniprep system (Qiagen), according to the manufacturer’s 
protocol.  Bacteria were harvested by centrifugation at 3500 rpm for 5 min in a 
1.5 mL eppendorf tube.  The bacterial pellet was resuspended in 250 µL of Buffer 
P1 followed by 250 µL Buffer P2, the sample was then mixed by inverting four-
six times and allowed to incubate at room temperature for no more than 5 min.  
After incubation 350 µL buffer P3 was added.  After the addition of Buffer P3 the 
tube was again inverted four-six times to mix.  The extract was centrifuged 
(20,000 x g for 10 min) and the supernatant removed to a QIAprep spin column.  
The spin column was centrifuged (20,000 x g for 1 min), washed with 0.75 mL 
Buffer PE and centrifuged twice to remove any traces of Buffer PE.  Plasmid 
DNA was eluted in 50 µL Buffer EB by centrifugation (20,000 x g for 1 min) after 
a 1 min incubation time. 
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2.2.5.2  Maxipreps (Large scale plasmid isolation) 
Large scale purification of plasmid DNA was performed using the Qiagen 
Plasmid Maxi kit (Qiagen) as per the protocol.  Briefly, 250 mL of overnight 
culture was harvested by centrifugation at 6000 x g for 15 min.  The pellet was 
then resuspended in 10 mL of buffer P1, mixed with 10 mL of Buffer P2 and 
incubated on ice for 20 min on addition of Buffer P3.  The mix was then 
centrifuged for 30 min at 20,000 x g followed by a second spin at 20,000 x g for 
15 min to remove any contaminants.  The plasmid DNA containing supernatant 
was passed through a pre-equilibrated Qiagen-column by gravity flow.  Plasmid 
DNA bound to the column was washed twice with Qiagen Buffer QC and eluted 
with Qiagen elution buffer.  The eluted DNA was precipitated with 0.7 volumes 
of isopropanol and pelleted by centrifugation at 20,000 x g for 10 min.  The pellet 
was washed twice with 70% ethanol, dried and resuspended in an appropriate 
volume of TE buffer. 
 
2.2.6  Polymerase Chain Reaction (PCR) 
2.2.6.1  First-strand synthesis using SuperScript II Reverse Transcriptase 
(Invitrogen) 
First-strand synthesis was performed using the SuperScript First-Strand Synthesis 
System (Invitrogen).  SuperScript II reverse transcriptase (RT) reactions were 
performed as described in the manufacturer’s protocol.  For the RT reaction, 0.5 
µg of Oligo(dT)12-18 was annealed to 1-5 µg of total RNA in a 10 µL reaction 
containing 1 µL dNTPs (10 mM).  This reaction was incubated at 65oC for 5 min 
than placed on ice for 1 min.  A separate 9 µL reaction containing 2 µL of 10 x RT 
Buffer, 4 µL of 25 mM MgCl2, 2 µL of 0.1 M DTT and 1 µL RNaseOUT 
recombinant RNase inhibitor was added to the RNA/primer mixture mixed and 
incubated at 42 oC for 2 min.  SuperScript II RT (50 U) was added to the mixture 
and incubated at 42 oC for 50 min.  The reaction was subsequently terminated by 
incubation at 70 oC for 15 min, followed by treatment with 1 µL of RNase H at 
37oC for 20 min.  The RT synthesised cDNA were used in subsequent PCR 
reactions.   
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2.2.6.2  PCR using Taq DNA polymerase 
Routine laboratory PCR reactions were carried out with Taq DNA Polymerase 
(Roche) and were performed as described in the manufacturer’s protocol.  PCR 
reactions (50 µL) contained 0.5 µL of Taq, 0.2 mM of each dNTP, 0.1 µM Fwd 
primer, 0.1 µM Rev primer, 5 µL of a 10 x PCR buffer, which included MgCl2 at 
a final concentration of 1.5 mM.  The reactions were carried out with various 
concentrations of DNA template.  The Hybaid MultiBlock System (MBS) 
utilising the 0.5S block (Hybaid) was used for all PCR thermocycling.  Specific 
PCR cycling temperatures and times are described in the Materials and Methods 
of the relevant results Chapters where PCR was used. 
 
2.2.6.3  PCR using ThermalAce DNA polymerase (Invitrogen) 
ThermalAce DNA polymerase was used to generate the PCR products for 
subsequent cloning into the pGL3b vector for future cell culture work, as this 
enzyme contains 3’-5’ exonuclease (proofreading) activity.  PCR amplifications 
were performed as described in the manufacturer’s protocol.  ThermalAce 
reactions were prepared as one mix with components added in the following 
order.  DNA template (1 µL) at varying concentrations, 0.2 µM of Fwd primer and 
0.2 µM of Rev primer, 0.2 mM of each dNTP, 5 µL of a 10 x ThermalAce buffer 
which includes MgSO4 at a final concentration of 1.5 mM, sterile water up to 49 
µL, and 2 U (1 µL) of the ThermalAce DNA polymerase.  The reaction was mixed 
and stored on ice until ready for cycling.  The Hybaid MultiBlock System (MBS) 
utilising the 0.5S block (Hybaid) was used for all PCR thermocycling.  Specific 
PCR cycling temperatures and times are described in the Materials and Methods 
of the relevant results Chapters in which ThermalAce DNA polymerase was used.  
Due to the 3’-5’ exonuclease (proofreading) activity of ThermalAce the PCR 
products had to be A-tailed before cloning into pGEM-T easy.  This reaction 
contained 43 µL of PCR product, 1 µL of Taq polymerase, 1 µL of 10 mM dATP, 
and 5 µL of 10 x PCR buffer.  This reaction was incubated at 72ºC for 30 min. 
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2.2.7  Radio-labelling of cDNA probes 
cDNA probes were labelled using a Rediprime II random prime labelling system 
(GE Healthcare Bio-Sciences Corp. Piscataway, NJ).  Labelling was performed as 
described in the manufacturer’s protocol.  DNA was diluted to 25 ng in a final 
volume of 12.5 µL.  The DNA was denatured by heating to 100oC for 5 min, 
cooled for 5 min on ice, and added to 10 µL (half of the total mix) of the 
Rediprime random priming mix.  In addition, 2.5 µL of (25 µCi) [α-32P]-dCTP 
was added and mixed.  The reaction was incubated at 37oC for 45 min.  The 
reaction was denatured using 5 µL of 4 M NaOH for 10 min at room temperature 
before incubation with the membrane. 
 
2.2.8  Mammalian cell culture 
 
2.2.8.1  Media components and the culturing of bovine and murine primary and 
C2C12 myoblasts.   
Bovine primary myoblast cultures were grown in minimum essential medium 
(MEM) Proliferation Medium containing, 10% FBS (Invitrogen), 7.22 nM Phenol 
red (Sigma), 1 x 105 IU/L penicillin (Sigma), 100 mg/L streptomycin (Sigma).  
The medium was buffered with 41.9 mM NaHCO3 (Sigma) and gaseous CO2.  All 
media and constituents were filter sterilised with 0.22 µm pore filters.  Bovine 
primary myoblasts were cultured on gelatin-coated plates at 37oC, in 5% CO2 in a 
Forma Scientific Water Jacketed Incubator 3250.  Plates were gelatinised by the 
method of Quinn and Nameroff (Quinn and Nameroff 1983).   
Murine myoblast cultures were maintained in proliferation medium containing 
DMEM supplemented with 20% FBS, 10% horse serum (HS) and 1% Chicken 
Embryo Extract (CEE) (see Section 2.2.8.4), 7.22 nM Phenol red, 1 x 105 IU/L 
penicillin, 100 mg/L streptomycin on 10% matrigel-coated plates.  The medium 
was buffered with 41.9 mM NaHCO3 and gaseous CO2.  All media and 
constituents were filter-sterilised with 0.22 µm pore filters.  Murine myoblasts 
were cultured at 37oC, in 5% CO2.   
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C2C12 myoblasts were cultured in Proliferation Medium which contained 
DMEM, 10% FBS, 7.22 nM Phenol red, 1 x 105 IU/L penicillin, 100 mg/L 
streptomycin.  The medium was buffered with 41.9 mM NaHCO3 and gaseous 
CO2.  All media and constituents were filter-sterilised with 0.22 µm pore filters.  
C2C12 myoblasts were cultured at 37oC, in 5% CO2.   
The culture dishes, seeding densities and treatments for specific experiments are 
described in the relevant Materials and Methods sections of the Result Chapters. 
 
2.2.8.2  Murine primary myoblast extraction 
Murine primary myoblasts were cultured from the hindlimb muscle of 4 to 6 week 
old mice, according to published protocols (Allen et al. 1997; Partridge 1997).  
Briefly, muscles were minced and then digested in 0.2% collagenase type-1A 
(Sigma) for 90 min.  Following digestion the cultures were centrifuged to pellet 
digested muscle, resuspended in PBS and triturated vigorously for 5 min.  The 
resulting slurry was then passed though a 100 µM cell strainer, centrifuged and 
the pellet resuspended in proliferation medium.  The cultures were enriched for 
myoblasts by pre-plating on uncoated plates for 3 hr. Myoblast cultures were 
maintained in proliferation medium containing DMEM supplemented with 20% 
FBS, 10% HS and 1% CEE on plates coated with 10% Matrigel (BD; Becton 
Dickinson, Franklin Lakes, NJ), at 37°C/5% CO2.  This method is well established 
in our laboratory and yields cultures of high (95%) myogenic purity (McCroskery 
et al. 2003).   
 
2.2.8.3  Bovine primary myoblast extraction 
Bovine primary myoblasts were generated from bovine muscle tissues by Mark 
Thomas, Animal Genomics, AgResearch, Hamilton, New Zealand. 
Briefly, mixed cultures containing both myoblasts and fibroblasts were liberated 
from thawed M. Semitendinosus by mincing muscle and then digesting with 
0.25% trypsin (Sigma) for 45 min at 37°C.  Medium for subsequent culture 
consisted of MEM, 10% FBS, 1x105 IU/L penicillin and 100 mg/L streptomycin.  
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Medium was buffered with 41.9 mM NaHCO3 and gaseous CO2 and 7.22 nM 
Phenol red (Sigma) was used as a pH indicator. 
The method of O’Malley et al. (O'Malley et al. 1996) was used to enrich cultures 
for myoblasts.  A total of 1 x 106 liberated cells were added to Matrigel coated 10 
cm dishes (Nalge Nunc).  Matrigel-coated dishes were prepared by adding 10 mL 
of 5.0 mL/L Matrigel in Earle’s Balanced Salt Solution (EBSS; obtained as a 10 x 
concentrate) (Invitrogen) to each 10 cm dish and then incubating at 37°C for 16 
hr.  Cultures were grown on Matrigel for 3 days, and then digested with 0.5 g/L 
type-IA collagenase for 10 min to preferentially detach fibroblasts.  Cultures were 
washed twice with EBSS before, and three times after collagenase digestion.  
When cultured under differentiating conditions, 90% of cells stained positive for 
the muscle-specific marker desmin, indicating a high purity of myoblasts (Thomas 
et al. 2000). 
 
2.2.8.4  Chicken embryo extract 
Fertilised Cobb eggs (Bromley Park Hatcheries) were incubated at 37.5°C and 65-
70% humidity for 9 days. The eggs shells were wiped clean with sterile water, 
followed by 2 x washes with 70% ethanol.  With sterile scissors, the wide end of 
the shell was cut open and the embryo was removed with a sterile surgical spoon.  
The embryos were weighed and 1 mL 1 x EBSS (Invitrogen) per gram of embryo 
weight was added. The solution was blended on a high speed for 15 s, 3 times, 
with 15 s rests on ice between blending. The solution was then centrifuged at 
3,000 x g for 15 min at 4°C. The supernatant was later aliquoted into 1 mL, 0.5 
mL and 0.25 mL lots and stored at -80°C. Sterility of the CEE was checked by 
preparing DMEM + 10% FBS + 1% CEE medium which was incubated for 48 hr 
at 37°C and observed for any bacterial or fungal growth. 
 
2.2.8.5  Media components and the culturing of C3H10T1/2 fibroblasts and 
Chinese Hamster Ovary (CHO) cells.   
C3H10T1/2 fibroblasts were cultured in Proliferation Medium which contained 
Eagle’s Basal Medium (BME; Invitrogen), 10% FBS, 7.22 nM Phenol red, 1 x 105 
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IU/L penicillin, 100 mg/L streptomycin.  The medium was buffered with 41.9 
mM NaHCO3 and gaseous CO2.  All media and constituents were filter-sterilised 
with 0.22 µm pore filters.  C3H10T1/2 fibroblasts were cultured at 37oC, in 5% 
CO2 incubator.   
Chinese Hamster Ovary (CHO) cells were cultured in Proliferation Medium 
which contained DMEM/F12 (Invitrogen), 10% FBS, 7.22 nM Phenol red, 1 x 105 
IU/L penicillin, 100 mg/L streptomycin.  The medium was buffered with 41.9 
mM NaHCO3 and gaseous CO2.  All media and constituents were filter-sterilised 
with 0.22 µm pore filters.  CHO were cultured at 37oC, in 5% CO2 incubator.   
 
2.2.8.6  Differentiation of myoblasts. 
Myoblast differentiation was induced in murine primary, bovine primary and 
C2C12 myoblasts by the switching the cells from Proliferation Medium to 
Differentiation Medium.  Differentiation Media were the same as described for 
Proliferation Media except the 10% FBS was replaced with 2% HS.   
 
2.2.8.7  The passage and trypsinisation of mammalian cells 
The passage and harvesting of cells was achieved by the removal of medium, 
followed by two washes with phosphate buffered saline (PBS).  Trypsin (1 x, 
volume dependent on the size of the culture dish) was added to the cells and 
incubated at 37°C until cells had lifted off (~10 min).  After the cells had detached 
from the plastic, fresh medium was added and cells were aliquoted into new 
dishes at the required densities and returned to the incubator.  Cells to be 
harvested were washed off the culture dishes with Proliferation Medium 
depending on conditions at the time of extraction.  The cells were then transferred 
to a centrifuge tube, pelleted by centrifugation (4000 x g) and the pellets washed 
with PBS. 
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2.2.8.8  Transfection of mammalian cells on 10 cm cell culture plates 
Mammalian cells were transfected with the mammalian expression vectors 
described in the relevant Materials and Methods sections of the Results Chapters.  
Transfection of the constructs was performed using Lipofectamine 2000 (LF2000) 
reagent (Invitrogen) according to the manufacturer’s protocol.  Cells cultured on 
10 cm plates were approximately 80-90% confluent when transfected.  In separate 
tubes, 12.5 µg DNA and 40 µL LF2000 reagent were diluted in 800 µL serum-free 
DMEM each.  The diluted DNA and LF2000 were then complexed by the 
dropwise addition of LF2000 to the DNA and incubation at room temperature.  
After 20 min incubation, the DNA/LF2000 transfection mix was added to 6.4 mL 
of Proliferation Medium and added to pre-washed cells.  Cells were incubated 
with the transfection mix/Proliferation Medium at 37oC, in 5% CO2 overnight, 
after which the medium was replaced with straight Proliferation Medium and 
other relevant treatments. 
 
2.2.8.9  Transfection of C2C12 myoblast cells on 6 well cell culture plates 
C2C12 myoblast cells were transfected with the mammalian expression vectors 
described in the relevant Materials and Methods sections of the Results Chapters.  
Transfection of the constructs was performed using LF2000 reagent according to 
the manufacturer’s protocol.  Cells cultured on 6 well plates were transfected at 
densities dependent on the relevant medium to be used or the time interval for 
which the cells were to be treated, to prevent the cells reaching confluence prior to 
extraction.  In separate tubes, 2.0 µg of each DNA and 8 µL LF2000 reagent were 
diluted in 250 µL serum-free DMEM per well.  The diluted DNA and LF2000 
were then complexed by the dropwise addition of LF2000 to the DNA and 
incubation at room temperature.  After 20 min incubation, the DNA/LF2000 
transfection mix was added dropwise to 2 mL of Proliferation Medium contained 
within the relevant well(s), at the same time the plate was being rocked.  
Myoblasts were incubated with the transfection mix/Proliferation Medium at 
37oC, in 5% CO2 overnight, after which the medium was replaced with 
Proliferation Medium or Differentiation Medium and relevant treatments. 
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2.2.8.10  Transfection of C2C12 myoblasts with siRNA using HiPerFect 
C2C12 myoblast cells were transfected with the siRNA described in the relevant 
Materials and Methods sections of Chapter 5.  Transfection of siRNA was 
performed according to the manufacturer’s protocol (Qiagen).  Cells were cultured 
on 6 well plates in Proliferation Medium prior to transfection.  In a tube, 7.5 ng of 
each siRNA was diluted in 100 µL of DMEM (no serum) medium to a final 
concentration of 1 nM per well.  HiPerFect reagent (3 µL) was added to the 
diluted siRNA, mixed by vortexing, and incubated at room temperature for 5-10 
min.  The complexes were subsequently added drop-wise to the cells while the 
plates were gently swirled.  The cells were incubated with the transfection 
complexes for an appropriate time as per the experimental requirements. 
 
2.2.8.11  Selection of myoblasts containing stable integration of transfected 
constructs 
Mammalian cells were transfected as described in Section 2.2.8.8.  Following 48 
hr of incubation with Proliferation Medium, the antibiotic Geneticin (Invitrogen) 
was added to the medium at 400 µg/mL.  Cells were incubated as before for 24 hr 
and passaged to two 10 cm plastic dishes (Falcon).  Passaged cells were 
maintained in duplicate lines, with separate medium to safeguard against the loss 
of cell line by contamination.  Selection with Geneticin was continued for 20 
days, adding fresh Proliferation Medium when needed.  Negative control cells 
(not transfected, neomycin sensitive) had all died before day ten.  Resistant cells 
(expressing the neomycin resistance cassette) had formed individual colonies (at 
least 100), which were pooled to overcome individual variation and integration 
effects.  Clonal cell lines were generated by plating transfected cells at a clonal 
density of 25 cells/cm2, individual neomycin resistant colonies were isolated and 
further expanded to allow for expression analysis of the gene of interest.  Based 
on expression analysis, stable over-expressing clonal cell lines were selected for 
further study. 
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2.2.9  Harvesting of protein, the luciferase assay and β-gal assay 
C2C12 myoblasts grown on 6 well plates were transfected (see Section 2.2.8.9) 
and harvested following 2 washes with 5 mL PBS.  Harvesting occurred by 
scraping the cells off the wells using 300 µL of Reporter Lysis Buffer (Promega), 
the resulting lysate was transferred to a 1.5 mL eppendorf.  Following a vortex for 
10 s, the lysate was rapidly frozen on dry ice, directly followed by thawing to 
room temperature.  The lysates were subjected to a second 10 s vortex before they 
were centrifuged at 20,000 x g for 15 s to pellet cell debris.  The supernatant was 
then transferred to a new tube to be used in the subsequent luciferase or β-gal 
assay.   
The Luciferase Assay System (Promega) was used to measure the level of 
luciferase expression in C2C12 cells that had been transfected with promoter-
luciferase constructs.  The luciferase assays were performed according to the 
manufacturer’s protocol.  Relative luciferase activity of each of the extracted 
protein samples was measured by addition of 10 µL of each protein to 1.5 mL 
eppendorfs in triplicate.  Fifty µL of Luciferase Assay Reagent was then added to 
the protein and the subsequent luciferase activity measured using a Luminometer 
(TD-20/20 Turner Designs) with a delay time of 3 s and an integration time of 20 
s. 
Transfections of C2C12 myoblasts with 1 µg the pCH110 vector per well allowed 
for analyses of β-gal expression, which was used to normalise the luciferase 
values as a measure of transfection efficiency.  β-gal expression levels were 
detected using the β-Galactosidase Enzyme Asssay System (Promega) according 
to the manufacturer’s protocol.  Cell lysates were analysed using a 96 Well Plate 
Assay, where 50 µL of the extract was pipetted into the 96 well plate (Nalge 
Nunc).  Standards were also used which varied from 0-5.0 mU of β-gal.  All 
standards and samples were plated in duplicate.  Fifty µL of 2 x Assay Buffer was 
added to each well with pipetting to mix, followed by an incubation period at 
37ºC for 30 min.  Finally, 150 µL of 1 M Na2CO3 was added to each well to stop 
the reaction.  The absorbance of each sample was then measured using the EL-311 
microplate autoreader (Bio-Tek Instruments) at 420 nm.  The β-gal activity of 
each sample was determined by comparing each sample to the generated standard 
curve. 
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2.2.10  RNA extraction from cultured C2C12 myoblasts and muscle tissue 
Total RNA was isolated from cultured cells using TRIZOL as per the 
manufacturer’s protocol.  Proliferation Medium was removed from the culture 
dishes and the cells were washed twice with PBS to remove any cell debris.  Cells 
were lysed by the addition of TRIZOL (Invitrogen) reagent (2 mL per 10 cm plate) 
and the subsequent repeated passing of the lysates through a pipette.  The cell 
lysates were removed from the plate and placed in a 10 mL tube.  Following 5 
min incubation at room temperature 400 µL of Chloroform was added and the 
tubes were shaken vigorously for 15 s.  After 3 min incubation at room 
temperature the samples were centrifuged at 12,000 x g for 15 min.  The upper 
clear aqueous phase was then removed to a new tube and the RNA was 
precipitated with 1 mL of isopropyl alcohol.  Following 10 min incubation at 
room temperature the samples were centrifuged at 12,000 x g for 10 min.  The 
total RNA was then washed with 2 mL of 75 % ethanol and finally pelleted at 
7,500 x g for 5 min and resuspended in an appropriate volume of DEPC-treated 
MQ water.   
Total RNA was isolated from muscle tissue using TRIZOL as per the 
manufacturer’s protocol.  For every 50-100 mg of muscle tissue 1 mL TRIZOL 
was added and the sample was homogenised using an Ultraturrex (IKA).  After 5 
min incubation at room temperature, 200 µL of chloroform was added, and the 
tubes were shaken for 15 s.  Following incubation at room temperature for a 
further 3 min, the samples were centrifuged at 12,000 x g for 15 min.  The 
aqueous phase was removed to a new tube and total RNA precipitated with 0.5 
mL of isopropanol for 10 min at room temperature.  Total RNA was pelleted by 
centrifugation at 14,000 x g for 10 min.  The pellet was washed with 1 mL of 75% 
ethanol and resuspended in an appropriate volume of DEPC-treated MQ water.  
RNA isolated from cells and muscle was quantified using the NanoDrop 
spectrophotometer to measure concentration and purity.  In addition, RNA was 
subjected to electrophoresis (see Section 2.2.1.2) to check RNA quality.  All RNA 
samples were stored at -80°C prior to use. 
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2.2.11  RNA purification using the RNeasy midi kit (Qiagen) 
RNA was purified using the RNeasy kit for subsequent microarray analysis 
(Chapter 5 and Chapter 6).  RNA was initially isolated using TRIZOL reagent as 
per the manufacturer’s protocol (see Section 2.2.10).  Following isolation, the 
volume of the RNA solution (0.5-1.0 mg) was adjusted to 1 mL with DEPC-
treated water.  To the diluted RNA sample 4 mL of Buffer RLT along with 2.8 
mL of 100% ethanol was added.  The sample was subsequently applied to an 
RNeasy midi column and centrifuged for 5 min at 5000 x g with flowthrough 
discarded.  Buffer RW1 (2 mL) was then added to the column followed by 
centrifugation at 5000 x g for 4 min.  Two 2.5 mL volumes of Buffer RPE were 
subsequently applied to the column followed by centrifugation at 5000 x g for 4 
min and 10 min respectively.  The RNA was eluted from the column with 2 x 250 
µL applications of RNase-free water and centrifugation for 3 min at 5000 x g.  
The RNA was subsequently precipitated overnight with 1:10 volume of 0.3 M 
NaCl and three volumes of 100% ethanol at -20oC.  The DNA was then pelleted 
by centrifugation (>10,000 x g for 10-15 min).  The DNA pellet was washed twice 
in 70% ethanol, dried and resuspended in an appropriate volume of DEPC-treated 
MQ water.  The RNA was quantified using the NanoDrop spectrophotometer to 
measure concentration and purity.  In addition, the RNA was subjected to 
electrophoresis (see Section 2.2.1.2) to check RNA quality.  RNA samples were 
stored at -80°C prior to use. 
 
2.2.12  Northern Blotting 
Northern Blot analyses were performed to quantify gene expression changes in 
the relevant Results Chapters.  RNA samples were run out using formaldehyde gel 
electrophoresis as described in Section 2.2.1.2.  The gel was then soaked in 10 x 
SSC for 30 min to remove any contaminating formaldehyde.  The RNA was 
transferred to Hybond N+ (GE Healthcare Bio-Sciences) membrane by capillary 
action.  Following transfer, the blots were washed and the RNA was covalently 
cross-linked to the membrane using a UV light Stratalinker 1800 (Stratagene).  
Efficiency of the transfer and quality of the RNA was assessed by examining the 
membrane under UV light. 
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Cross-linked membranes were prehybridised in glass Hybaid bottles with 20 mL 
of Church and Gilbert hybridisation buffer at 55°C for approximately 1 hr prior to 
hybridisation.  Radiolabelled cDNA probes (see Section 2.2.7) were added to the 
hybridisation bottles (avoiding contact with the membrane) with fresh Church and 
Gilbert hybridisation buffer after the probes had been denatured with 0.2 volumes 
(5 µL) of 4 M NaOH for 5 min.  Hybridisation was performed in a hybridisation 
oven (Hybaid) for 16 hr.  Hybridisation temperatures and washing procedures are 
listed in the relevant Materials and Methods section of the Results Chapter where 
they were used.  Membranes were heat sealed in plastic and exposed to XAR film 
for the required time. 
 
2.2.13  Protein extraction from cultured mammalian cells and muscle tissue 
Total protein was extracted from myoblasts and C3H10T1/2 fibroblasts for 
immunoprecipitation and Western Blot analyses.  Harvesting of the cells was 
undertaken as described in Section 2.2.8.7 with the cell pellet resuspended in 200 
µL of Lysis Buffer (protein extraction buffer).  The cell lysate was either 
sonicated (1 s pulses for 30 s) using a Vibra Cell Sonicator (Sonics and Materials 
Inc.), or passed through as 26 gauge syringe needle 10 times.  To pellet cell debris 
the lysate was centrifuged at 12,000 x g for 10 min with the supernatant (protein 
extract) removed and transferred to a new 1.5 mL eppendorf tube for storage at -
80ºC until needed. 
Total proteins were extracted from muscle tissue for Western Blot analyses.  For 
muscle tissue protein extraction, whole muscle tissues were homogenised in at 
least 1 mL Lysis Buffer (protein extraction buffer) using an Ultraturrex (IKA).  
The homogenised sample was centrifuged (14,000 x g for 5 min) to pellet cell 
debris and the supernatant (protein extract) was stored at -80°C until needed.   
 
2.2.14  Bradford Assay 
The Bradford Assay (Bradford 1976) was used to provide an estimation of the 
total protein concentrations in protein extract samples.  Total protein (2 µL) was 
added to PBS to give a final volume of 100 µL Bradford Reagent concentrate 
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(Bio-Rad) was diluted 1 in 5 with MQ water and 1.2 mL was added to the diluted 
protein.  Samples were then mixed and the absorbance at 595 nm was measured 
using a UV spectrophotometer (Thermo Spectronic).  The absorbances of BSA 
standards (0 to 10 µg) were measured to generate a standard curve with which the 
unknown sample protein was compared. 
 
2.2.15  Western Blotting 
Western Blot analyses were performed to quantify gene expression changes in the 
relevant Results Chapters.  SDS-PAGE electrophoresis was undertaken as 
described in Section 2.2.1.3.  Following electrophoresis, the pre-cast gels were 
washed in Western Blot Transfer Buffer.  The protein was transferred to Trans-
Blot (Bio-Rad) Nitrocellulose membrane by electroblotting using the XCell II 
Blot Module (Invitrogen).  The membranes were then blocked overnight at 4ºC 
using a solution of TBST/5% low fat milk.  Alternatively, membranes were 
blocked for 1 hr at room temperature in 0.3% BSA solution.  Once blocking was 
complete, the membranes were ready for probing with the primary and secondary 
antibodies corresponding to the gene of interest. 
Antibodies used, concentrations and the detection of specific proteins is described 
in the Materials and Methods section of the Results Chapters where Western Blot 
analysis was used.  The secondary antibody (conjugated to Horseradish 
Peroxidase; HRP; Dako) was detected using Western Lightning (PerkinElmer) 
Western Blot Chemiluminescence Reagent. 
 
2.2.16  MHC immunocytochemistry 
Myoblasts were fixed with 70% ethanol:formaldehyde:glacial acetic acid (20:2:1) 
for 30 s, and then rinsed three times with PBS.  Cells were blocked overnight at 
4oC in 0.35% Carrageenen λ (Cλ) containing 5% normal sheep serum (NSS).  
Cells were incubated with primary antibody, 1:200 dilution mouse anti-MHC 
(MF20; DSHB), in Cλ/5% NSS for 1 hr.  Cells were washed (3 x 5 min) with 
TBST and incubated with secondary antibody, 1:300 dilution sheep anti-mouse 
IgG (RPN1001; GE Healthcare Bio-Sciences), in Cλ/5% NSS for 30 min.  Cells 
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were washed as before and incubated with tertiary antibody, 1:300 dilution of 
streptavidin-biotin peroxidase complex (RPN1051; GE Healthcare Bio-Sciences), 
in Cλ/5% NSS for 30 min.  MHC immunostaining was visualised using 3,3-
diaminobenzidine tetrahydrochloride (DAB; Invitrogen) enhanced with 0.0375 % 
CoCl.  MHC-immunostained cultures were counterstained with Gill’s 
haematoxylin and/or 1% eosin, dehydrated and mounted as described in Section 
2.2.17. 
 
2.2.17  Haematoxylin and eosin cell staining 
Cells were fixed with 70% ethanol:formaldehyde:glacial acetic acid (20:2:1) prior 
to staining.  Haematoxylin and eosin staining was performed as described below.  
Cells were incubated with 1:1 Gill’s haematoxylin for 2-4 min, rinsed with 
tapwater, then incubated for 2 min with Scott’s tapwater before counterstaining 
with 1% eosin for 2 min.  Following a rinse with tapwater the cells were 
dehydrated with washes of increasing concentrations of ethanol (1 x 50%, 1 x 
70%, 1 x 95%, and 2 x 100%) for 2 min each.  The cells were then incubated in 
Xylene for 2 x 5 min before mounting onto slides with DPX solution (BDH).   
 
2.2.18  Calculations used 
2.2.18.1  RNA quantification from absorbance 
µg RNA = 40 x (A260 / dilution) 
 
2.2.18.2  DNA quantification from absorbance 
µg DNA = 50 x (A260 / dilution) 
 
2.2.18.3  DNA concentration conversion from pM to µg and vice versa 
pM of dsDNA = µg (of dsDNA) x 106 pg x  1 pM  x    1     =  µg (of dsDNA) x 1,515 
                 1 µg        660 pg    n(bp)                     n(bp) 
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µg of dsDNA = pM (of dsDNA) x 660 pg x 1 µg  x n(bp) = pM (of dsDNA) x n(bp) x 6.6 x 10-4 
                1 pM     106 pg     
 
2.2.18.4  Insert:vector ratio calculation 
ng of vector x kb size of insert  x  insert:vector molar ratio  =  ng insert 
 kb size of vector 
 
2.2.19  Statistics 
Statistical analyses performed throughout this thesis are described in the specific 
results Chapters, 3, 4, 5 and 6. 
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Chapter 3  Proteolytic processing of myostatin 
 
The results in this Chapter are published in Developmental Biology vol. 283 
pages 58-69 (2005).  See CD attached to the back cover of this thesis (Appendix 
1) for a PDF copy of this paper. 
 
 
Abstract 
Myostatin, a potent negative regulator of myogenesis is proteolytically processed 
by furin proteases into active mature myostatin before secretion from myoblasts.  
Here it is show that mature myostatin auto-regulates its processing during 
myogenesis.  In a cell culture model of myogenesis, Northern Blot analysis 
revealed no appreciable change in myostatin mRNA levels between proliferating 
myoblasts and differentiated myotubes.  However, Western Blot analysis 
confirmed a relative reduction in myostatin processing and secretion by 
differentiated myotubes as compared to proliferating myoblasts.  Furthermore, in 
vivo results demonstrate a lower level of myostatin processing during foetal 
muscle development when compared to post-natal adult muscle.  Consequently, 
high levels of circulatory mature Myostatin were detected in post-natal serum, 
while foetal circulatory Myostatin levels were undetectable.  Furin proteases are 
important for proteolytically processing members of the TGF-β superfamily, 
therefore the ability of myostatin to control the transcription of furin and auto-
regulate the extent of its processing was investigated.  Transfection experiments 
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indicated that mature Myostatin indeed regulates furin protease promoter activity.  
Based on these results, it is proposed that myostatin negatively regulates its 
proteolytic processing during foetal development, ultimately facilitating the 
differentiation of myoblasts by controlling both furin protease gene expression 
and subsequent active concentrations of mature Myostatin peptide. 
 
3.1  Introduction 
 
Myostatin is a secreted growth factor and a member of TGF-β superfamily.  While 
lack of myostatin leads to increased muscle growth (Kambadur et al. 1997; 
McPherron et al. 1997), systemic injection of Myostatin leads to muscle wasting 
(Zimmers et al. 2002) indicating that myostatin acts as a potent negative regulator 
of skeletal muscle growth.  Myostatin expression is detected in embryonic, foetal, 
and post-natal myogenic cells suggesting it plays a role in all stages of 
myogenesis.  It is first detected in the myogenic precursor cells of the myotome 
compartment of developing somites (McPherron et al. 1997).  Myostatin 
expression continues throughout myogenesis and is detected post-natally at 
varying levels in different axial and paraxial muscles (Kambadur et al. 1997; 
McPherron et al. 1997).  Myostatin expression has also been detected at low 
levels in other mammalian tissues (McPherron et al. 1997; Ji et al. 1998; Sharma 
et al. 1999). 
The primary structure of myostatin contains several features shared with all 
members of the TGF-β superfamily.  These features include a hydrophobic core of 
amino acids near the N-terminus that functions as a secretory signal and a putative 
proteolytic processing site (RSRR) in the C-terminal half of the precursor protein 
(McPherron and Lee 1996).  The proteolytic processing of Myostatin is carried 
out by a calcium-dependent serine protease called furin (Lee and McPherron 
2001).  Furin belongs to a family of mammalian processing enzymes called 
proprotein convertases (PCs), of which seven members have so far been identified 
(Thomas 2002).  All PCs have overlapping cleavage site specificity and tissue 
distribution (Seidah and Chretien 1997; Steiner 1998).  In particular, furin is 
highly concentrated in the trans-Golgi network (Molloy et al. 1994; Molloy et al. 
1999).  Importantly, several TGF-β superfamily precursor proteins have been 
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shown to be cleaved by furin, including TGF-β1 (Dubois et al. 2001) and BMP-4 
(Cui et al. 1998; Constam and Robertson 1999; Cui et al. 2001).  The proteolytic 
processing of Myostatin results in both a N-terminal Latency-Associated Peptide 
(LAP, also referred to as pro-peptide) and a C-terminal mature Myostatin peptide 
(Thomas et al. 2000).  The mature Myostatin is secreted into circulation as a high 
molecular weight protein in association with various interacting proteins.  Titin 
cap and human Small Glutamine-rich Tetratricopeptide repeat-containing protein 
(hSGT) have been shown to associate with intracellular forms of myostatin 
(Nicholas et al. 2002; Wang et al. 2003).  While follistatin, Follistatin-Related 
Gene (FLRG) and Growth And differentiation factor-associated Serum Protein-1 
(GASP-1) have been shown to bind to the extracellular circulatory form of 
Myostatin (Lee and McPherron 2001; Hill et al. 2002; Hill et al. 2003).  Recently, 
it is shown that the circulatory latency Myostatin protein is activated by the BMP-
1/tolloid family of metalloproteinases (Wolfman et al. 2003) to release the mature 
Myostatin peptide.  The mature Myostatin presumably elicits its biological 
function by binding to its receptor, the Activin type-IIB receptor (Lee and 
McPherron 2001).  While the mature Myostatin can bind to the receptor, the N-
terminal LAP appears to be required for the correct folding, dimerisation and 
secretion of the mature peptide (Gray and Mason 1990).   
Mechanistically, myostatin appears to function by regulating myoblast cell cycle 
progression and differentiation.  During the active proliferation phase of myoblast 
growth, myostatin negatively regulates the G1 to S phase transition of the cell 
cycle through both Rb-dependent and -independent pathways (Thomas et al. 
2000; Langley et al. 2004).  In addition, excess myostatin also inhibits myoblast 
terminal differentiation by inactivating MyoD (Langley et al. 2002).  Although 
the function of myostatin is well defined, the significance of Myostatin processing 
and secretion during myogenesis has yet to be investigated.  Thus in this Chapter, 
myostatin expression, processing and secretion during myogenesis is investigated.  
The results presented here indicate that Myostatin processing and secretion is 
reduced during myogenesis.  An auto-regulatory loop, whereby myostatin self-
regulates its own converting enzyme appears to be a possible mechanism for the 
regulation of Myostatin processing during development.   
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3.2  Materials and Methods 
 
3.2.1  Cell culture 
Comprehensive methods covering cell culture and primary myoblast extraction 
are detailed previously (Thomas et al. 2000) (see Section 2.2.8).  Briefly, C2C12 
myoblasts were grown prior to assay in Proliferation Medium (Dulbecco’s 
modified Eagle’s medium, (DMEM; Invitrogen, Carlsbad, CA) containing 10% 
foetal bovine serum (FBS, Invitrogen) on uncoated plates, while primary bovine 
myoblasts were grown in minimum essential medium-Proliferation Medium 
(MEM, Invitrogen) containing 10% FBS on gelatin (Sigma, St Louis, MO) coated 
plates.  Differentiation was induced in the C2C12 myoblasts by culture in 
Differentiation Medium (DMEM) containing 2% horse serum (HS, Invitrogen) for 
24, 48, or 72 hr, and in primary bovine myoblasts by culture in MEM-
Differentiation Medium (with 2% HS) for 24, 48, or 72 hr.  
 
3.2.2  Transfections and luciferase assays 
For transfections C2C12 cells were seeded at a density of 15,000 cells/cm2 in 6-
well plates (Nalge Nunc International, Rochester, NY) with DMEM medium 
containing 10% FBS.  After a 24 hr attachment period the cells were transfected 
with 3 µg total plasmid DNA (2 µg of P1 Furin promoter (Blanchette et al. 2001) 
construct and 1 µg of SV40-β-galactosidase (β-gal) control vector, pCH110 (GE 
Healthcare Bio-Sciences Corp. Piscataway, NJ) using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s recommendations (see Section 
2.2.8.9).  The cultures were then incubated in an atmosphere of 5% CO2/37oC for 
a further 18 hr.  The medium was removed and replaced with either proliferation 
or differentiation medium.  Cultures were incubated in 5% CO2/37oC for a further 
24 hr.  Medium was then removed and cells rinsed twice with PBS (pH 7.4) and 
lysed in 300 µL of 1 x Reporter lysis buffer (Promega Corporation, Madison, WI).  
Lysates were collected and vortexed for 10 s. After a quick freeze-thaw the lysates 
were centrifuged at 12,000 x g for 15 s and 10 µL of the supernatant was analysed 
for luciferase reporter gene activity (Promega) in a Turner Designs Luminometer 
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(Model TD-20/20).  To control for variations in transfection efficiency, the 
transfections were performed in triplicate and each experiment repeated a 
minimum of three times.  The individual luciferase value for each assay was 
normalised against β-galactosidase expression. 
 
3.2.3  Myostatin indirect immunofluorescence microscopy and photography 
C2C12 myoblasts were grown prior to immunostaining in Proliferation Medium 
and seeded on Thermonox coverslips (Nalge Nunc) at a density of 15,000 
cells/cm2 for proliferation studies or 25,000 cells/cm2 for differentiation studies.  
Following a 16 hr attachment period, medium was changed to either Proliferation 
Medium (for the maintenance of actively proliferating myoblasts) or 
Differentiation Medium (for the induction of differentiation and formation of 
myotubes).  After 72 hr of incubation, cells were rinsed once with PBS and then 
fixed with 70% ethanol:formaldehyde:glacial acetic acid (20:2:1) for 30 s, rinsed 
three times with PBS and blocked overnight at 4oC in TBS containing 1% normal 
sheep serum (NSS).  Cells were incubated with the specific primary antibody; 
1:100 dilution anti-Myostatin antibody (Sharma et al. 1999) in TBS containing 
1% NSS for 1 hr.  Rabbit IgG (5 µg/mL; Dako, Copenhagen, Denmark) was used 
as a negative control.  Cells were washed (3 x 5 min) with TBS containing 0.1% 
Tween 20 (TBST) and incubated with secondary antibody; 1:150 dilution 
biotinylated donkey anti-rabbit IgG (RPN1004; GE Healthcare Bio-Sciences) in 
TBS/1% NSS for 30 min.  Cells were washed as before and incubated with 
tertiary antibody; 1:100 dilution of streptavidin-biotin fluorescein isothiocynate 
complex (FITC; RPN1232; GE Healthcare Bio-Sciences) in TBS/1% NSS for 30 
minutes.  Cells were again washed.  Myostatin-immunofluorescence was 
visualised using an UV emission wavelength of 520 nm (U-MWIG) filter, BH2-
RFL-T3 burner; Olympus Optical Co., Germany).  Cell nuclei were visualised by 
the addition of 0.3 µM 4, 6-diamidino-2-phenylindole, dihydrochloride (DAPI, 
Invitrogen) to the cells for 5 minutes followed by TBST wash (3 x 5 min), and an 
UV emission wavelength of 420 nm (U-MWU2 filter, BH2-RFL-T3 burner; 
Olympus).  FITC and DAPI fluorescence was photographed using an Olympus 
BX50 microscope (Olympus) fitted with a DAGE-MTI DC-330 colour camera 
(DAGE-MTI) and Scion Image Capture software. 
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3.2.4  Detection of Myostatin secreted into cell culture medium 
Mouse C2C12 myoblasts were seeded at the density mentioned above in 6-well 
plates and cultured in either Proliferation Medium or induced to differentiate in 
Differentiation Medium for 72 hr.  The formation of myotubes in Differentiation 
Medium cultured cells was confirmed by light microscopy.  After washing three 
times with PBS, the cultured myoblasts and myotubes were incubated with 
methionine-free Proliferation or Differentiation medium, respectively.  After 30 
min the cells were washed, followed by the addition of test medium.  Test 
medium consisted of methionine-free Proliferation or Differentiation Medium 
supplemented with 0.5 mCi/mL of L-[35S]-methionine (1 mCi = 37 MBq; GE 
Healthcare Bio-Sciences).  Cells were incubated in precisely 2 mL of this medium 
for 24 hr.  Conditioned media were collected for the immunoprecipitation of 
proteins, while the cells were harvested for the quantification of DNA content 
(Hoechst assay).   
 
3.2.5  Immunoprecipitation of Myostatin from conditioned medium.   
The conditioned media (300 µL) were pre-cleared prior to myostatin 
immunoprecipitation by incubating with 0.3 µg of anti-rabbit IgG HRP conjugate 
(P0448; Dako) for 30 minutes at 4°C.  Conditioned media were then incubated 
with 100 µL of 50% Protein A-Agarose (Invitrogen), washed twice with Lysis 
Buffer for 1 hr at 4°C, centrifuged and the supernatant (precleared medium) 
collected.  The precleared media were then incubated with 4 µL anti-Myostatin 
antibody for 1 hr at 4°C, incubated with 50% Protein A-Agarose (Invitrogen) 
(washed twice with Lysis Buffer) for 1 hr at 4°C and centrifuged to pellet the 
immunoprecipitated complexes.  Pellets were washed five times with lysis buffer.  
Pellets were then resuspended in 20 µL 4 x NuPAGE sample buffer (Invitrogen). 
Western Blot analysis for Myostatin was performed as described in Section 3.2.6.   
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3.2.6  Protein isolation and Western Blot analysis 
C2C12 and bovine primary myoblasts were cultured in Proliferation or 
Differentiation medium as outlined above (see Section 3.2.1).  Protein was 
isolated from the cultured cells as previously described (see Section 2.2.13).  
Briefly, myoblasts were resuspended in 200 µL lysis buffer (50 mM Tris pH 7.6; 
250 mM NaCl; 5 mM EDTA; 0.1% Nonidet P-40; Complete protease inhibitor 
(Roche Diagnostics Corporation, Indianapolis, IN) and passed through a 26 gauge 
needle 10 times.  Protein was isolated from muscle tissue as previously described 
(see Section 2.2.13).  Briefly, skeletal muscle tissue from M. vastus lateralis and 
M. semitendinosus were resuspended in 500 µL of lysis buffer and homogenised.  
The cell and muscle tissue extracts were then centrifuged to pellet cell debris with 
protein containing supernatant recovered.  Bradford Reagent (Bio-Rad 
Laboratories, Hercules, CA) was used to estimate total protein content to ensure 
equal loadings (see Section 2.2.14).  Total protein (15 µg) was separated by 4-
12% SDS-PAGE (Invitrogen) electrophoresis and transferred to nitrocellulose 
membrane by electroblotting.  The membranes were blocked in 5% milk in TBST 
overnight at 4ºC, followed by incubation with 1:2000 dilution of rabbit anti-
Myostatin antibody (Sharma et al. 1999) for 3 hr at room temperature.  The 
membranes were washed (5 x 5 min) with TBST and further incubated with 
1:2,000 dilution anti-rabbit IgG Horseradish Peroxidase (HRP) conjugate (P0448; 
Dako, Glostrup, Denmark) secondary antibody for 1 hr at room temperature.  The 
membranes were washed as above, and HRP activity was detected using Western 
Lightning Chemiluminescence Reagent Plus (NEL104; PerkinElmer Life And 
Analytical Sciences, Inc., Wellesley, MA) and exposure to XOMAT XAR film 
(Eastman Kodak Company, Rochester, NY).   
 
3.2.7  Hoechst assay for the quantification of DNA 
After the removal of the conditioned medium from the cultures, cells were washed 
in PBS and detached from the culture dishes by incubating with 0.25% Trypsin 
(Sigma) in PBS.  Cells were washed again with PBS and transferred to eppendorf 
tubes with 800 µL Phosphate buffered saline EDTA (PBSE; 40 mM 
Na2HPO4.H2O, 10 mM NaH2PO4.H2O, 2 M NaCl, 2 mM EDTA, pH7.4) 
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incubated on ice and sonicated twice for 15 s.  In a 96 well plate (Nalge Nunc), 15 
µL of each sample was added to 35 µL PBSE in triplicate.  Standards, (50 µL of 0 
to 20 µg/mL DNA) were also added to the 96-well plate (Nalge Nunc).  Freshly 
made Hoechst buffer (250 µL of 0.5 µg/mL Hoechst in PBSE) was added to each 
well and the plates read using a microplate reader (model 3550; Bio-Rad, 
Hercules, CA, USA) at 360 nm excitation and 460 nm emission wavelengths. 
 
3.2.8  Northern Blot analysis 
For Northern Blot analysis, mouse C2C12 or bovine primary myoblasts were 
cultured as described in Section 3.2.1 in either Proliferation Medium or 
Differentiation Medium.  RNA was isolated from cultured cells and skeletal 
muscle tissue using TRIZOL Reagent (Invitrogen) as per the manufacturer’s 
protocol (see Section 2.2.10).  Northern Blot analysis was performed as described 
in Section 2.2.12, using 12 µg total RNA and 0.66 M formaldehyde-1% agarose 
gel electrophoresis.  The membranes were hybridised with a 32P-labelled 
myostatin cDNA probe in Church and Gilbert Hybridisation Buffer at 60°C, 
overnight.  The membrane was washed at 60°C for 15 min each with 2 x SSC, 
0.5% SDS, and then 1 x SSC, 0.5% SDS.  The myostatin cDNA was obtained by 
RT-PCR.  First-strand cDNA was synthesised in a 20 µL reverse transcriptase 
(RT) reaction from 5 µg total RNA (from C2C12 cells) using the SuperScript II 
First-Strand Synthesis System (Invitrogen), according to the manufacturer’s 
protocol (see Section 2.2.6.1).  PCR was performed with 2 µL of the RT reaction 
at 94°C for 20 s, 52°C for 20 s, and 72°C for 1 min for 35 cycles using Taq 
polymerase (Roche).  This was followed by a single 72°C extension step for 5 
min.  The primers used for the amplification were 5’-GGT ATT TGG CAG AGT 
ATT GAT GTG-3’ and 5’-GTC TAC TAC CAT GGC TGG AAT-3’ (514 bp). 
The myostatin cDNA was radioactively labelled using α32P-(dCTP) (GE 
Healthcare Bio-Sciences) and Rediprime II labelling kit (GE Healthcare Bio-
Sciences) as described in Section 2.2.7. 
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3.2.9  Detection of circulating levels of Myostatin.   
Bovine serum samples were obtained from foetal days 70, 90, 138, 150, 165, 240 
through to adult.  2 µL of serum from each sample was loaded onto a 4-12% Bis-
Tris pre-cast gel (Invitrogen).  Subsequent Western Blot analysis for Myostatin 
was performed as described in Section 3.2.6. 
 
3.2.10  Detection of myostatin in wild-type and myostatin-null mice. 
One mL of lysis buffer (PBS, pH 7.2) with 0.05% IGEPAL detergent (Sigma) and 
an enzyme inhibitor (Roche) was added to 100 mg of muscle from each animal. 
Samples were homogenised on ice, then centrifuged at 11,000 x g for 10 min. 
Supernatant was recovered, mixed with Laemmli loading buffer (Laemmli 1970), 
boiled for 5 min, then stored at -20°C until analysis. The protein concentration of 
the supernatant was determined using the bicinchoninic acid assay (Sigma).  
Twenty µg of protein from each muscle sample was loaded and separated in a 
10% SDS-polyacrylamide gel under reducing conditions, then transferred to a 
nitrocellulose membrane.  After transfer, membranes were stained with Ponceau S 
to verify transfer of protein.  Membranes were blocked and incubated in 0.05 M 
tris buffered saline with 0.05% Tween 20 (TBST, pH 7.6), containing 0.3% BSA, 
1% polyethylene glycol (3,350 Mw), 1% polyvinylpyrrolidone (10,000 Mw).  
Membranes were incubated with either rabbit anti-Myostatin, or goat anti-
Myostatin (1:5000, sc-6884, Santa Cruz Biotechnology Inc.).  Twenty four hr 
later, membranes were washed in TBST, then incubated for 2 hr with either 
1:10,000 dilution of HRP conjugated anti-rabbit antibody (A0545; Sigma), or 
1:5,000 dilution of HRP conjugated anti-goat antibody (P0160; Dako. Glostrup, 
Denmark) against respective primary antibodies, then washed again in TBST.  
Bound HRP activity was detected with enhanced chemiluminescence and then 
blots were exposed to XOMAT XAR film (Eastman Kodak Company).   
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3.2.11  Biological activity of circulating Myostatin 
The AgResearch Ruakura Animal Ethics Committee approved all animal 
manipulations described in this paper.  Standard superovulation and embryo 
transfer techniques were used to generate bovine Hereford x Friesian crossbreed 
foetuses as described by Kambadur et al. (Kambadur et al. 1997).  Cows were 
slaughtered at the Ruakura abattoir when foetuses were at gestational age 120, 
210 and 260 days. Foetal blood was collected via cardiac puncture and allowed to 
clot at 4oC overnight. Serum was then separated from the clot via centrifugation at 
4200 rpm for 20 min. Serum was then filtered through a sterile 0.22 µm 
membrane. 
Serum was then added to test medium at a concentration of 10%. This test 
medium consisted of DMEM (Invitrogen), buffered with NaHCO3 (41.9 mmol/l, 
Sigma) and gaseous CO2.  Phenol red (7.22 nmol/L, Sigma) was used as a pH 
indicator.  Penicillin (1 x 105 IU/l) and Streptomycin (100 mg/l, Sigma) were also 
included in the medium. 
Cell proliferation assays were then conducted to test the biological activity of the 
serum.  C2C12 (Yaffe and Saxel 1977) cultures were seeded at 1,000 cells/well (3 
x 103 cells/cm2) in Nalge Nunc 96 well dishes in Proliferation Medium.  After a 
24 hr attachment period medium was decanted and test medium described above 
added back to the plates. Test samples were randomly distributed over the plate in 
order to avoid possible edge effects. 
Plates wrapped in parafilm then incubated in an atmosphere of 37oC 5% CO2.  
The plate was fixed at 72 hr post medium change, and assayed for proliferation by 
the method of Oliver et al. (1989) (Oliver et al. 1989).  Briefly, Proliferation 
Medium was decanted and cells washed once with PBS then fixed for 30 min in 
10% formol saline.  The fixed cells were then stained for 30 min with 10 g/L 
methylene blue in 0.01 M borate buffer (pH 8.5).  Excess stain was then removed 
by four sequential washes in borate buffer.  Methylene blue was then eluted off 
the fixed cells by the addition of 100 µL of 1:1 (v/v) ethanol and 0.1 M HCL.   
The plates were then gently shaken for 30 s and absorbance at 655 nm measured 
for each well by a microplate photometer (Bio-Rad model 3550 microplate reader, 
Bio-Rad, Hercules, CA). Absorbance is directly proportional to cell number in 
this assay. 
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3.2.12  Statistics 
For the transfection experiments, the mean luciferase values were calculated per 
well and the three means averaged over three independent experiments.  
Myostatin secretion was measured by densitometry analysis of Autoradiographs, 
which were adjusted for background and normalised to total DNA content of the 
cells.  The ratio between three replicates was calculated.  To determine the 
significance level of differences between two groups Student’s-T test was used.  
Statistical analysis was performed in Excel.  A P value of <0.05 was deemed 
significant for all experiments. 
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3.3  Results 
 
3.3.1  Intracellular localisation of Myostatin 
Indirect immunofluorescence microscopy was performed on myoblasts and 
myotubes to investigate if there are any qualitative changes in Myostatin 
distribution during myogenesis.  C2C12 cell cultures were used for 
immunostaining.  The immunofluorescence microscopy studies show that 
Myostatin protein was detected in actively proliferating C2C12 myoblasts (Figure 
3.1A and Figure 3.1C).  Specifically, Myostatin immunofluorescence was mainly 
localised in a peri-nuclear pattern, often showing the characteristic reticular 
morphology seen for TGF-β1 (Figure 3.1C) (Miyazono et al. 1992; Mizoi et al. 
1993; Roth-Eichhorn et al. 1998).  In contrast to actively proliferating myoblasts, 
Myostatin immunostaining in differentiated myotubes was mainly localised 
throughout the cytoplasm (Figure 3.1E).   
 
3.3.2  Myostatin processing is regulated during differentiation 
Myostatin protein is synthesised and secreted from myoblasts and it is shown that 
secreted Myostatin regulates myoblast growth and differentiation systemically 
(Zimmers et al. 2002). Thus processing and/or secretion of Myostatin play a 
critical role in the myogenesis.  To investigate if changes in either transcription or 
post transcription events regulate active levels of myostatin during myogenesis, 
the levels of myostatin mRNA and the level of Myostatin processing was 
examined during the differentiation of myoblasts in a cell culture system.  In this 
experiment, bovine primary myoblasts were grown in either Proliferation Medium 
or induced to differentiate in Differentiation Medium for 24, 48 and 72 hr before 
being harvested for total RNA and protein.  Northern Blot analysis revealed that 
myostatin mRNA (2.9 kb) was present in all of the total RNA extracts, with no 
appreciable change in the levels between myoblasts cultured in Proliferation 
Medium and myoblasts undergoing differentiation in Differentiation Medium 
(Figure 3.2A).   
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Figure 3.1  Myostatin intracellular localisation is altered between C2C12 
myoblast and myotube populations 
Immunofluorescence microscopy showing Myostatin localisation in (A) 
proliferating C2C12 myoblasts and (E) differentiated C2C12 myotubes.  
Myostatin-immunoreactive protein was detected using anti-Myostatin antibodies 
and FITC staining.  (G) Anti-rabbit IgG negative-control on differentiated C2C12 
myotubes.  (B), (D), (F) and (H) DAPI stained cell nuclei of plates (A), (C), (E) 
and (G) respectively.  Bar equals 50 µM.  Panels (C) and (D) are larger inserts of 
(A) and (B) respectively. 
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In the Western Blot analysis using Myostatin-specific antibodies, no precursor 
Myostatin was observed in the myoblasts cultured in Proliferation Medium.  In 
the myoblasts undergoing differentiation, however, a relatively high level of 
precursor Myostatin was detected (Figure 3.2B).  In contrast to the precursor 
Myostatin, the level of LAP and mature Myostatin appeared to be slightly higher 
in actively proliferating myoblasts than in the differentiating myoblasts (Figure 
3.2B).  In addition, Western Blot analysis was performed using our in-house 
Myostatin-specific antibody and a commercially available GDF-8 antibody (sc-
6884, Santa Cruz), using muscle protein extracts from wild-type and myostatin-
null mice.  As shown in Figure 3.2C the myostatin-specific antibodies fail to 
detect the strong 26-kDa protein band, which is observed in the wild-type 
controls.  Therefore this supports the assignment of the 26-kDa band to mature 
Myostatin. 
In addition to the bovine primary myoblasts, mouse C2C12 myoblasts were 
cultured in either Proliferation Medium or Differentiation Medium for 24 hr and 
myostatin processing was examined by Western Blot analysis.  In the C2C12 
myoblasts cultured in Proliferation Medium, the majority of Myostatin protein 
that was detected was the 26-kDa mature and 40-kDa LAP forms.  Only a 
relatively low level of precursor Myostatin was detected (Figure 3.3A).  In 
myotubes by contrast, relatively high levels of the 52-kDa precursor Myostatin 
were detected, while low levels of the 40-kDa LAP and no 26-kDa mature 
Myostatin were detected (Figure 3.3A).  These results suggest that there is a 
change in the in the level of proteolytic processing of Myostatin during myogenic 
differentiation.   
 
3.3.3  Myoblasts and myotubes secrete Myostatin protein 
Northern and Western Blot analysis performed on myoblast extracts indicated that 
while there is no change in myostatin mRNA during myogenic differentiation, 
there is a dramatic difference in proteolytic processing of Myostatin protein.  
Since proteolytic processing of the TGF-β superfamily members must occur for 
secretion, it is possible that more Myostatin protein is retained in myotubes 
compared to myoblasts where the majority of Myostatin is processed and  
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Figure 3.2  Myostatin processing is regulated during myogenic differentiation 
A) Northern Blot showing myostatin mRNA levels in primary bovine myoblasts 
cultured from foetal day 70 hindlimb muscle in Proliferation Medium (prolif.) or 
Differentiation Medium for 24, 48 or 72 hr.  The Northern Blot was probed with a 
514 bp myostatin cDNA probe.  The 2.9 kb myostatin transcript is indicated.  
Ethidium bromide stained formaldehyde/agarose gel showing 28S and 18S rRNA 
is also included.  B) Western Blot showing the levels of precursor, LAP and 
mature Myostatin in primary bovine myoblasts cultured from foetal day 70 
hindlimb muscle in Proliferation Medium (prolif.) or Differentiation Medium for 
24, 48 or 72 hr.  C) Western Blot showing the levels of LAP and mature 
Myostatin between muscle samples obtained from wild type (WT) and myostatin-
null mice (KO).  Two different antibodies were used, our in house anti-Myostatin 
antibody (FMG) and a commercially available GDF-8 antibody from Santa Cruz 
(SC). 
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presumably secreted.  To investigate if the rate of Myostatin secretion differs 
between myoblasts and differentiated myotubes, C2C12 myoblasts or myotubes 
were cultured for 72 hr and Myostatin protein was immunoprecipitated from the 
conditioned medium.  To distinguish between exogenous Myostatin in the 
medium serum (10% and 2% in proliferating and differentiated cultures, 
respectively) and endogenous Myostatin secreted from the cells, the cultures were 
pulsed with S35-methionine for a period of 24 hr.  Myostatin labelled with S35-
methionine therefore represented de novo synthesised and secreted Myostatin.  A 
Hoechst Assay was also performed on the cultured cells to normalise the detected 
myostatin to DNA content.  As can be seen in Figure 3.3B and Figure 3.3C, less 
mature and LAP Myostatin protein was detected, per DNA content, in the 
myotube conditioned medium than in the proliferating myoblast conditioned 
medium.  This result supports the above observations that there is greater 
proteolytically processing of precursor Myostatin to LAP and mature forms in 
proliferating myoblasts than in differentiated tubes.  Thus an increase in 
processing results in more secretion of Myostatin by the myoblasts, while 
unprocessed precursor Myostatin is retained intracellularly in the myotubes. 
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Figure 3.3  Secretion of Myostatin is regulated during myogenic differentiation 
A) Western Blot showing the levels of precursor, LAP and mature Myostatin in 
C2C12 myoblasts cultured in Proliferation Medium (prolif.) or Differentiation 
Medium (diff.) for 24 hr.  Myostatin-immunoreactive protein was detected using 
anti-Myostatin antibodies.  B) Autoradiograph of metabolically-labelled LAP and 
mature Myostatin immunoprecipitated from the conditioned medium of 
proliferating C2C12 myoblasts (prolif.) or differentiated C2C12 myoblasts (diff.).  
Myostatin-immunoreactive protein was immunoprecipitated using anti-Myostatin 
antibodies and fractionated by SDS-polyacrylamide gel electrophoresis.  C) Graph 
showing the ratio of Myostatin secretion between proliferating and differentiated 
myoblasts for the LAP and Processed forms.  Myostatin secretion was measured 
by densitometry analysis of Autoradiographs in (B), adjusted for background and 
normalised to total DNA content of the cells.  Bars represent the average ratio of 
three replicates.  Statistical differences determined by Student’s-T test are 
indicated, P<0.01 (**) and P<0.05 (*) compared to Prolif. sample.   
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3.3.4  Myostatin processing is regulated during development 
Previously it has been demonstrated that precursor Myostatin protein is 
synthesised in myoblasts and proteolytically processed prior to secretion as a 
mature form (Thomas et al. 2000).  Since mature Myostatin is the active signaling 
peptide, proteolytic processing plays a significant role in the regulation of 
myostatin function during myogenesis.  Although it has been shown that 
Myostatin protein is present in myoblasts and adult muscle fibres, the pattern of 
myostatin processing during myogenic development is not yet known.  Hence, 
Western Blot analysis was performed on protein extracts from bovine foetal day 
61 hind limb, as well as M. vastus lateralis (vl.) and bovine M. semitendinosus 
(st.) muscles collected from various time points (foetal day 120 to post-natal day 
14).  Myostatin protein was detected in the precursor (52-kDa) and LAP (40-kDa) 
forms in nearly all of the bovine vl. muscle extracts (Figure 3.4A).  In the foetal 
day 61 muscle extract, a relatively high level of precursor Myostatin was 
observed.  No LAP was detected, even with a longer exposure of the Western Blot 
to autoradiography film (Figure 3.4A).  As the foetal age increased (foetal days 
120-260) a decrease in the amount of precursor Myostatin and a corresponding 
increase in LAP was observed (Figure 3.4A).  Post-natally, the predominant form 
of Myostatin present was LAP, with very little precursor Myostatin being detected 
(Figure 3.4A).  To determine the level of myostatin mRNA expression, Northern 
Blot analysis was performed on total RNA extracted from the same source 
(Bovine hindlimb muscle, foetal day 61 and vl. Muscle, foetal day 120 to post-
natal day 14) used in the Western Blot analyses.  As shown in Figure 3.4B, 
myostatin mRNA of 2.9 kb was detected in all of the bovine muscle samples from 
foetal day 61 through to post-natal day 14.  At foetal days 61 and 120, myostatin 
mRNA was relatively abundant.  At foetal days 160 to 260 and full-term 
(280/post-natal day 1) the relative levels of myostatin mRNA were increased, 
peaking at the day 260 and full-term time points.  Post-natally, myostatin mRNA 
levels dramatically declined, as seen by the relatively low level of myostatin 
mRNA in post-natal days 8 to adult (Figure 3.4B).  In addition to the vl. muscle, 
myostatin processing during development was also examined in the M. 
semitendinosis muscle.  A similar overall pattern of processing that is seen in the 
vl. muscle was also observed in the st. muscle (Figure 3.4C).  The observed 
increase in Myostatin processing during gestation suggests that the extent of 
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Myostatin processing is regulated during embryonic and foetal bovine 
myogenesis. 
Like other TGF-β superfamily members, proteolytic processing of the Myostatin 
precursor molecule results in the formation of two distinct peptides, the LAP 
peptide and the C-terminal mature peptide (McPherron et al. 1997).  Following 
processing both The LAP and mature Myostatin dimer are maintained in a 
circulatory latent complex (Lee and McPherron 2001).  Thus, to investigate if the 
extent of Myostatin processing at the site of synthesis correlated with the amount 
of circulatory Myostatin, the levels of Myostatin in foetal blood during 
development was analysed.  The results show that mature Myostatin was virtually 
undetectable during early embryonic and foetal growth.  However, post-natally 
high levels of 26-kDa mature Myostatin was detected, confirming that reduced 
processing indeed results in low systemic levels of Myostatin (Figure 3.4D).  
These results, investigating the expression of myostatin, suggest that there is an 
increase in myostatin mRNA and an increase in the proteolytic processing of 
myostatin during foetal development.  Post-natally however, myostatin mRNA 
expression declines but a high level of processing is still maintained.   
To determine if the increase in myostatin processing during foetal development is 
significant with respect to myostatin function, the biological activity of circulating 
Myostatin was measured.  As shown in Figure 3.5, C2C12 cells treated with 
serum obtained from day 260 bovine foetuses showed a 13% decrease in 
proliferation when compared to cells treated with serum obtained from earlier 
gestational time points.  This decrease in proliferation coincides with the large 
increase in Myostatin processing seen from day 260 onwards (Figure 3.4).   
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Figure 3.4  Myostatin processing is regulated during development 
A) Western Blot showing the levels of Myostatin precursor and Latency-
Associated Peptide (LAP) in M. vastus lateralis.  B) Northern Blot showing 
myostatin expression in M. vastus lateralis from foetal days 61, 120, 160, 210, 
260 and post-natal 1, 8, 14 and adult cattle.  The Northern Blot was probed with a 
514 bp myostatin cDNA probe.  The 2.9 kb myostatin transcript is indicated.  
Ethidium bromide stained formaldehyde/agarose gel showing 28S and 18S rRNA 
is also included.  C) Western Blot showing the levels of Myostatin precursor and 
LAP in M. semitendinosus from foetal days 61, 120, 160, 210, 260 and post-natal 
1, 8 and 14 cattle.  Myostatin-immunoreactive protein was detected using anti-
Myostatin antibodies. D)  Western Blot showing the serum levels of mature 
Myostatin from foetal days 70, 90, 138, 150, 165, 240 to adult.  2 µL of total 
serum was loaded and analysed for Myostatin expression using specific anti-
Myostatin antibodies. 
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Figure 3.5  Biological activity of circulating Myostatin is altered during foetal 
development 
The biological activity of Myostatin in circulating foetal blood was assessed by 
collecting blood from known age bovine foetuses. This blood was then used to 
make serum and the biological activity of the serum assessed by its ability to 
promote the proliferation of C2C12 myoblasts in a 72 hr methylene blue cell 
staining proliferation assay. Absorbance at 655 nm is directly proportional to cell 
number at the conclusion of the assay. 
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3.3.5  Mature Myostatin regulates furin promoter activity 
Results shown above clearly indicate that differentiation somehow reduces 
processing of Myostatin.  Furin proteases are responsible for proteolytically 
processing TGF-β superfamily members; therefore the observed reduction in the 
processing may be due to reduced furin expression.  To prove this, the P1 furin 
promoter-luciferase reporter construct was transfected into C2C12 myoblasts, 
with subsequent promoter reporter activity measured during proliferating and 
differentiating conditions.  Consistent with the reduction in processing of 
Myostatin protein, furin promoter activity is also reduced in differentiated tubes as 
compared to actively growing myoblasts (Figure 3.6A).  This result indirectly 
suggested that furin gene expression could be regulated by myostatin.  Thus furin 
promoter-luciferase reporter activity was measured in the presence and in the 
absence of Myostatin.  As shown in Figure 3.6B, treatment of the P1 furin 
promoter with Myostatin decreases the promoter activity in a concentration 
dependent manner.  This result indicates that the furin promoter is negatively 
regulated by myostatin. 
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Figure 3.6  Mature Myostatin regulates furin promoter activity 
A) in vitro analysis of the furin promoter during proliferation and differentiation 
conditions.  The furin promoter and β-galactosidase (β-gal) expression plasmids 
were transfected into C2C12 myoblasts.  The cells were grown for a further 24 hr 
in either Proliferation or Differentiation Medium after which luciferase and β-gal 
activity was measured.  Results reflect relative furin promoter-luciferase activity 
normalised to β-gal.  Bars indicate means ± standard error of three independent 
experiments.  Statistical differences determined by Student’s-T test are indicated, 
P<0.05 (*) compared to Prolif. control.  B) in vitro analysis of the effect of 
myostatin on furin promoter activity during proliferation conditions.  The furin 
promoter and β-galactosidase (β-gal) expression plasmids were transfected into 
C2C12 myoblasts.  The cells were grown for a further 24 hr in Proliferation 
medium after which luciferase and β-gal activity was measured.  Results reflect 
relative change in furin promoter luciferase activity with increasing Myostatin 
concentration (+ 0.5 µg/mL, ++ 3 µg/mL) as compared to the un-treated control (-
).  Luciferase values were normalised to β-gal and the bars indicate means ± 
standard error of three independent experiments.  Statistical differences 
determined by Student’s-T test are indicated, P<0.001 (***) and P<0.01 (**) 
compared to un-treated control (-). 
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3.4  Discussion 
 
Previously published results have shown that myostatin is synthesised in both 
myoblasts and in muscle fibres, proteolytically processed, and secreted as a 
mature Myostatin peptide (Thomas et al. 2000).  However, the processing and 
secretion during myogenesis has not been widely investigated.  In this Chapter, it 
is demonstrated that the processing and secretion of Myostatin is reduced upon 
differentiation or during foetal fibre formation stages.  Furthermore it is shown 
that myostatin auto-regulates the extent of processing by regulating the gene 
expression of its converting enzyme, furin.   
Myostatin expression during development - Northern Blot analysis revealed that 
myostatin expression is developmentally regulated (Figure 3.4B).  Myostatin 
mRNA was abundant during early foetal development (days 61 and 160), 
increasing at foetal day 160.  A relatively high level of myostatin mRNA was 
observed in each gestational time point from day 160 onward, the peak expression 
being observed in the day 260 sample.  After birth, the levels of myostatin mRNA 
declined dramatically and remained low in all the post-natal days (8, 14 and adult) 
observed.  These results are predominantly in agreement with other results 
published from our laboratory in which myostatin expression is examined by RT-
PCR in bovine M. semitendinosus muscle over the same time period (Oldham et 
al. 2001).  In the published results, a dramatic and transient increase in myostatin 
expression is also observed at foetal day 90; which lies between the two foetal 
time points, day 61 and 120, examined by Northern Blot analysis in this study.  
This peak expression of myostatin coincides with the peak expression of MyoD.  
In addition, published results from our laboratory has demonstrated that the 
bovine myostatin promoter is a downstream target gene of MyoD (Spiller et al. 
2002).  Thus it is quite possible that the developmental expression pattern of 
myostatin is predominately regulated by MyoD.   
Myostatin indirect immunofluorescence microscopy experiments on myoblasts 
and myotubes confirmed that myostatin is synthesised in muscle cells (Figure 
3.1).  Myostatin-immunoreactive protein was detected in both proliferating 
myoblasts and nascent myotubes; localised in a perinuclear pattern (Figure 3.1).  
In addition, Myostatin was localised throughout the cytoplasm in the myotubes 
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(Figure 3.1).  These findings are consistent with studies examining TGF-β in 
several cell types, whereby TGF-β1 is localised to a perinuclear region, 
sometimes showing a characteristic reticular morphology (Miyazono et al. 1992; 
Mizoi et al. 1993; Roth-Eichhorn et al. 1998).  In one of these studies, the 
subcellular localisation of TGF-β1 was determined by immunoelectron 
microscopy to be in the lumen of the rER and perinuclear cisternae of fibroblasts, 
macrophages, and endothelial cells, indicating the biosynthetic process of the 
protein (Mizoi et al. 1993).  In another study, immunofluorescence microscopy of 
human erythroleukemia cells (HEL) revealed that TGF-β co-localises with 
mannosidase II, an integral Golgi protein (Miyazono et al. 1992).  Taken together 
these studies indicate TGF-β is synthesised and secreted via the endoplasmic 
reticulum and Golgi, respectively (Miyazono et al. 1992; Mizoi et al. 1993; Roth-
Eichhorn et al. 1998).  Based on these reports, it is possible that the perinuclear 
localisation of Myostatin reflects its synthesis and processing in the endoplasmic 
reticulum and Golgi.  However, co-localisation studies using Golgi-specific 
markers, such as mannosidase II, would be required to determine this for certain.  
In addition to the perinuclear localisation of Myostatin, a diffuse 
immunofluorescence was detected in the cytoplasm of the nascent myotubes 
supporting the observation that less Myostatin is secreted in myotubes.  
Intracellular retention has also been observed for other members of the TGF-β 
superfamily, including Activin A, TGF-β1 (Miyazono et al. 1992; Roth-Eichhorn 
et al. 1998), TGF-β2 (Jakowlew et al. 1991; Roth-Eichhorn et al. 1998) and TGF-
β3 (Roth-Eichhorn et al. 1998).  Latent TGF-β binding proteins (LTBPs) have 
been proposed to play a role in the cytoplasmic retention of TGF-β1, -β2 and -β3 
(Oklu and Hesketh 2000).  It is unlikely that LTBPs would regulate Myostatin 
secretion, since yeast two hybrid and co-immunoprecipitation studies did not 
detect any interaction between LTBPs and Myostatin (data not shown).  However, 
previously published results from our laboratory suggest that the protein Titin-Cap 
(T-cap) could regulate the intracellular levels of Myostatin, due to the fact that 
over-expression of T-cap leads to reduced secretion of Myostatin (Nicholas et al. 
2002).  Further myostatin-interacting proteins, including follistatin, FLRG and 
GASP-1, appear to be unlikely candidates since they have been shown to interact 
with Myostatin in circulation, following secretion (Lee and McPherron 2001; Hill 
et al. 2002; Hill et al. 2003). 
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Processing and secretion of myostatin during myogenic differentiation - Changes 
in the extent of Myostatin proteolytic processing and secretion were observed 
between actively proliferating myoblasts and differentiated myotubes (Figure 3.2 
and 3.3).  In actively proliferating mouse C2C12 and bovine primary myoblasts, 
the predominating forms of Myostatin detected were the mature Myostatin and/or 
LAP suggesting that the Myostatin precursor protein is being proteolytically 
processed.  In differentiating and nascent myotubes by contrast, Myostatin was 
observed predominantly in the precursor form.  Consistent with the processing 
results, relatively more Myostatin was secreted in proliferating myoblasts as 
compared to fully differentiated myotubes.  Since the Myostatin that was detected 
was metabolically labeled, it likely reflects the de novo synthesis from the cells 
and not Myostatin introduced by medium differences.  Although the processing of 
myostatin is altered during myogenesis, no appreciable change in myostatin 
mRNA expression was observed in the bovine primary myoblasts.  Levels of LAP 
and mature Myostatin were measured between muscle tissues from wild-type and 
myostatin-null mice.  A dramatic loss of the 26-kDa mature Myostatin protein 
band was observed in myostatin-null mice when using two different Myostatin-
specific antibodies (Figure 3.2C), thus providing evidence for the validity of the 
protein bands assigned to Myostatin.  However, a faint band running at 26-kDa is 
observed in the myostatin-null muscle tissue, this could be attributed to antibody 
cross reactivity with GDF-11 as GDF-11 shares a high homology with the mature 
region of Myostatin. 
Processing and secretion of myostatin during myogenesis - Lowered levels of 
Myostatin processing occur during foetal muscle development when compared to 
post-natal adult muscle (Figure 3.4).  The primary observation in the examination 
of Myostatin expression by Western Blot analysis is the progressive shift in 
Myostatin expression from precursor protein to LAP (Figure 3.4A & Figure 
3.4C).  At foetal day 61 most of the Myostatin detected was present in the 
precursor form.  Between foetal days 160 and 210, relatively more processing 
resulted in reduced precursor Myostatin and increased LAP.  From foetal day 260 
onward, the majority of observed Myostatin was present in the LAP form 
suggesting almost all of the synthesised Myostatin is processed.  Since the 
processing of TGF-β superfamily members is required for secretion, and 
moreover secretion occurs rapidly after processing (Miyazono et al. 1992; Roth-
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Eichhorn et al. 1998), this observation suggests that during late foetal 
development more Myostatin is secreted.  This increase in myostatin secretion, in 
conjunction with an up-regulation of myostatin gene expression, implies that there 
is a large increase in mature Myostatin from day 210 in the developing foetus.  
This is indeed supported by western analysis results of foetal systemic Myostatin 
levels (Figure 3.4D).  While virtually all the secreted Myostatin is undetectable 
during early foetal development, during post-natal adult stages abundant levels of 
Myostatin were present.  Myostatin systemic expression was not detected during 
days 165 and 240 despite processing occurring.  This could be due to the fact that 
Myostatin circulatory levels during these time points were below the limits of 
detection for Western Blot analysis.  The dramatic increase in mature Myostatin 
from day 210 in the foetus may result in the production of biologically active 
Myostatin.  To examine this a well characterised bioassay for myostatin was 
performed (Thomas et al. 2000).  The results show there is a 13% drop in C2C12 
proliferation rate in cells treated with serum obtained from foetal day 260 cattle 
compared to cells treated with foetal day 210 serum (Figure 3.5).  This drop in 
proliferation rate is consistent with known myostatin function and interestingly, 
coincides with the dramatic increase in Myostatin processing observed during 
foetal day 260 (Figure 3.4).   
Low levels of circulatory Myostatin during early foetal development may allow 
for the differentiation of primary and secondary waves of myoblasts to occur 
during myogenesis, due to the fact that excess amounts of mature Myostatin have 
been shown to cause a down-regulation of MyoD expression, resulting in the 
inhibition of myogenic differentiation of C2C12 myoblasts (Langley et al. 2002).  
Thus to reduce the availability of biologically active Myostatin and facilitate the 
process of post-mitotic differentiation, myoblasts could facilitate a reduction in 
processing of Myostatin by an auto-regulatory mechanism.  For such an auto-
regulatory mechanism to be feasible, ligands involved in the functioning of TGF-β 
family members should be able to directly regulate proteolytic processing 
enzymes.  Furin has been shown to cleave several TGF-β family members 
including bone morphogenetic protein-4 (BMP-4) and TGF-β1 (Cui et al. 1998; 
Dubois et al. 2001).  Previously, it has been shown that TGF-β up-regulates its 
own converting enzyme furin (Blanchette et al. 1997).  In contrast, the results 
presented here demonstrate that myostatin can negatively regulate furin protease 
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promoter expression (Figure 3.6B).  Recently it has been demonstrated that 
myostatin expression peaks at the onset of primary bovine myoblast fusion with a 
subsequent reduction during differentiation (Deveaux et al. 2003).  Therefore it is 
quite possible that the reduced processing of Myostatin seen during differentiation 
is due to down-regulation of furin protease activity by an increase in myostatin 
expression prior to differentiation.  In other words, a peak in Myostatin levels 
during the onset of differentiation results in lowered furin protein expression and 
subsequent reduction in Myostatin processing during differentiation.  This novel 
mechanism of negative auto-regulation allows for timely myogenic differentiation 
during development leading to the formation of myogenic fibres. 
An analysis of the furin P1 promoter has identified several consensus E-Box 
sequences (data not shown), which could indicate the involvement of bHLH 
transcription factors in the regulation of furin gene expression.  MyoD is an 
important bHLH transcription factor involved in regulating myogenesis.  
Previously published results from our laboratory have shown that myostatin can 
cause a down-regulation of MyoD expression, resulting in an inhibition of C2C12 
myoblast differentiation (Langley et al. 2002).  Therefore increased myostatin 
expression may cause a decrease in furin promoter activation by down-regulating 
MyoD expression. 
Collectively this study demonstrates that there is reduced proteolytic processing of 
Myostatin protein during myogenesis and that myostatin negatively regulates the 
transcription of its own converting enzyme, furin.  Given that myostatin is a 
negative regulator of myogenesis, it is hypothesised that myostatin auto-regulates 
its processing, thereby regulating the process of myoblast terminal differentiation.   
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Chapter 4  Pax7, myostatin and post-natal myogenesis  
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Abstract 
The paired-box transcription factor Pax7 has been implicated in satellite cell 
biology.  In this Chapter the role of Pax7 in myogenesis and regulation of satellite 
cell growth has been further characterised.  Over-expression of Pax7 in 
C3H10T1/2 multipotent cells resulted in enhanced expression of MyoD 
concomitant with increased myogenic specification of these cells.  However, 
when Pax7 was over-expressed in myogenic C2C12 cells delayed differentiation 
was observed, this was accompanied by an increase in the proportion of quiescent 
reserve cells.  These reserve cells may form a population analogous to self-
renewed satellite cells; indeed Pax7 expression was higher in reserve cells as 
compared to that of either actively growing C2C12 cells or myotube populations.  
Myostatin, a Transforming Growth Factor-beta (TGF-β) superfamily member, has 
been well characterised as a negative regulator of post-natal myogenesis, and in 
fact myostatin has previously been shown to inhibit satellite cell activation and 
self-renewal.  Thus the ability of myostatin to signal through Pax7 to regulate 
satellite cell function was investigated.  Treatment with recombinant Myostatin 
protein down-regulated the expression of Pax7, while Pax7 expression was higher 
in myostatin-null myoblasts as compared to wild-type myoblast cultures.  
Furthermore, absence of myostatin altered cell heterogeneity, resulting in a 
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reduction in Pax7+/MyoD+ cells, concomitant with an increase in the population 
of Pax7+/MyoD- cells.  Pax7 expression persisted through differentiation in 
cultured primary myoblasts from myostatin-null animals when compared to wild-
type counterparts.  Therefore, the reserve cell population was measured and, 
consistent with increased expression of Pax7, there was an increased pool of 
quiescent “self-renewed” reserve cells in differentiated cultures from myostatin-
null mice as compared with wild-type cultures.  Taken together, these results 
suggest that increased expression of Pax7 regulates the self-renewal process of 
satellite cells, and furthermore, growth factors such as myostatin signal through 
Pax7 to regulate the self-renewed pool of satellite cells.  
 
4.1  Introduction 
 
Skeletal muscle is primarily involved with active force production, resulting in 
voluntary movement of the skeletal system.  Repair and maintenance of skeletal 
muscle is attributed to the skeletal muscle stem cell pool, the satellite cells.  
Satellite cells represent a unique population of muscle precursor cells that are 
located between the basal lamina and sarcolemma of adult myofibres (Grounds 
and Yablonka-Reuveni 1993; Bischoff and Heintz 1994).  In response to several 
stimuli including muscle injury, quiescent satellite cells activate, proliferate and 
differentiate to repair damaged skeletal muscle (Bischoff 1989). 
MyoD and Myf-5 are myogenic regulatory factors (MRFs) critical for myogenic 
specification.  However, recent evidence has implicated the paired-box 
transcription factor Pax7 in specification of the myogenic lineage, as observed 
with enhanced myogenic conversion of CD45+:Sca1+ stem cells following over-
expression of Pax7 (Seale et al. 2004).  MyoD, Myf-5 and Pax7 appear to play 
critical roles during satellite cell activation, proliferation and differentiation.  In 
fact Myf-5 expression is present in the majority of quiescent satellite cells 
(Beauchamp et al. 2000).  Similarly, Pax7 is expressed in quiescent satellite cells 
and moreover is transcriptionally active in these quiescent cells (Seale et al. 2000; 
Zammit et al. 2006).  Following activation, satellite cells co-express Pax7 and 
MyoD (Yablonka-Reuveni and Rivera 1994; Seale et al. 2000; Asakura et al. 
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2001), proliferate and then down-regulate Pax7 prior to differentiation (Olguin 
and Olwin 2004; Zammit et al. 2004). 
Within healthy skeletal muscle quiescent satellite cell number remains constant 
irrespective of repeated cycles of degeneration and regeneration, thus indicating 
that mechanisms exist which maintain the satellite cell pool, such as self-renewal 
(Schmalbruch and Lewis 2000; Heslop et al. 2001; Yoshida 2004).  Pax7 has been 
implicated in the regulation of satellite cell self-renewal.  Indeed pax7-null mice 
have impaired regenerative capacity concomitant with a progressive loss in 
satellite cell number due to cell cycle defects and increased apoptosis (Oustanina 
et al. 2004; Kuang et al. 2006; Relaix et al. 2006). Further evidence for a role of 
Pax7 in self-renewal is observed in satellite cell cultures whereby populations of 
cells express Pax7 but lose MyoD and adopt a phenotype similar to quiescent 
satellite cells (Halevy et al. 2004; Zammit et al. 2004).  In addition, over-
expression of Pax7 has also been shown to inhibit MyoD, block myogenin and 
induce cell cycle exit without commitment to differentiation (Olguin and Olwin 
2004).  Although evidence strongly supports a role for Pax7 in myogenic 
specification and satellite cell self-renewal, the mechanism(s) through which Pax7 
regulates these processes remains a matter of contention. 
Myostatin, a member of the Transforming Growth Factor-beta (TGF-β) 
superfamily, has been shown to be a negative regulator of skeletal muscle 
myogenesis.  While addition of Myostatin inhibits myoblast proliferation and 
differentiation (Thomas et al. 2000; Langley et al. 2002), a lack functional 
myostatin in vivo results in a heavy muscled phenotype (Kambadur et al. 1997; 
McPherron et al. 1997; McPherron and Lee 1997; Schuelke et al. 2004).  
Myostatin expression is detected during embryonic and post-natal stages of 
growth, thus myostatin may play an important role throughout myogenesis 
(Kambadur et al. 1997; McPherron et al. 1997).  Indeed myostatin has been 
implicated in several forms of muscle wasting, including severe cachexia, 
observed as a result of conditions such as AIDS and liver cirrhosis (Gonzalez-
Cadavid et al. 1998; Dasarathy et al. 2004).  Furthermore, over-expression of 
Myostatin has been shown to induce cachexia (Zimmers et al. 2002) through 
regulation of the ubiquitin-proteasome pathway (McFarlane et al. 2006).  
Conversely, loss of myostatin enhances the regenerative capacity of skeletal 
muscle following injury (McCroskery et al. 2005).  The dramatic effect of 
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myostatin on post-natal growth is primarily due to the ability of myostatin to 
negatively regulate skeletal muscle satellite cell activation, proliferation and 
satellite cell self-renewal (McCroskery et al. 2003); however little is known about 
the mechanism(s) behind the intrinsic ability of Myostatin to regulate satellite cell 
physiology. 
In this Chapter in vitro models have been used to study the role of Pax7 in 
myogenic specification and satellite cell self-renewal.  In addition, the ability of 
myostatin to regulate Pax7 was assessed in an effort to further delineate the 
complex mechanism behind myostatin regulation of post-natal myogenesis.  It is 
proposed that Pax7 is capable of promoting the conversion of non-myogenic cell 
lines to the myogenic lineage.  Furthermore, results from this Chapter suggest that 
over-expression of Pax7 in a committed myoblast cell line results in increased 
self-renewal, thus supporting a role for Pax7 in the maintenance of the quiescent 
satellite cell pool primed for activation and contribution to skeletal muscle 
regeneration.  It is further proposed that myostatin negatively regulates satellite 
cell expansion and self-renewal through preceding regulation of Pax7. 
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4.2 Materials and Methods 
 
4.2.1  Cell culture 
C2C12 myoblasts (American Type Culture Collection; ATCC, Manassas, VA) 
(Yaffe and Saxel 1977), C3H10T1/2 fibroblasts (ATCC) (Reznikoff et al. 1973) 
and primary myoblasts were utilised in this Chapter.  C2C12 cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Carlsbad, CA), 
while C3H10T1/2 cells were cultured in Eagle’s Basal Medium (BME; 
Invitrogen).  Foetal Bovine Serum (FBS, 10%, Invitrogen) was added to the 
medium for culturing cells under growth conditions. Following the method of 
Taylor and Jones (1979) (Taylor and Jones 1979), myogenic conversion of 
C3H10T1/2 cells was induced by the addition of 0.3 nM 5-Aza-2’-deoxycytidine 
in Proliferation Medium for 24 hr, C3H10T1/2 cultures were then maintained for 
16 days in Proliferation Medium in the absence of 5-Aza-2’-deoxycytidine.  For 
differentiation studies C2C12 cells were plated at a density of 25,000 cells/cm2, 
following an overnight attachment period, the cells were induced to differentiate 
under low serum conditions in DMEM 2% Horse Serum (HS, Invitrogen) and 
grown for periods as experimentally required.  The AgResearch Ruakura Animal 
Ethics Committee approved all animal manipulations described in this paper.  
Primary myoblasts were cultured from the hindlimb muscle of 4 to 6 week old 
mice, according to published protocols (Allen et al. 1997; Partridge 1997).  
Briefly, muscles were minced and then digested in 0.2% collagenase type 1A for 
90 min. Cultures were enriched for myoblasts by pre-plating on uncoated plates 
for 3 hr. Myoblast cultures were maintained in DMEM supplemented with 20% 
FBS, 10% HS and 1% Chicken Embryo Extract (CEE) on 10% matrigel-coated 
plates, at 37°C/5% CO2.  This method is well established in our laboratory and 
yields cultures of high (95%) myogenic purity (McCroskery et al. 2003).  The 
recombinant Myostatin protein (Mstn) used in these in vitro experiments was 
generated and purified in our laboratory (Sharma et al. 1999). 
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4.2.2  Stable transfection and generation of clonal cell lines 
Pax7 over-expressing C3H10T1/2 and C2C12 cells were generated by stable 
transfection of a pcDNA3-Pax7 construct encoding full-length murine Pax7 
driven by a CMV promoter and including neomycin and ampicillin resistance 
cassettes.  The Pax7 cassette was kindly gifted by Dr Michael Rudnicki.  Stable 
cell lines were generated by stable transfection with 12.5 µg of pcDNA3-Pax7 or 
pcDNA3 in 0.8 mL DMEM (no serum) mixed with 40 µL of Lipofectamine 2000 
(Invitrogen) in 0.8 mL DMEM (no serum).  After 20 min at room temperature the 
transfection mixture was added to the appropriate plates and incubated for 24 hr at 
37˚C. Cells were then subjected to neomycin treatment at a concentration of 0.6 
mg/mL and selected based on their ability to grow in the presence of neomycin.  
After 21 days, neomycin resistant cells were taken for further analysis or frozen in 
liquid nitrogen for later use.  Clonal cell lines were generated by plating Pax7 
transfected cells at a clonal density of 25 cells/cm2, individual neomycin-resistant 
colonies were isolated and further expanded to allow for analysis of Pax7 
expression.  Two Pax7 over-expressing clonal cell lines were selected for further 
study. 
 
4.2.3  Limited trypsinisation to obtain myotubes and reserve cells 
The protocol of Kitzmann et al (1998) (Kitzmann et al. 1998) was used to 
separate myotube and reserve cell populations.  C2C12 cells were plated at a 
density of 25,000 cells/cm2, allowed to attach overnight, then induced to 
differentiate under low serum conditions in DMEM 2% HS for 96 hr.  Following 
incubation, a short trypsinisation period (5 min, 0.15% trypsin) and two phosphate 
buffered saline (PBS) washes were used to preferentially detach myotubes.  
Reserve cells, which remained attached to the culture dish, were then removed 
with 10 min incubation in 0.25% trypsin. 
 
4.2.4  Detection of MHC, Myf-5, Pax7 and MyoD by immunocytochemistry 
Detection of Myosin Heavy Chain (MHC) in C3H10T1/2 cells was performed as 
previously described (see Section 2.2.16).  MHC (MF-20, Developmental Studies 
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Hybridoma Bank; DSHB, University of Iowa, Iowa City, IA) was used at a final 
dilution of 1:100.  Detection of Myf-5, Pax7 and MyoD is outlined below.  
Myoblast and myotube cultures grown on Permanox chamber slides (Nalge Nunc 
International, Rochester, NY) were fixed with 70% ethanol:formaldehyde:glacial 
acetic acid (20:2:1) for 30 s, then rinsed three times with PBS.  Cells were 
permeabilised with 0.1% triton X-100 in PBS for 10 min at room temperature then 
washed with PBS. Cells were then blocked in 5% NGS in 0.35% Carrageenen λ 
(Sigma, St. Louis, MO) in PBS for 1 hr at room temperature; the same solution 
was used for subsequent antibody and fluorophore dilutions. Cells were incubated 
with primary antibodies overnight at 4˚C.  Rabbit polyclonal anti-Myf-5 antibody 
(sc-302, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-
MyoD antibody (sc-304, Santa Cruz Biotechnology) and mouse monoclonal anti-
Pax7 antibody (DSHB) were added at a dilution of 1:100.  The next day, slides 
were washed 3 times for 5 min in TBST before secondary incubation with 
biotinylated donkey anti-rabbit IgG (RPN1004; GE Healthcare Bio-Sciences 
Corp. Piscataway, NJ) at 1:300 for 1 hr at room temperature.  Following another 3 
washes in TBST, fluorescent complexes Alexa Fluor anti-mouse 546 (A11030; 
Invitrogen) and Alexa Fluor 488 (S11223; Invitrogen) were added at dilutions of 
1:300 and 1:400 respectively and incubated for 1 hr at room temperature. After a 
further 3 washes in TBST, slides were incubated with DAPI (1:1000 in PBS, 
Invitrogen) for 5 min at room temperature, rinsed with PBS, and mounted using 
fluorescent mounting medium (Dako, Glostrup, Denmark).  Cells were visualised 
using an Olympus BX50 microscope (Olympus Optical Co, Germany) with a 
SPOT RT camera (Diagnostic Instruments Inc, Sterling Heights, MI) and the 
Windows Version 4.0.1 SPOT Basic software program (Diagnostic Instruments 
Inc). 
 
4.2.5  Cell staining 
To assess Pax7 clone myotube formation during differentiation, cultures were 
grown on Thermanox coverslips (Nalge Nunc) under low serum conditions 
(DMEM 2% HS), fixed with 20:2:1 and stained with Gill’s haematoxylin 
followed by 1% eosin, photographed as above, and myotube number counted.  To 
quantitate the number of myotubes present in C3H10T1/2 cultures, a six-well 
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culture plate (Nalge Nunc) of each cell type was grown and treated with 5-Aza-2’-
deoxycytidine as above.  Following treatment, cultures were stained with 
methylene blue.  Briefly, cells were covered in 1% methylene blue in 0.01M 
borate buffer, pH8, and left at room temperature for 2 min. The methylene blue 
stain was then removed and plates washed twice for 2 min with 0.01M borate 
buffer (pH8) in order to remove all unbound dye.  Cells were photographed as 
above and myotube number counted. 
 
4.2.6  Proliferation assay 
Myoblast proliferation was assessed as described previously (Thomas et al. 2000).  
Briefly, C2C12 cultures were seeded on 96 well plates (Nalge Nunc) at a density 
of 1,000 cells per well in Proliferation Medium.  After an overnight attachment 
period, cells were supplemented with fresh Proliferation Medium (DMEM 10% 
FBS). Cultures were subsequently fixed at 24 hr intervals.  Cells were fixed in 100 
µL of 10% formal saline (0.17% saline, 10% formaldehyde).  Following the 
incubation periods, proliferation was assessed using the methylene blue 
photometric end-point assay, as previously described (Oliver et al. 1989).  Briefly, 
the fixative was removed, 100 µL of stain (1% methylene blue, 0.01 M Borate 
buffer, pH 8.5) was added to each well and the cells were incubated for 30 min at 
room temperature.  The stain solution was removed and the cells washed four 
times with 200 µL Borate buffer, followed by the addition of 200 µL 0.1 N 
HCl:70% ethanol, (1:1).  The absorbance of the cells was read on a microplate 
reader (model 3550; Bio-Rad), at 655 nm.  In this assay absorbance at 655 nm is 
directly proportional to final cell number. Samples were run in replicates of eight 
with the results representing two independent experiments.   
 
4.2.7  Protein isolation and Western Blot analysis 
C2C12 and C3H10T1/2 cells were resuspended in 200 µL lysis buffer (50 mM 
Tris pH 7.6; 250 mM NaCl; 5 mM EDTA; 0.1% Nonidet P-40; Complete protease 
inhibitor [Roche Diagnostics Corporation, Indianapolis, IN]) and passed through a 
26 gauge needle 10 times.  The cell extracts were then centrifuged to pellet cell 
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debris.  Bradford Reagent (Bio-Rad Laboratories, Hercules, CA) was used to 
estimate total protein content to ensure equal loadings.  Total protein (15 µg) was 
separated by 4-12% SDS-PAGE (Invitrogen) electrophoresis and transferred to 
nitrocellulose membrane by electroblotting.  The membranes were blocked in 5% 
milk in TBST overnight at 4ºC, followed by incubation with specific primary 
antibodies for 3 hr at room temperature.  The following primary antibodies were 
used for immunoblotting; 1:500 dilution of purified mouse monoclonal anti-Pax7 
antibody (DSHB, Iowa City, IA); 1:400 dilution of rabbit polyclonal anti-MyoD 
antibody (sc-304; Santa Cruz Biotechnology Inc, Santa Cruz, CA); 1:400 dilution 
of purified rabbit polyclonal anti-Myf-5 antibody (sc-302; Santa Cruz 
Biotechnology Inc.); 1:400 dilution of purified rabbit polyclonal anti-myogenin 
antibody (sc-576; Santa Cruz Biotechnology Inc.); 1:400 dilution of purified 
mouse monoclonal anti-p21 antibody (556430; BD Pharmingen, San Diego, CA); 
1:10,000 dilution of purified mouse monoclonal α-Tubulin antibody (T-9026; 
Sigma); 1:10,000 dilution of purified mouse monoclonal anti-GAPDH antibody 
(RDI-TRK5G4-6C5, Research Diagnostics, Concord, MA).  The membranes were 
washed (5 x 5 min) with TBST and further incubated with 1:2,000 dilution anti-
rabbit IgG Horseradish Peroxidase (HRP) conjugate (P0448; Dako, Glostrup, 
Denmark) or 1:2,000 dilution anti-mouse IgG HRP conjugate (P0447; Dako) 
secondary antibodies for 1 hr at room temperature.  The membranes were washed 
as above, and HRP activity was detected using Western Lightning 
Chemiluminescence Reagent Plus (NEL104; PerkinElmer Life And Analytical 
Sciences, Inc., Wellesley, MA) and exposure to autoradiography film.  Blots were 
quantified by densitometry analysis using the GS-800 densitometer (Bio-Rad). 
 
4.2.8  Statistics 
For quantification, the number of cells in each category (i.e. Pax7+/MyoD-, 
Pax7+/MyoD+, or Myf-5 positives) were counted and expressed as a percentage of 
the total cell pool (DAPI stained cells), and the data from multiple wells were 
pooled to give a population mean (±SEM).  For C3H10T1/2 myotube assessment, 
six wells per culture were counted, with the mean number of myotubes ±SEM 
calculated.  For Pax7 over-expressing clone and control myotube assessment, 
average myotube number (±SEM) over 3 coverslips per timepoint was calculated.  
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Total myotubes were counted in 5 random images per coverslip.  To determine the 
significance level of differences between two groups, comparisons were made 
using Student’s-T test.  Statistical analysis was performed in Excel.  A P value of 
<0.05 was deemed significant for all experiments. 
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4.3  Results 
 
4.3.1  Pax7 over-expression enhances myogenic conversion of the mesenchymal 
multipotent C3H10T1/2 cell line 
Previously published data has highlighted a role for Pax7 in the specification of 
the myogenic lineage (Seale et al. 2004).  In particular, Pax7 over-expression has 
been shown to convert CD45+:Sca1+ muscle-derived cells to the myogenic lineage 
as supported by the up-regulation of markers specific to the myogenic lineage, 
such as Myf-5 and MyoD, and by the formation of MHC positive myotubes (Seale 
et al. 2004).  In contrast, Pax7 over-expression in the multipotent mesenchymal 
C3H10T1/2 fibroblast cell line fails to induce myogenic conversion (Seale et al. 
2004).  Furthermore, Pax7 over-expression has been shown to inhibit MyoD-
mediated myogenic conversion of the C3H10T1/2 cell line (Olguin and Olwin 
2004).  To study this in further detail we analysed the ability of Pax7 to enhance 
myogenic conversion of C3H10T1/2 cells following treatment with 5-Aza-2’-
deoxycytidine, a well-characterised compound which causes DNA demethylation.  
Pax7 expression was quantified by Western Blot analysis to ensure over-
expression of Pax7 was achieved (Figure 4.1A).  Following 5-Aza-2’-
deoxycytidine treatment, we found that C3H10T1/2 cells stably over-expressing 
Pax7 adopted an enhanced myogenic program, whereby the expression of the 
myogenic marker MyoD was significantly increased (Figure 4.1B).  As expected, 
treatment of C3H10T1/2 cells with 5-Aza-2’-deoxycytidine resulted in the 
formation of MHC positive myotubes (Figure 4.1C).  Methylene blue stained 
myotubes were counted, and consistent with enhanced myogenesis, Pax7 over-
expression increased myotube formation with an  ~8-fold increase in myotube 
number following Pax7 over-expression as compared to control empty vector 
transfected cells (Figure 4.1D).  These data further confirm a role for Pax7 in the 
specification of cells to a myogenic lineage and highlight the ability of Pax7 to 
control the expression of MyoD, a key regulatory factor during the induction of 
the myogenic program.  
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Figure 4.1  Pax7 enhances C3H10T1/2 myogenic conversion 
A)  Western Blot examining Pax7 expression between control C3H10T1/2 cells 
(Control C3H) and Pax7 over-expressing C3H10T1/2 cells (Pax7 C3H).  Tubulin 
levels were measured to ensure equal loadings.  B)  Western Blot showing MyoD 
expression in control C3H10T1/2 cells (Control C3H) compared to Pax7 over-
expressing C3H10T1/2 cells (Pax7 C3H) at day 0 (d0) and day 8 (d8) following 
treatment with 5-Aza-2’-deoxycytidine.  GAPDH levels were measured to ensure 
equal loadings.  C)  Myosin Heavy Chain (MHC) immunostained myotubes 
formed in day 15 control C3H10T1/2 (Control C3H) and Pax7 over-expressing 
C3H10T1/2 (Pax7 C3H) cultures following treatment with 5-Aza-2’-
deoxycytidine, cells were counterstained with Gill’s haematoxylin.  Scale bar 
represents 10 µm. D) Methylene blue staining of day 15 control C3H10T1/2 
(Control C3H) and Pax7 over-expressing C3H10T1/2 (Pax7 C3H) cultures, 
following treatment with 5-Aza-2’-deoxycytidine.  Scale bar represents 20 µm; 
arrows indicate methylene blue positive myotubes.  The corresponding graph 
represents the number of myotubes for control C3H10T1/2 (Control C3H) and 
Pax7 over-expressing C3H10T1/2 (Pax7 C3H) cultures, determined by counting 
methylene blue stained myotubes.  Six wells per culture were counted, with the 
mean number of myotubes ±SEM represented graphically as counts per well.  
Statistical differences determined by Student’s-T test are indicated, P<0.001 (***) 
compared to Control C3H. 
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4.3.2  Pax7 over-expression in C2C12 myoblasts impairs myogenesis 
Previous published results have indicated that Pax7 over-expression in the C2C12 
and MM14 adult myoblast cell lines is refractory to myogenesis (Olguin and 
Olwin 2004).  In particular, Pax7 over-expression in MM14 myoblasts resulted in 
reduced MyoD levels, prevented myogenin expression, and promoted cell cycle 
exit to a quiescent, differentiation-resistant phenotype (Olguin and Olwin 2004).  
Furthermore, it has been stated that Pax7 over-expression in C2C12 cells inhibited 
the formation of MHC positive myotubes (Seale et al. 2004).  To better 
understand the effect of Pax7 on adult myoblast growth we generated two stable 
clonal C2C12 cell lines over-expressing Pax7, termed Pax7 Clone 1 and Pax7 
Clone 2.  Initially we measured the expression of Pax7 by Western Blot to ensure 
over-expression of Pax7, and as shown in Figure 4.2A, both Pax7 clonal cell lines 
have greatly increased expression of Pax7.  In addition, we compared the 
proliferation capacity of the Pax7 clonal cell lines to that of control cell lines.  As 
shown in Figure 4.2B, both Pax7 clonal cell lines had a reduced rate of 
proliferation compared to that of control C2C12 cells, as determined by methylene 
blue assay.  Pax7 over-expression has been documented to inhibit the 
differentiation of C2C12 myoblasts (Seale et al. 2004; Zammit et al. 2006), thus 
we analysed the ability of the Pax7 clonal cell lines to undergo myogenic 
differentiation.  Up-regulation of Pax7 in C2C12 cells did not inhibit myogenic 
differentiation; rather an extreme delay in differentiation phenotype was observed, 
with a small number of myotubes present in the Pax7 over-expressing cell lines at 
96 hr differentiation (Figure 4.2C).  In fact, at 48 hr differentiation, control C2C12 
cultures contained at least 7-fold more myotubes as compared to Pax7 clonal cell 
lines (Figure 4.2D).  This variation in myotube number continued with the 
progression of differentiation, with comparable differences at 72 hr and 96 hr 
differentiation. 
Next we analysed gene expression changes during differentiation in the Pax7 
clones compared to control cells.  MyoD levels were similar between control and 
Pax7 over-expressing clones at Time 0, however during the induction of 
differentiation MyoD levels appeared to be significantly reduced in both of the 
Pax7 clonal cell lines as compared to controls (Figure 4.3A, Figure 4.3B and 
Figure 4.3C).  MyoD is an important myogenic regulatory factor which is capable 
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of promoting and maintaining cell cycle arrest through regulation of the cyclin-
dependent kinase inhibitor p21 (Guo et al. 1995; Halevy et al. 1995).  Thus p21 
levels were measured, and as expected p21 expression appeared to closely follow 
the expression of MyoD and was considerably lower in the Pax7 clonal cell lines 
as compared to controls during the induction of differentiation (Figure 4.3A, 
Figure 4.3B and Figure 4.3C).  Interestingly, the expression of p21 appeared to be 
higher in both of the Pax7 clones at Time 0 (Figure 4.3A, Figure 4.3B and Figure 
4.3C).  Myf-5, like MyoD, is an important myogenic regulatory factor involved 
with the specification of the myogenic lineage (Rudnicki et al. 1993; Tajbakhsh et 
al. 1996).  Interestingly, elevated levels of Myf-5 were detected in the Pax7 clonal 
cell lines at Time 0 (Figure 4.3A, Figure 4.3B and Figure 4.3C), and although 
Myf-5 expression decreased during differentiation, levels were consistently higher 
than in control cell lines (Figure 4.3A and Figure 4.3B and Figure 4.3C).  As 
stated above, both Pax7 clones differentiated considerably slower than controls.  
Consistent with this, myogenin expression was significantly delayed in the Pax7 
clones (Figure 4.3A, Figure 4.3B and Figure 4.3C).  However, myogenin 
expression gradually increased as differentiation proceeded, which coincides with 
the eventual formation of myotubes in the Pax7 clonal cells (Figure 4.3A, Figure 
4.3B and Figure 4.3C).  Thus Pax7 appears to play a critical role in controlling the 
ability of myogenic cell lines to undergo differentiation, and as shown, Pax7 has 
the ability to down-regulate several key myogenic regulatory factors including 
MyoD and myogenin, both critical to the successful adoption of a myotube 
phenotype.  This gene regulation may form the underlying basis of Pax7 
regulation of myogenic progression. 
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Figure 4.2  Pax7 regulates proliferation and differentiation in C2C12 myoblasts 
A)  Western Blots showing protein expression of Pax7 during actively growing 
conditions in Pax7 over-expressing (Pax7 Clone 1 and 2) lysates compared to 
control (C2C12) lysates.  Tubulin expression was analysed to ensure equal 
loading of samples.  B)  Methylene blue assay showing proliferation of control 
(C2C12) cells compared to Pax7 over-expressing clones (Pax7 Clone 1 and 2) 
over a 72 hr period.  Statistical differences determined by Student’s-T test are 
indicated, P<0.001 (***) compared to C2C12 at each timepoint.  C)  
Representative images of differentiating cells for Pax7 over-expressing clones 
(Pax7 Clone 1 and 2) compared to control (C2C12) cells at 48 hr, 72 hr and 96 hr 
differentiation; cells were stained with Gill’s haematoxylin and eosin.  Scale bar 
represents 5 µm.  D)  The graph shows the average myotube number ±SEM over 3 
coverslips per timepoint for Pax7 over-expressing clones (Pax7 Clone 1 and 2) 
and control (C2C12) cells, total myotubes were counted in 5 random images per 
coverslip.  Statistical differences determined by Student’s-T test are indicated, 
P<0.05 (*) and P<0.01 (**) as compared to C2C12 at each timepoint. 
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4.3.3  Pax7 over-expression increases the population of reserve cells in C2C12 
myotube cultures 
During the induction of differentiation there is a rapid decrease in the expression 
of Pax7, however in differentiated myotube cultures a small subset of cells retain 
Pax7 expression (Olguin and Olwin 2004; Zammit et al. 2004).  When 
differentiation is induced through serum-withdrawal, two distinct populations of 
cells arise, differentiated post-mitotic myotubes and quiescent differentiation-
resistant reserve cells.  Reserve cells share several similarities with skeletal 
muscle stem cells, for example reserve cells can re-enter the cell cycle, where they 
proliferate and then differentiate to form new myotubes (Kitzmann et al. 1998; 
Yoshida et al. 1998).  Reserve cells, much akin to skeletal muscle stem cells, can 
also renew their population to maintain the reserve cell numbers in vitro (Yoshida 
et al. 1998).  Furthermore the marker genes Myf-5 and CD34 which are expressed 
by skeletal muscle stem cells are also expressed at high levels in reserve cell 
populations (Kitzmann et al. 1998; Lindon et al. 1998; Beauchamp et al. 2000).  
To study in detail the changes in Pax7 expression during differentiation, C2C12 
cultures were enriched for myotube and reserve cell populations by limited 
trypsinisation.  Interestingly, during differentiation Pax7 expression appeared to 
coincide with Myf-5 expression and became restricted to the reserve cell pool, 
while MyoD expression was maintained in the myotube population (Figure 4.4A).  
As stated above, over-expression of Pax7 delayed the induction of differentiation 
(Figure 4.2C and 4.2D) and increased the expression of Myf-5 (Figure 4.3A, 
Figure 4.3B and Figure 4.3C), thus we quantified the reserve cell population in the 
Pax7 over-expressing clones.   
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Figure 4.3  Pax7 over-expression alters the expression of several critical 
myogenic genes.   
A), B)  Western Blots showing protein expression of MyoD, p21, Myf-5 and 
myogenin at Time 0 and after 24, 48, 72 and 96 hr of differentiation in Pax7 over-
expressing (Pax7 Clone 1 [A] and Pax7 Clone 2 [B]) lysates compared to control 
(C2C12) lysates.  Tubulin expression was analysed to ensure equal loading of 
samples.  C)  Densitometry analysis of protein expression for Western Blots 
(MyoD, p21, Myf-5, myogenin), normalised to Tubulin expression, for Pax7 over-
expressing clones (Clone 1 and 2) compared to control (C2C12) cells. 
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Pax7 clonal cells and control C2C12 cells were differentiated for 144 hr, fixed and 
analysed for Myf-5 expression by immunocytochemistry.  Myf-5 was used to 
mark the reserve cell populations in both Pax7 clonal and control C2C12 cell 
lines.  As shown in Figure 4.4B, of the total cell number there were 17.5% ± 1.4% 
Myf-5 positive reserve cells following over-expression of Pax7 as compared with 
1.6% ± 0.5% Myf-5 positive reserve cells in the control cell line.  Thus there was 
a ~10-fold increase in the number of reserve cells in C2C12 cells stably over-
expressing Pax7 (Pax7 Clone 1) as compared with control C2C12 cells.  
Therefore, increasing the expression of Pax7 appears to delay differentiation, 
concomitant with an increase in the quiescent Myf-5 positive reserve cell 
population in the established C2C12 myogenic cell line.  As stated above, reserve 
cell populations share several characteristics with quiescent satellite cells, and 
thus over-expression of Pax7 may recapitulate the process of self-renewal seen in 
skeletal muscle stem cells. 
 
4.3.4  Myostatin regulates Pax7 expression during myogenesis 
Myostatin is a potent negative regulator of skeletal myogenesis, in fact myostatin 
functions to block both myoblast proliferation and differentiation (Thomas et al. 
2000; Langley et al. 2002). More recently myostatin has been implicated in the 
regulation of post-natal muscle growth through, in part, the regulation of satellite 
cell growth and self-renewal (McCroskery et al. 2003).  Although myostatin has 
been shown to negatively regulate satellite cell self-renewal, the mechanism 
behind this process remains unclear.  Pax7 has gained recent interest as an 
important mediator of satellite cell self-renewal, thus we analysed the ability of 
myostatin to regulate Pax7.  As shown in Figure 4.5A, Myostatin treatment 
severely down-regulated the expression of Pax7 in actively growing primary 
myoblast cultures as determined by Western Blot analysis.  Consistent with this, 
Western Blot analysis of Pax7 expression between wild-type and myostatin-null 
primary myoblast cultures revealed a consistently higher expression of Pax7 in the 
myostatin-null cultures (Figure 4.5B).   
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Figure 4.4  Over-expression of Pax7 increases the resident reserve cell 
population 
A)  Western Blots for Pax7, Myf-5 and MyoD in C2C12 myotubes (M.T.) 
compared to reserve cells (R.C.).  Ponceau S staining is shown to demonstrate 
equal loading of protein samples.  B)  Myf-5 immunocytochemistry (green), with 
the corresponding DAPI staining (blue), for Pax7 over-expressing cells (Pax7 
Clone) compared to Control (C2C12) cells after 144 hr differentiation.  Scale bar 
represents 5 µm.  The corresponding graph shows Myf-5 positive cells as a 
proportion of total cell number (shown by DAPI staining) for Pax7 over-
expressing cells (Pax7 Clone) as compared to control (C2C12) cells.  Statistical 
differences determined by Student’s-T test are indicated, P<0.01 (**) compared to 
C2C12. 
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Furthermore, analysis of Pax7 expression patterns during differentiation of both 
wild-type and myostatin-null primary cultures highlighted a dramatic difference in 
the expression profile of Pax7, whereby Pax7 levels are maintained considerably 
longer in the myostatin-null primary myoblasts when compared to wild-type 
controls (Figure 4.5B).  We further analysed the populations of Pax7 and MyoD 
expressing cells between wild-type and myostatin-null cultures by 
immunofluorescence.  Subsequently we observed an increase in the population of 
Pax7+/MyoD- expressing cells in the myostatin-null cultures, specifically there 
was a significant increase from 2.3% ± 0.94% in wild-type cultures to 9.1% ± 
1.3% in myostatin-null cultures, an overall increase of ~4-fold (Figure 4.5C).  
Furthermore, we observed a significant drop in Pax7+/MyoD+ populations from 
63.9% ± 2.9% in wild-type cultures to 55.3% ± 1.6% in myostatin-null cultures 
(Figure 4.5C).  Thus, absence of Myostatin appears to affect cell population 
heterogeneity, increasing the numbers of Pax7+/MyoD- cells concomitant with a 
decrease in Pax7+/MyoD+ cells.  As stated before, increased expression of Pax7 in 
C2C12 cells increased the resident population of Myf-5 positive reserve cells in 
vitro.  Thus we analysed the inherent population of reserve cells in both 
myostatin-null and wild-type cultures.  Interestingly, we found that differentiated 
cultures from myostatin-null mice contained a greater proportion of quiescent 
reserve cells, as determined by Myf-5 immunocytochemistry (Figure 4.5D).  
Indeed, we found Myf-5 positive reserve cell populations of 8% ± 0.28% in wild-
type and 10% ± 0.18% in myostatin-null cultures, thus there was a ~20% increase 
in the number of reserve cells in differentiating myostatin-null cultures as 
compared with wild-type controls.  As stated before, Pax7 expression is restricted 
to reserve cell populations during myoblast differentiation, thus the observed 
persistent expression of Pax7, the increased Pax7+/MyoD- pool and the enhanced 
reserve cell populations in myostatin-null cultures during differentiation, may 
highlight a potential Pax7-dependent mechanism behind myostatin regulation of 
satellite cell self-renewal. 
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Figure 4.5  Myostatin regulates Pax7 during myogenesis 
A)  Western Blot for Pax7 in primary cell lysates after culture in the absence (-) or 
presence (+) of recombinant Myostatin protein (Mstn).  Cells were treated with 10 
µg/mL Mstn for a period of 6 hr.  GAPDH expression was analysed to ensure 
equal loading of samples.  B)  Western Blot for Pax7 in primary cell cultures from 
wild-type and myostatin-null mice during both actively growing (Ag) and 
differentiation (Diff 24 hr and Diff 48 hr) conditions.  Ponceau S staining is used 
to ensure equal loading of samples.  C)  Pax7 (red), MyoD (green) and double-
stained (yellow) immunofluorescence in wild-type compared to myostatin-null 
mouse primary cultures.  The corresponding images for DAPI (blue) are also 
shown.  Scale bar represents 5 µm.  The graph represents the proportions of 
Pax7+/MyoD- and Pax7+/MyoD+ cells between wild-type and myostatin-null 
cultures.  Statistical differences determined by Student’s-T test are indicated, 
P<0.01 (**) and P<0.05 (*) compared to wild-type.  D)  Myf-5 
immunocytochemistry in 72 hr differentiated wild-type and myostatin-null mouse 
myoblast cultures.  The corresponding images for DAPI are also shown.  Scale 
bar represents 5 µm.  The proportion of Myf-5 positive reserve cells for wild-type 
and myostatin-null cultures is represented graphically.  Statistical differences 
determined by Student’s-T test are indicated, P<0.01 (**) compared to wild-type. 
 175
 
 
 
 176
4.4  Discussion 
 
The dynamic paired-box transcription factor Pax7 has been reported to play a role 
in many processes throughout skeletal muscle myogenesis.  Pax7 has been 
implicated in myogenic commitment (Seale et al. 2004) and Pax7 expression 
appears to be detected, and moreover is transcriptionally active, in quiescent 
satellite cells (Seale et al. 2000; Zammit and Beauchamp 2001; Zammit et al. 
2006).  Furthermore, Pax7 persists during the progression from satellite cell 
quiescence to activation and is maintained during proliferation (Seale et al. 2000; 
Asakura et al. 2001), however, Pax7 expression appears to be progressively lost 
during myogenic differentiation (Olguin and Olwin 2004; Zammit et al. 2004).  
Pax7 is further thought to be involved with the maintenance of quiescence, 
satellite cell survival, and the induction of satellite cell self-renewal (Olguin and 
Olwin 2004; Oustanina et al. 2004; Kuang et al. 2006; Relaix et al. 2006).  
Although much work has been done to elucidate a role for Pax7 in the regulation 
of myogenesis, little is known about the underlying mechanism of Pax7 function, 
and indeed factors which regulate Pax7. 
Pax7 has been implicated in the specification of myogenic identity; indeed Pax7 
can direct the specification of CD45+/Sca1+ stem cells to the myogenic lineage 
(Seale et al. 2004).  In contrast however, it has been recently shown that Pax7 
over-expression blocks MyoD-dependent myogenic conversion of the C3H10T1/2 
multipotent mesenchymal stem cell line (Olguin and Olwin 2004).  Previously it 
has been demonstrated that treatment of the C3H10T1/2 cell line with 5-Aza-2’-
deoxycytidine induces the formation of myogenic cells capable of undergoing 
differentiation into multinucleated myotubes (Konieczny and Emerson 1984; Liu 
et al. 1986), a function that has been attributed to the ability of 5-Aza-2’-
deoxycytidine to inhibit DNA methylation (Konieczny and Emerson 1984).  To 
further characterise the role of Pax7 in myogenic specification we have studied 
the effect of over-expressing Pax7 in the C3H10T1/2 cell line in the presence of 
5-Aza-2’-deoxycytidine (Figure 4.1).  In Pax7 stably over-expressing C3H10T1/2 
cell lines, we observe an increase in the expression of MyoD (Figure 4.1B); this is 
in agreement with the pre-established idea that Pax7 lies upstream of MyoD.  
Indeed previously published data whereby over-expression of Pax7 in a C2C12 
 177
subclone lacking Pax7, has been reported to result in an increase in MyoD 
expressing cells (Zammit et al. 2006).  Furthermore over-expression of a 
dominant-negative form of Pax7 has been shown to inhibit myoD expression in 
satellite cell cultures (Relaix et al. 2006).  We also find that over-expression of 
Pax7 in the C3H10T1/2 cell line enhances the myogenic program, with an 
increase in the formation of multinucleated myotubes over and above that seen in 
C3H10T1/2 controls (Figure 4.1D).  Thus we conclude that Pax7 over-expression 
in the non-myogenic C3H10T1/2 cell line results in an enhancement of 5-Aza-2’-
deoxycytidine induced myogenic conversion concomitant with an increase in the 
levels of MyoD, thus Pax7 may regulate adoption of a myogenic program through 
preceding regulation of MyoD.  It is noteworthy to mention that while Pax7 can 
induce myogenic commitment of CD45+:Sca1+ stem cells, Pax7 is unable to 
directly induce myogenic specification of C3H10T1/2 cells (Seale et al. 2004).  
This may indicate that CD45+:Sca1+ lineages have true stem cell features and as 
such are more amenable to lineage change as compared to the multipotent 
C3H10T1/2 cell line.  In contrast to Pax7, it is well documented that MyoD is able 
to directly induce myogenic conversion of the C3H10T1/2 cell line (Edmondson 
and Olson 1989; Guo et al. 1995).  One of the salient features of MyoD is its 
ability to interact with p300 and PCAF, members of the histone acetyl transferase 
family, which function as critical co-activators of MyoD, regulating key events of 
myogenesis including myogenic commitment and induction of differentiation 
(Puri et al. 1997a; Puri et al. 1997b; Sartorelli et al. 1997).  Thus it is interesting 
to surmise that the ability of MyoD to spontaneously direct the C3H10T1/2 cell 
line to follow a myogenic lineage is in some manner due to the ability of MyoD to 
function in conjunction with enzymes critical for gene regulation at the chromatin 
level, a function perhaps beyond the inherent role of Pax7 during myogenesis. 
In addition to Pax7 over-expression in a non-myogenic cell line, we analysed the 
effects of Pax7 exogenous expression on the adult committed myogenic C2C12 
cell line.  Initially we analysed the proliferative capacity of the Pax7 clonal cell 
lines as compared with control levels.  As shown in Figure 4.2B, both Pax7 clones 
share a similarly reduced proliferation rate to that of control.  However, albeit a 
statistically significant reduction, the proliferation observed in both Pax7 clones is 
not dramatically lower than that seen in the control. One point of interest is that 
we observe significantly increased expression of the cyclin-dependent kinase 
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inhibitor p21 in both Pax7 clones during proliferation (Time 0) (Figure 4.3A, 
Figure 4.3B and Figure 4.3C).  p21 is a member of the Cip/Kip family of cyclin-
dependent kinase inhibitors (CKIs) and as the name suggests CKIs block the 
action of cyclin-dependent kinases and their obligate partners, the cyclins (Harper 
et al. 1993; Xiong et al. 1993).  Cyclin-dependent kinases regulate 
Retinoblastoma (Rb)-mediated cell cycle progression by phosphorylating Rb.  
Subsequent phosphorylation of Rb results in activation of the E2F transcription 
factor family which are essential for the induction of genes required for DNA 
synthesis (S phase) (Guo and Walsh 1997).  Thus it is conceivable that the 
increased expression of p21 we observe in the Pax7 clones may result in a delay 
in cell cycle transition into the S phase which may in turn affect the cell 
proliferation rate. 
MyoD is critical in the decision to terminally differentiate and in fact, MyoD can 
induce differentiation through, in part, the up-regulation of p21.  However, as 
differentiation proceeds in the Pax7 clonal cell lines we observe that the up-
regulation of both MyoD and p21 is dramatically delayed, as compared with the 
control cell line (Figure 4.3A, Figure 4.3B and Figure 4.3C).  Consistent with 
these data, we also find a delay in the progression of myogenic differentiation as 
quantified through myotube counts (Figure 4.2D).  It is important to mention that 
although MyoD expression increased during differentiation in Clone 2, the levels 
of MyoD did not exceed or equal that observed in the control cell line; this is 
consistent with the reduced differentiation we observed in Pax7 Clone 2 compared 
to that of Pax7 Clone 1 (Figure 4.2D).  Myogenin, a marker of myoblast 
differentiation, was also dramatically reduced in the Pax7 over-expressing clones 
(Figure 4.3A, Figure 4.3B and Figure 4.3C).  Thus we conclude that C2C12 
myogenic cell lines over-expressing Pax7 are indeed amenable to differentiation, 
however it appears that the normal progression of differentiation seen in the 
C2C12 cell line is severely disrupted. 
During the onset of differentiation we observe a rapid down-regulation of Pax7 
expression, which is consistent with previously published accounts (Olguin and 
Olwin 2004; Zammit et al. 2004).  However, we also observe a down-regulation 
of Pax7 protein expression in the over-expressing cells lines, despite constitutive 
expression of Pax7 (data not shown).  This reduction of Pax7 in the over-
expressing clones does indeed coincide with the eventual formation of myotubes 
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during differentiation (Figure 4.2C and 4.2D).  Thus it is feasible that post-
transcriptional or post-translational mechanisms may exist which regulate the 
levels of Pax7 during the progression of myogenic differentiation.   
Two protein isoforms of Pax7 have previously been reported (Vorobyov and 
Horst 2004).  It is thus noteworthy to mention that following over-expression of 
Pax7 in the C2C12 cell line we detect both the 54-kDa and 57-kDa isoforms of 
Pax7, whereas in C2C12 controls we only observe the 57-kDa band at measurable 
levels (Figure 4.2A).  Interestingly, at early timepoints the predominant Pax7 
isoform is the 57-kDa band, however as differentiation continues both isoforms 
were expressed at similar levels (data not shown).  The significance of the two 
Pax7 isoforms is yet to be determined; however it is interesting to surmise that the 
two differing Pax7 isoforms may perform separate functions in vivo. 
Previously it has been reported that during differentiation a subset of cells retain 
expression of Pax7, lack myogenin expression and remain in an undifferentiated 
state (Olguin and Olwin 2004).  To study this in further detail we enriched 
cultures of differentiated C2C12 cells into reserve cell and myotube populations.  
Following Western Blot analysis we identify that Pax7 appears to become 
restricted to the reserve cell pool along with Myf-5 (Figure 4.4A), a previously 
identified marker of reserve cells (Kitzmann et al. 1998; Lindon et al. 1998; 
Beauchamp et al. 2000).  In agreement with previously published data (Kitzmann 
et al. 1998; Friday and Pavlath 2001), MyoD expression is retained in the 
myotube population (Figure 4.4A).  Interestingly, examination of Myf-5 
expression during differentiation in the Pax7 over-expressing clones demonstrates 
that Myf-5 is maintained at a considerably higher level during differentiation in 
the Pax7 over-expressing clones versus control C2C12 cells (Figure 4.3A, Figure 
4.3B and Figure 4.3C).  Thus we examined the proportion of Myf-5 positive 
reserve cells following over-expression of Pax7, compared to that of the control 
C2C12 cell line (Figure 4.4B).  In support of gene expression analysis we find that 
there is a considerable increase (10-fold) in the number of Myf-5 positive reserve 
cells as a consequence of increased Pax7 expression (Figure 4.4B).  Thus these 
data demonstrate that up-regulation of Pax7 increases the expression of Myf-5 
concomitant with an increase in the reserve cell population during differentiation.  
As previously stated reserve cells share many characteristics with quiescent 
skeletal muscle stem cells, including reversible quiescence, the ability to renew 
 180
their population and the expression of such markers as Myf-5 and CD34.  Thus 
over-expression of Pax7 in the C2C12 cell line may enhance the generation of a 
cell pool reminiscent of self-renewed satellite cells primed for re-entry into the 
cell cycle and eventual contribution to the myogenic program. 
The utility of myostatin as a growth factor responsible for the control of skeletal 
muscle mass is well-documented.  In support, a multitude of evidence now exists 
highlighting the important role of myostatin in the negative regulation of myoblast 
proliferation (Thomas et al. 2000; Taylor et al. 2001; Joulia et al. 2003; 
McCroskery et al. 2003), differentiation (Langley et al. 2002; Rios et al. 2002; 
Joulia et al. 2003) and more recently, satellite cell activation and self-renewal 
(McCroskery et al. 2003).  However, further work is required to carefully define 
the mechanism(s) behind myostatin regulation of satellite cell growth and post-
natal myogenesis.   
Given the dual role of Pax7 in enhancing myogenic specification and in the 
induction of self-renewal as outlined above, we sought to investigate the 
involvement of myostatin in the regulation of Pax7.  In this Chapter we 
demonstrated that exogenous addition of Myostatin dramatically reduced Pax7 
expression in primary cell cultures (Figure 4.5A). In support, we also found an 
increase in Pax7 expression in primary myoblasts isolated from myostatin-null 
mice as compared with wild-type cultures (Figure 4.5B).  This may have 
importance with respect to satellite cell numbers in vivo.  Indeed we have 
previously shown that there is an increase in satellite cell number per unit fibre 
length in myostatin-null mice as compared with wild-type controls and more 
recently, siRNA-mediated reduction of myostatin resulted in an observed increase 
in Pax7-positive satellite cells (Magee et al. 2006).  In contrast, recent published 
data stated that myostatin does not alter the expression of Pax7 during embryonic 
HH-stage 21-23 in the chick, however, consistent with the known function of 
Myostatin, the proliferation of Pax7-positive muscle precursor cells was inhibited 
(Amthor et al. 2006).  Thus separate mechanisms may exist which regulate Pax7 
during embryonic and post-natal myogenesis with myostatin playing a role in the 
latter. 
Increased satellite cell number is in some part due to enhanced satellite cell self-
renewal.  The critical role of Pax7 in the process of self-renewal is evident in 
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pax7-null mice, at birth pax7-null mice appear normal but fail to thrive, dying 
between 2-3 weeks of age (Mansouri et al. 1996; Seale et al. 2000).  Although 
there are large numbers of satellite cells present at birth there appears to be a 
constant decline in satellite cell number concomitant with impaired muscle 
regeneration in these mice (Oustanina et al. 2004).  Further evidence for the 
involvement of Pax7 in self-renewal is seen in heterogeneous satellite cell 
populations.  Indeed, in mouse myofibre cultures, populations of cells retain high 
expression of Pax7 but have a down-regulated expression of MyoD (Zammit et al. 
2004).  Interestingly, these cells do not commit to differentiation and in fact 
proliferate slowly or not at all, thus adopting characteristics of quiescent satellite 
cells (Zammit et al. 2004).  Similarly, reserve cell-like populations of 
Pax7+/MyoD- cells have been identified in the chicken (Halevy et al. 2004).  
Together these data strongly support a role for Pax7 in satellite cell renewal.   
In agreement with previously published data (Halevy et al. 2004; Olguin and 
Olwin 2004; Zammit et al. 2004), we found heterogeneity in the expression of 
Pax7 and MyoD in satellite cell cultures.  Interestingly, on analysis of wild-type 
and myostatin-null cultures we found a significant increase in Pax7+/MyoD- 
populations concomitant with a reduction in Pax7+/MyoD+ populations in the 
absence of myostatin (Figure 4.5C).  Thus it is interesting to surmise that loss of 
myostatin may result in a switch in cell fate determination, thus increasing the 
Pax7+/MyoD- quiescent reserve cell-like population.  Further evidence was 
observed upon analysis of Myf-5 positive reserve cell populations between wild-
type and myostatin-null cultures.  We saw a significant 20% increase in the 
number of Myf-5 positive reserve cells, expressed as a percentage of total cell 
number, in differentiated primary cultures of myostatin-null mice compared to 
wild-type (Figure 4.5D).  It is noteworthy to mention that although both the wild-
type and myostatin-null cultures were plated at the same density for study, 
myostatin-null myoblast numbers quickly overtook those of wild-type cultures 
(data not shown), presumably due to an enhanced cell proliferation rate as we 
have previously described (McCroskery et al. 2003).  Thus, if we then consider 
total Myf-5 positive reserve cell numbers irrespective of total cell number we 
found a marked 75% increase in the reserve cell population in differentiated 
myostatin-null cultures as compared to wild-type cultures (data not shown).  This 
increase has importance if we consider in vivo situations, whereby enhanced self-
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renewal would increase the available pool of quiescent satellite cells primed for 
activation and subsequent contribution to muscle regeneration, indeed consistent 
with the enhanced regenerative capacity observed in myostatin-null mice 
(McCroskery et al. 2005).  Therefore, we have further delineated the mechanism 
behind myostatin regulation of satellite cell self-renewal.  As shown in Figure 4.6, 
satellite cells become activated, proliferate and form myoblasts, which can either 
fuse to damaged myofibres or differentiate to form new myotubes.  A proportion 
of these cells can exit the cell cycle, without commitment to differentiation, and 
self-renew via increased expression of Pax7, a process which is negatively 
regulated by myostatin.  Thus we propose a mechanism whereby myostatin 
inhibits satellite cell expansion and self-renewal through preceding regulation of 
Pax7 (Figure 4.6).   
In this Chapter we have highlighted a dual function for Pax7, whereby Pax7 
enhances commitment of non-myogenic multipotent cells to the myogenic 
lineage, while retaining the ability to promote the adoption of a quiescent self-
renewed phenotype in committed myogenic cell lines.  Thus, in agreement with 
pre-established theories, we suggest that Pax7 promotes myogenic specification, 
in addition to maintaining muscle stem cell populations through increased self-
renewal.  In addition, we have further delineated the complex mechanism(s) 
behind myostatin regulation of satellite cell self-renewal, namely the ability of 
myostatin to control the replenishment of the skeletal muscle stem cell pool 
through negative regulation of Pax7. 
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Figure 4.6  Model of myostatin regulation of Pax7 during myogenesis 
Quiescent satellite cells on muscle fibres are activated in response to various 
stimuli giving rise to myoblasts (MB).  Following subsequent proliferation, 
myoblasts can fuse with existing damaged myofibres, differentiate to form new 
myotubes or self-renew to replenish the satellite cell pool via continued 
expression of Pax7.  Myostatin inhibits Pax7 expression during myoblast 
proliferation, implicating it in the negative regulation of satellite cell self-renewal. 
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Chapter 5  Mechanism of myostatin-mediated cachexia 
 
The results of this Chapter are published in the Journal of Cellular Physiology vol. 
209 pages 501-514 (2006).  See CD attached to the back cover of this thesis 
(Appendix 1) for a PDF copy of this paper. 
 
 
 
Abstract 
Myostatin, a Transforming Growth Factor-beta (TGF-β) superfamily member, has 
been well characterised as a negative regulator of muscle growth and 
development.  Myostatin has been implicated in several forms of muscle wasting 
including the severe cachexia observed as a result of conditions such as AIDS and 
liver cirrhosis.  Here it is shown that myostatin induces cachexia by a mechanism 
independent of NF-κB.  Myostatin treatment resulted in a reduction in both 
myotube number and size in vitro, as well as a loss in body mass in vivo.  
Furthermore, the expression of the myogenic genes myoD and pax3 was reduced, 
while NF-κB (the p65 subunit) localisation and expression remained unchanged.  
In addition, promoter analysis has confirmed Myostatin inhibition of myoD and 
pax3. An increase in the expression of genes involved in ubiquitin-mediated 
proteolysis is observed during many forms of muscle wasting.  Hence the effect of 
Myostatin treatment on proteolytic gene expression was analysed.  The ubiquitin-
associated genes atrogin-1, MuRF-1 and E214k were up-regulated following 
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Myostatin treatment.  The signalling mechanism behind myostatin-induced 
cachexia was subsequently studied.  Myostatin signalling reversed the IGF-1/PI3-
K/AKT hypertrophy pathway by inhibiting AKT phosphorylation thereby 
increasing the levels of active FoxO1, allowing for increased expression of 
atrophy-related genes.  Therefore these data suggest that myostatin induces 
cachexia through an NF-κB-independent mechanism.  Furthermore, increased 
Myostatin levels appear to antagonise hypertrophy signalling through regulation 
of the AKT-FoxO1 pathway. 
 
5.1  Introduction 
 
Skeletal muscle cachexia is an all too common disease with up to 50% of all 
cancer patients experiencing some degree of muscle loss (Tisdale 2003), thus 
cachexia is a condition which almost certainly contributes to the high morbidity 
and mortality rates associated with this disease (Nelson 2000; Tisdale 2002).   
Proinflammatory cytokines appear to play a critical role during the initiation of 
cachectic conditions (Moldawer and Copeland 1997).  The expression of several 
cytokines including Interleukin-1 (IL-1), Interleukin-6 (IL-6) and Tumor Necrosis 
Factor-alpha (TNF-α) have been previously shown to increase during cachexia 
(Stovroff et al. 1989; Moldawer and Copeland 1997) and indeed, TNF-α appears 
to play an important role in tumour-induced muscle wasting (Torelli et al. 1999; 
Karayiannakis et al. 2001).  A well studied pathway activated by TNF-α involves 
the downstream target transcription factor Nuclear Factor-kappa B (NF-κB). TNF-
α is a potent regulator of NF-κB and in fact TNF-α induction of NF-κB has been 
linked to increased proteolysis and reduced expression of Myosin Heavy Chain 
(Li et al. 1998; Guttridge et al. 2000; Li and Reid 2000).  MyoD, a myogenic 
basic Helix-Loop-Helix (bHLH) transcription factor, is critically involved in 
regulating skeletal muscle differentiation and is essential for the repair of 
damaged skeletal muscle (Megeney et al. 1996; Cornelison et al. 2000; Guttridge 
et al. 2000; Montarras et al. 2000).  MyoD expression has been shown to decline 
dramatically during tumour-associated muscle wasting (Costelli et al. 2005).  
Interestingly, TNF-α signalling through NF-κB results in the inhibition of C2C12 
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myoblast differentiation through down-regulation of MyoD expression (Guttridge 
et al. 2000).  Furthermore, TNF-α in conjunction with the cytokine Interferon-
gamma (IFN-γ), functions through NF-κB to inhibit MyoD expression in fully 
differentiated myotube cultures, thus facilitating myotube degeneration (Guttridge 
et al. 2000).   
One of the principal catabolic systems behind the induction of skeletal muscle 
atrophy in many forms of disease is the ubiquitin-proteasome pathway.  Two 
important muscle-specific ubiquitin E3 ligases, MuRF-1 and Atrogin-1 (MAFbx) 
(Bodine et al. 2001; Gomes et al. 2001), have recently been associated with a 
variety of atrophic conditions.  In particular, an up-regulation in the expression of 
MuRF-1 and atrogin-1 was observed in five independent models of skeletal 
muscle atrophy including immobilisation, denervation, hindlimb suspension, 
administration of IL-1 and administration of the glucocorticoid dexamethasone 
(Bodine et al. 2001).  Furthermore, mice deficient in either atrogin-1 or MuRF-1 
were found to be resistant to atrophy in a denervation and disuse model (Bodine et 
al. 2001). 
The activity of the IGF-1/PI3-K/AKT pathway decreases during muscle atrophy 
(Sandri et al. 2004).  Reduced activity of the IGF-1/PI3-K/AKT signalling 
pathway appears to result in the accumulation of hypo-phosphorylated active 
forms of the Forkhead box O (FoxO) class of transcription factors (Sandri et al. 
2004).  The FoxO transcription factors have gained recent attention in the field of 
muscle wasting.  Indeed FoxO1 (FKHR) expression is greatly induced during 
atrophic conditions including fasting, cancer, diabetes mellitus and renal failure 
(Lecker et al. 2004).  Furthermore, FoxO transcription factors have recently been 
shown to induce skeletal muscle wasting through the regulation of atrophy-related 
genes (“atrogenes”) including Atrogin-1 (Sandri et al. 2004). 
Myostatin, a TGF-β superfamily member, is a secreted growth factor that is well 
recognised as a negative regulator of muscle growth.  Myostatin expression is 
detected during embryonic, foetal and post-natal stages of development, 
suggesting that it may play a vital role throughout myogenesis (Kambadur et al. 
1997; McPherron et al. 1997).  Myostatin expression is first detected in myogenic 
precursor cells of the myotome compartment in developing somites (McPherron et 
al. 1997).  During prenatal development myostatin appears to function by 
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negatively regulating myoblast proliferation via control of the G1 to S transition of 
the cell cycle through both Retinoblastoma-dependent and -independent 
mechanisms (Thomas et al. 2000; Langley et al. 2004).  In addition, myostatin 
blocks myoblast differentiation through the regulation of MyoD activity (Langley 
et al. 2002).  Post-natally, myostatin expression has pronounced effects on muscle 
growth; indeed the expression of a non-functional allele of myostatin in cattle 
(Kambadur et al. 1997) and humans (Schuelke et al. 2004), or targeted disruption 
of myostatin in mice (McPherron et al. 1997), result in severe hyperplasia and 
extreme muscle growth.  In addition, molecular analysis suggests that a lack of 
myostatin results in increased muscle regeneration through enhanced satellite cell 
activation and self renewal, thereby promoting post-natal muscle growth and 
repair (McCroskery et al. 2003; McCroskery et al. 2005).  Alternatively, 
increased myostatin expression has been implicated in atrophic conditions seen 
during AIDS (Gonzalez-Cadavid et al. 1998), sarcopenia (Schulte and Yarasheski 
2001; Yarasheski et al. 2002) and muscle disuse such as chronic human disuse 
atrophy (Zachwieja et al. 1999; Reardon et al. 2001), hindlimb unloading 
(Carlson et al. 1999; Wehling et al. 2000) and space flight (Lalani et al. 2000).  In 
addition, myostatin expression increases during glucocorticoid-induced muscle 
atrophy (Ma et al. 2003).  Furthermore, systemic administration of Myostatin 
protein has been shown to induce cachexia (Zimmers et al. 2002).  Functional 
myostatin blockade in mdx mice, a model of Duchenne Muscular Dystrophy, 
results in an increase in muscle mass and more importantly, muscle force 
production (Bogdanovich et al. 2002).  Therefore, it is well established that 
myostatin plays a critical role during the induction of cachectic conditions; 
however the mechanism behind this process is not known.   
Thus in vitro and in vivo models of myostatin-induced cachexia have been utilised 
to identify the mechanism by which myostatin induces this cachexia.  It is 
proposed that myostatin acts independently of NF-κB to induce skeletal muscle 
atrophy by inhibiting muscle protein synthesis via the down-regulation of Pax3 
and the subsequent loss of MyoD. In addition, it appears that myostatin induces 
atrophy by activating the expression of components of the ubiquitin-proteasome 
pathway, such as Atrogin-1, through regulation of the Forkhead Box O 
transcription factor FoxO1. 
 195
5.2  Materials and Methods 
 
5.2.1  Cell cultures 
For in vitro studies of myostatin-induced muscle wasting, C2C12 myoblasts 
(American Type Culture Collection; ATCC, Manassas, VA) were used (Yaffe and 
Saxel 1977).  Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen, Carlsbad, CA), buffered with 17 mM of NaHCO3 (Sigma, St 
Louis, MO) and 5% gaseous CO2.  2.93 nM of Phenol Red (Sigma) was used as a 
pH indicator and antibiotics 1 x 105 IU/L penicillin (Sigma) and 100 mg/L 
streptomycin (Sigma) were added.  Foetal Bovine Serum (FBS, Invitrogen) was 
added to the DMEM for culturing cells under growth conditions.  The 
recombinant Myostatin protein (Mstn) used in these in vitro experiments was 
generated and purified in our laboratory (Sharma et al. 1999). 
 
5.2.2  In vitro atrophy model 
To assess the ability of myostatin to induce cachexia in vitro, C2C12 cells were 
grown as above, on Thermanox coverslips (Nalge Nunc International, Rochester, 
NY).  The C2C12 cells were differentiated for 72 hr in Differentiation Medium 
(DMEM + 2% Horse Serum; HS) followed by a further 24 hr in Differentiation 
Medium with 0, 3 or 10 µg/mL Mstn.  The coverslips were then stained with 
Gill’s haematoxylin and eosin.  Dimensions of myotubes were analysed 
microscopically using the Windows Version 4.0.1 SPOT Basic software program 
(Diagnostic Instruments Inc).  Fifty images of non-overlapping areas of each of 
three coverslips were taken under 200 x magnification.  The maximal width of all 
myotubes within each image (n = 150) was measured. 
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5.2.3  Establishment and testing of an in vivo model of myostatin-induced 
cachexia 
The AgResearch Ruakura Animal Ethics Committee approved the animal 
manipulations described in this study.  Athymic nude mice were used for the 
generation of the in vivo model of myostatin-induced cachexia.  Animals were 
maintained in rooms set at a constant temperature (20-22°C) with a 12:12 hr 
day/night cycle.  They were provided with sterile water and near-sterile food ad 
libitum.  All animals were handled in accordance with the guidelines set out in 
both the AgResearch Small Animal Containment Facility and AgResearch Small 
Animal Colony quarantine manuals.   
The in vivo model of myostatin-induced skeletal muscle atrophy was developed 
based on that of Zimmers et al (Zimmers et al. 2002).  These authors introduced 
high levels of circulatory Myostatin to nude mice via the injection of Myostatin-
expressing Chinese Hamster Ovary (CHO) cells intramuscularly.  These CHO 
cells express Myostatin under the control of a metallothionein promoter inducible 
by zinc.  An aliquot of these Myostatin-expressing cells was kindly given to our 
laboratory by Dr S.J. Lee (Zimmers et al. 2002).   
Control and Myostatin-expressing CHO cells were grown in DMEM/F12 + 10% 
FBS medium (Invitrogen).  Cell cultures were trypsinised and resuspended in 
DMEM/F12 + 10% FBS, then centrifuged at 500 x g for 5 min.  The cells were 
resuspended in 10 mL of Phosphate Buffered Saline (PBS) and re-centrifuged at 
500 x g for 5 min.  The supernatant was removed and the cells resuspended in 
PBS for injection into the mice. 
Four week old male athymic nude mice were used for this experiment. Mice were 
anaesthetised with 1.2-1.6 mL of Ketamine/Rompun (National Veterinary 
Supplies Ltd) intra-peritoneally.  Each mouse received an injection of 100 µL of 
cell suspension containing 5.0 x 106 cells in PBS.  This injection was administered 
to a depth of 4 mm into the right M. quadriceps femoris muscle of each mouse.  
Tumours developed at the site of injection.  Seven four-week old mice were 
injected with Myostatin-expressing CHO cells and six additional mice were given 
control CHO cells in PBS.  All mice were given a sterile 25 mM ZnSO4 solution 
in place of tap water to drink.  The body mass of each mouse was monitored 
regularly.  In the Zimmers et al paper, mice had lost body weight (~33%) by Day 
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16 of the experiment.  Most of the mice in this in vivo trial had not lost body 
weight by Day 16, so the experiment was continued until each mouse was 
experiencing 15-20% of body mass loss.  This occurred at approximately 30 days 
after cell administration. 
 
5.2.4  Transient co-transfections 
Transfections were performed on C2C12 cells to test the effect of Mstn on either 
the pax3 promoter or the myoD promoter enhancer region. C2C12 myoblasts were 
seeded in 6 well plates at a density of 15,000 cells/cm2.  Following a 24 hr 
attachment period, the cells were transfected with 2 µg of each plasmid DNA 
using Lipofectamine 2000 (Invitrogen) reagent as per the manufacturer’s 
guidelines (see Section 2.2.8.9).  The myoblasts were then incubated overnight at 
37oC, in 5% CO2.  Proliferation medium (DMEM + 10% FBS) was then removed 
and replaced with Differentiation Medium with or without Mstn, for a further 24 
hr.  C2C12 cells were transfected with the pax3 promoter and the β-galactosidase 
(β-gal) expression plasmid pCH110 (GE Healthcare Bio-Sciences Corp. 
Piscataway, NJ), followed by treatment with 0, 4 or 8 µg/mL Mstn.  The pax3 
promoter, a gift from Dr J.A. Epstein (Li et al. 1999), was sub-cloned into the 
pGL3b Luciferase vector.  In addition, C2C12 cells were transfected with both the 
myoD core enhancer; gifted by Dr J.P. Capone (Hunter et al. 2001), and pCH110 
followed by treatment with 0 or 3 µg/mL Mstn.  Following treatment the medium 
was removed and cells were washed twice with 5 mL PBS per plate and lysed in 
300 µL of Reporter Lysis Buffer (Promega).  Lysates were analysed for luciferase 
reporter gene activity (Promega) in a Turner Designs luminometer (Model TD-
20/20).  β-gal expression levels were also detected in each supernatant using the 
β-gal Enzyme Assay System (Promega) as per the manufacturer’s guidelines (see 
Section 2.2.9).  The luciferase values for each sample were normalised to the 
corresponding β-gal value as a measure of transfection efficiency. 
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5.2.5  Gene expression analysis of selected myogenic and proteolytic genes   
C2C12 cells were seeded on 10 cm plates at a density of 25,000 cells/cm2 in 
Proliferation Medium. After a 24 hr attachment period cultures were differentiated 
for 72 hr in Differentiation Medium followed by a further 48 hr in Differentiation 
Medium with or without 3 µg/mL of Mstn.  RNA was isolated from both C2C12 
cells and M. quadriceps femoris muscle from CHO injected mice using TRIZOL 
reagent (Invitrogen) as per the manufacturer’s protocol (see Section 2.2.10).  RNA 
was used for Northern analysis, and was also reverse-transcribed into cDNA for 
use in semi-quantitative RT-PCR (Q-RT-PCR) analysis of gene expression. 
Northern analysis was performed as described by Sambrook et al. (Sambrook et 
al. 1989) (see Section 2.2.12). 15 µg of total RNA was separated by 1% 
formaldehyde agarose gel electrophoresis.  RNA was transferred to Hybond N+ 
membrane (GE Healthcare Bio-Sciences) by capillary transfer using a 10 × SSC 
solution. The membrane was prehybridised in Church and Gilbert hybridisation 
buffer (0.5 M pH 7.2 Na2HPO4, 7% SDS and 1 mM EDTA) at 55°C for 1 hr, 
followed by hybridisation with 32P-labeled DNA probe in fresh hybridisation 
buffer at 55°C, overnight. The membrane was rinsed twice with 5 × SSC + 0.5% 
SDS, and then washed successively with 2 × SSC + 0.5% SDS, and 1 × 
SSC + 0.5% SDS for 15 min each at 55°C.   
In addition, the expression patterns of several genes were analysed by Q-RT-PCR.  
First-strand cDNA was synthesised in a 20 µL reverse transcriptase (RT) reaction 
from 5 µg of total RNA using a SuperScript II First-Strand Synthesis System 
(Invitrogen), according to the manufacturer’s protocol (see Section 2.2.6.1). PCR 
was performed with Taq DNA polymerase (Roche Diagnostics Corporation, 
Indianapolis, IN) using 1 µL of the RT reaction at 94°C for 2 min, followed by 
94°C for 20 s, a gene specific annealing temperature for 30 s (see Table 2.7), then 
72°C for 2 min.  This process was repeated for 35 cycles for the generation of 
cDNA probes, or for 14 cycles for GAPDH and 18 cycles for myoD, pax3, E214k, 
atrogin-1, MuRF-1, NF-κB and FoxO1.  This was followed by a single 72°C 
extension step for 5 min.  These PCR conditions were used for Q-RT-PCR 
expression analysis.  The cDNA probes for Northern Blot analysis and Q-RT-PCR 
were made from 25 ng of RT-PCR product that was radioactively labelled with 
[α32P]dCTP (GE Healthcare Bio-Sciences) and a Rediprime DNA labelling 
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system kit (GE Healthcare Bio-Sciences), according to the manufacturer’s 
protocol (see Section 2.2.7). 
The following murine specific primers were used for performing the Q-RT-PCR:  
myoD Fwd, 5’-GGA TCC TAA GAC GAC TCT CAC-3’; myoD Rev, 5’-GGA 
TCC AGT GCC TAC GGT GG-3’; pax3 Fwd, 5’-GCA AGA TGG AGG AAA 
CAA GC-3’; pax3 Rev, 5’-CGT TCT CAA GCA AGA GGT G-3’; E214k Fwd, 5’-
ATG TCG CCC CGG CCC GGA GGC TCA TG-3’; E214k Rev, 5’-ATG AAT 
CAT TCC AGC TTT GTT CAA C-3’; atrogin-1 Fwd, 5’-AAC ATG TGG GTG 
TAT CGG-3’; atrogin-1 Rev, 5’-TCT TGA GGG GAA AGT GAG-3’; MuRF-1 
Fwd, 5’-GTT AAA CCA GAG GTT CGA G-3’; MuRF-1 Rev, 5’-ATG GTT 
CGC AAC ATT TCG G-3’; NF-κB Fwd, 5’-ATG GAC GAT CTG TTT CCC 
CTC-3’; NF-κB Rev, 5’-TTA GGA GCT GAT CTG ACT C-3’; GAPDH Fwd, 5’-
GTG GCA AAG TGG AGA TTG TTG GCC-3’; GAPDH Rev, 5’-GAT GAT 
GAC CCG TTT GGC TCC-3’; FoxO1 Fwd, 5’-TTC AAG GAT AAG GGC GAC 
AG-3’; FoxO1 Rev, 5’-ACT CGC AGG CCA CTT AGA AA-3’. 
 
5.2.6  NF-κB inhibitor cell line 
The IκBα super-repressor (IκBα SR) C2C12 cells were gifted by D.C. Guttridge 
(Guttridge et al. 1999). The IκBα SR expressing C2C12 cells were cultured in 
Differentiation Medium for 72 hr followed by a further 24 hr in Differentiation 
Medium with either 0 µg/mL or 10 µg/mL Mstn.    
 
5.2.7  Microarray analysis  
C2C12 cells were cultured in Differentiation Medium for 72 hr as outlined above 
followed by a further 24 hr in Differentiation Medium with or without 10 µg/mL 
Mstn.  RNA was then isolated using TRIZOL (Invitrogen) according to 
manufacturer’s guidelines (see Section 2.2.10).  Contaminating DNA was 
removed by DNase1 (Invitrogen) treatment.  The RNA was then column purified 
using the RNeasy Midi Kit (Qiagen) following the manufacturer’s guidelines (see 
Section 2.2.11), ethanol precipitated overnight at -20°C and resuspended in 
RNase-free water.  Microarray analysis was performed by MWG, Ebersberg, 
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Germany as per their standardised techniques, using the MWG mouse 30k array.  
Briefly, the Myostatin-untreated and -treated RNA samples were reverse 
transcribed and directly labelled with Cy3 or Cy5, respectively, or conversely 
Cy5/Cy3 as a control.  Following co-hybridisation spots were scanned numerous 
times and signal intensities determined using Imagene software (BioDiscovery).  
The MWG proprietary software MAVI was then used for combining the data from 
multiple scans, normalisation and background correction.  The ratio between 
signal intensity for both Cy3 to Cy5 and Cy5 to Cy3 was used to generate mean 
values for intensity of each gene, corresponding to fold up or down-regulation.  
Gene expression changes were deemed significant if expression was up-regulated 
or down-regulated by ≥ 1.5-fold. 
 
5.2.8  Protein isolation 
Cells were cultured for 72 hr in Differentiation Medium as outlined above 
followed by a further 24 hr in Differentiation Medium with 0, 4, 6 or 10 µg/mL 
Mstn.  For quantitative FoxO1, phosphorylated FoxO1 (p-FoxO1) and 
phosphorylated AKT (p-AKT) immunoblot analyses, mouse C2C12 myotubes 
were cultured as described above.  C2C12 cells were resuspended in 200 µL lysis 
buffer (50 mM Tris pH 7.6; 250 mM NaCl; 5 mM EDTA; 0.1% Nonidet P-40; 
Complete protease inhibitor [Roche]) and passed through a 26 gauge needle 10 
times.  Whole muscle lysates from M. Biceps femoris isolated from CHO-injected 
mice were resuspended in 500 µL of lysis buffer and homogenised.  The cell and 
whole muscle extracts were then centrifuged to pellet cell debris.  To isolate 
cytoplasmic and nuclear fractions, C2C12 cells were pelleted, washed in PBS and 
resuspended in ice cold Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM 
KCl, 1 mM dithiothreitol (DTT) and Complete protease inhibitor cocktail tablets). 
The cells were passed through a 26 gauge needle 10 times on ice.  The suspension 
was centrifuged at 20,000 x g for 15 s and the supernatant recovered as the 
cytoplasmic fraction.  The pellets were resuspended in ice cold Buffer B (20 mM 
HEPES pH 7.9, 0.2 mM EDTA, 420 mM KCl, 1 mM DTT, and Complete 
protease inhibitor cocktail tablets), incubated 20 min on ice and passed through a 
26 gauge needle 10 times on ice. The suspension was centrifuged at 20,000 x g for 
15 s and the supernatant recovered as the nuclear fraction.  Bradford Reagent 
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(Bio-Rad Laboratories, Hercules, CA) was used to estimate total protein content 
to ensure equal loadings. 
 
5.2.9  Western Blot analysis 
Total protein (15 µg) was separated by 4-12% SDS-PAGE (Invitrogen) and 
transferred to nitrocellulose membrane by electroblotting.  The membranes were 
blocked in 0.3% BSA, 1% PEG (polyethylene glycol 4,000; Sigma), 1% PVP 
(polyvinylpyrrolidone 10,000; Sigma) for 1 hr at room temperature, then 
incubated with specific primary antibodies overnight at 4°C.  Alternatively, the 
membranes were blocked overnight at 4ºC using a solution of TBST/5% milk, 
then incubated with specific primary antibodies for 3 hr at room temperature.  The 
following primary antibodies were used for immunoblotting; 1:5,000 dilution of 
purified rabbit polyclonal anti-E214k antibody (A-605; Boston Biochem, 
Cambridge, MA); 1:5,000 dilution of rabbit anti-atrogin-1 antibody, kindly given 
to our laboratory by Dr Cam Patterson (Li et al. 2004); 1:10,000 dilution of 
purified mouse monoclonal anti-Ubiquitin antibody (sc-8017; Santa Cruz 
Biotechnology Inc, Santa Cruz, CA); 1:1,000 dilution of purified rabbit polyclonal 
anti-NF-κB (p65) antibody (sc-372; Santa Cruz Biotechnology Inc.); 1:5,000 
dilution of purified rabbit polyclonal anti-SP1 antibody (sc-59; Santa Cruz 
Biotechnology Inc.); 1:1,000 dilution of purified rabbit polyclonal anti-FKHR 
(FoxO1) antibody (sc-11350; Santa Cruz Biotechnology Inc.); 1:3,000 dilution of 
purified rabbit polyclonal anti-p-FKHR (p-FoxO1; Ser256) antibody (sc-22158-R; 
Santa Cruz Biotechnology Inc.); 1:1,000 dilution of purified rabbit polyclonal 
anti-p-AKT (Ser473) antibody (sc-7985; Santa Cruz Biotechnology Inc.) or 
1:10,000 dilution of purified mouse monoclonal α-Tubulin antibody (T-9026; 
Sigma).  The membranes were washed (5 x 5 min) with TBST and further 
incubated with anti-rabbit IgG Horseradish Peroxidase (HRP) conjugate, 1:5,000 
dilution (P0448; Dako, Glostrup, Denmark) or anti-mouse IgG HRP conjugate, 
1:5,000 dilution (P0447; Dako) secondary antibodies for 1 hr at room 
temperature.  The membranes were washed as above, and HRP activity was 
detected using Western Lightning Chemiluminescence Reagent Plus (NEL104; 
PerkinElmer Life And Analytical Sciences, Inc., Wellesley, MA). 
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5.2.10  FoxO1 siRNA analysis 
C2C12 cells were transfected at ~70% confluence with 1 nM of each specific 
siRNA.  The siRNA transfections were performed with HiPerFect Transfection 
Reagent (Qiagen) as per the manufacturer’s protocol (see Section 2.2.8.10).  The 
specific siRNA’s were generated and obtained from Qiagen:  Non-silencing 
control siRNA, rUUC UCC GAA CGU GUC ACG UdT dT; Mouse FoxO1 
siRNA, r(CGU UUG UUA GUG UGU GUU A)dTdT.   
 
5.2.11  Statistics 
The Student’s-T test was also used for the comparison of Myostatin-treated 
samples with control samples, for factors such as muscle weights. For the 
transfection experiments, the mean luciferase values were calculated per well and 
the three means averaged, and analysis of variance (ANOVA) performed.  
ANOVA was also used to analyse the data for the myotube size.  There were three 
slides of cells per treatment, with fifty images each slide.  The mean number of 
myotubes in each slide was calculated, and the mean of the means calculated.  A P 
value <0.05 was deemed significant for all experiments.   
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5.3  Results 
 
5.3.1  In vitro and in vivo models of myostatin-induced cachexia 
To study the mechanism behind myostatin-induced muscle wasting, both in vitro 
and in vivo models of myostatin-induced cachexia were generated.  In this study 
C2C12 cells were differentiated for 72 hr followed by a further 24 hr in 
Differentiation Medium with or without Myostatin.  The addition of recombinant 
Myostatin protein to the differentiated myotube cultures induced prominent 
atrophic changes (Figure 5.1A).  In fact, treatment with increasing levels of 
recombinant Myostatin protein resulted in a concomitant decrease in myotube 
diameter.  Specifically, the median myotube diameter was reduced by 57% with 
maximal Myostatin protein treatment (10 µg/mL) (Figure 5.1B).   
Next, an in vivo model of myostatin-induced cachexia was developed based on the 
report by Zimmers et al (Zimmers et al. 2002).  As such, mice were injected 
intramuscularly with Myostatin over-expressing CHO cells.  After a treatment 
period of 30 days the body mass of mice injected with Myostatin over-expressing 
CHO cells was 18% lower when compared to mice injected with control CHO 
cells (data not shown).   
 
5.3.2  Myostatin and myogenic gene expression 
Since Myostatin treatment resulted in atrophic changes both in vitro and in vivo, 
the myogenic gene expression patterns, in response to the Myostatin treatment, 
were monitored in both models.  MyoD is a Myogenic Regulatory Factor, and as 
such is a key regulator of muscle synthesis and regeneration (Megeney et al. 
1996; Black et al. 1998; Guttridge et al. 2000).  Myostatin has been previously 
shown to inhibit both MyoD expression and activity (Langley et al. 2002; Amthor 
et al. 2004).  Thus myoD expression was monitored to elucidate a possible role for 
MyoD in myostatin-induced cachexia.  Indeed, myoD was found to be 
dramatically down-regulated following Myostatin treatment in vitro (Figure 5.2A) 
furthermore, myoD expression was down-regulated by ~84% in vivo (Figure 
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5.2B).  This evidence suggests that Myostatin acts via a down-regulation of myoD 
to prevent muscle synthesis and regeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Myostatin decreases the size of myotubes in vitro 
C2C12 myotubes were stained with Gill’s haematoxylin and eosin and the 
physiology of the cells analysed.  A) C2C12 cells were seeded on coverslips in 
wells with Proliferation Medium at a density of 25,000 cells/cm2 for 24 hr and 
then differentiated for 72 hr (0 hr + 0 µg/mL Mstn) without Mstn (i).  Other cells 
were differentiated for a further 24 hr with 0 µg/mL (24 hr + 0 µg/mL Mstn) (ii), 3 
µg/mL (24 hr + 3 µg/mL Mstn) (iii) or 10 µg/mL (24 hr + 10 µg/mL Mstn) (iv) of 
Mstn.  Scale bar represents 25 µm.  B) The maximal diameter of each stained 
myotube was measured.  Bars represent the average median width of three 
independent experiments.  Statistical differences determined by ANOVA are 
indicated; P< 0.001 (***) compared to both untreated 0 hr (0 hr + 0 µg/mL Mstn) 
and 24 hr (24 hr + 0 µg/mL Mstn) controls. 
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Figure 5.2  Myogenic gene expression is altered during myostatin-induced 
cachexia in vitro and in vivo   
A) The myogenic gene expression differences for C2C12 cells treated with Mstn 
were measured by Northern Blot analyses.  Cells were seeded at a density of 
25,000 cells/cm2.  Following a 24 hr attachment period, cells were switched to 
Differentiation Medium for 72 hr.  The cells were then treated for an additional 48 
hr in Differentiation Medium with either 0 µg/mL (-) or 3 µg/mL (+) Mstn.   The 
in vitro Northern Blots demonstrate the effect of Mstn on myoD and pax3 
expression, with the 28S and 18S RNA bands demonstrating equal loading of 
RNA.  B) The myogenic gene expression differences for nude mice injected intra-
muscularly with either control CHO cells (-) or Myostatin-expressing CHO cells 
(+) were measured by Q-RT-PCR.  Q-RT-PCR was performed to analyse the 
expression of myoD and pax3.  GAPDH expression was analysed as a measure of 
RNA amounts used in Q-RT-PCR.  All Northern and Southern Blots pictured 
represent three independent experiments.  C) In vitro analysis of the effect of 
Myostatin on pax3 promoter activity.  The pax3 promoter and β-galactosidase (β-
gal) expression plasmids were transfected into C2C12 myoblasts using 
Lipofectamine 2000 reagent.  The cells were grown for a further 24 hr in 
Differentiation Medium, after which luciferase and β-gal activities were 
measured.  Results reflect relative pax3 promoter-luciferase activity with 
increasing Mstn concentrations of 4 µg/mL (4.0) and 8 µg/mL (8.0) as compared 
to the untreated control (0).  Values were normalised to β-gal and the bars indicate 
means ± standard error of three independent experiments.  Statistical significance 
was analysed using ANOVA, where P< 0.001 (***) compared to untreated 
control (0).  D) In vitro analysis of the effect of Mstn on the myoD core enhancer 
(promoter) activity.  The myoD promoter and β-galactosidase (β-gal) expression 
plasmids were transfected into C2C12 myoblasts.  The cells were grown for a 
further 24 hr in Differentiation Medium after which luciferase and β-gal activities 
were measured.  Results reflect relative myoD promoter luciferase activity 
following treatment with 3 µg/mL (3.0) Mstn as compared to the untreated control 
(0).  Values were normalised to β-gal and the bars indicate mean ± standard error 
of three independent experiments.  Statistical significance was analysed for the 
normalised luciferase values using ANOVA, where P< 0.01 (**) compared to 
untreated control (0). 
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In addition, the expression of pax3 was measured to further clarify how myostatin 
might signal the down-regulation of myoD during cachexia.  Myostatin has been 
shown to decrease the expression of pax3 and myoD in embryonic chick limb 
buds (Amthor et al. 2004).  In addition, it is well established that pax3 acts 
upstream to activate myoD expression (Epstein et al. 1995; Maroto et al. 1997; 
Tajbakhsh et al. 1997).  Based on this data, it was anticipated that myostatin may 
act via a Pax3 dependent pathway to down-regulate myoD during muscle atrophy.  
As expected, pax3 gene expression was down-regulated by ~52% in vitro and 
~30% in vivo following Myostatin treatment (Figure 5.2A and Figure 5.2B).  To 
demonstrate Myostatin regulation of pax3, C2C12 myoblasts were transiently 
transfected with a pax3 promoter-luciferase reporter construct.  Subsequent 
reporter analysis confirmed Myostatin inhibition of pax3 activity, as treatment 
with 8 µg/mL Myostatin resulted in a ~75% decrease in pax3 promoter activity 
(Figure 5.2C).  Furthermore, C2C12 myoblasts were transiently transfected with a 
myoD promoter/enhancer reporter construct in the presence or absence of 
recombinant Myostatin protein.  As shown in Figure 5.2D, treatment with 3 
µg/mL Myostatin resulted in a ~52% reduction in myoD reporter activity.  These 
data indicate that myostatin indeed inhibits the activity of both pax3 and myoD in 
differentiated C2C12 myotubes.   
 
5.3.3  Myostatin and proteolytic gene expression 
One of the major systems believed to be pivotal in inducing the skeletal muscle 
atrophy associated with many forms of disease is the ubiquitin-proteasome 
pathway.  Therefore the effect of myostatin on the induction of the ubiquitin-
proteasome pathway was assessed.  Proteins degraded by the ubiquitin-
proteasome pathway are first covalently bound to ubiquitin, a process that is 
regulated by an enzyme cascade consisting of ubiquitin-activating enzymes (E1), 
ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3) (Hasselgren et al. 
2002).  The resulting ubiquitinated proteins are then degraded by the 26S 
proteasome complex in an ATP-dependent process (Lecker et al. 1999).  Thus the 
expression levels of several candidate proteins including the ubiquitin-conjugating 
enzymes E214k and E220k, and the ubiquitin-ligases MuRF-1 and Atrogin-1, were 
monitored by Northern and Southern Blot analysis.  As shown in Figure 5.3A, 
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C2C12 myotubes treated with Myostatin exhibited a ~90% increase in E214k 
mRNA levels; however no significant change in E214k expression was detected in 
vivo (Figure 5.3B).  In addition, no change was observed in the expression of 
E220k mRNA in response to Myostatin treatment in vitro (Data not shown).  The 
expression levels of E3 enzymes in response to Myostatin treatment were 
subsequently evaluated.  A ~60% increase in atrogin-1 expression during 
myostatin-induced myotube atrophy was observed (Figure 5.3A) and a dramatic 
~150% increase in atrogin-1 expression during myostatin-induced cachexia in 
vivo (Figure 5.3B).  In contrast, MuRF-1 levels did not increase in response to 
Myostatin treatment in vitro (Figure 5.3A) however, a ~58% increase in MuRF-1 
expression was observed following in vivo treatment (Figure 5.3B).  The protein 
expression of both E214k and Atrogin-1 were also measured by Western Blot 
analysis.  As shown in Figure 5.3C, myostatin up-regulates E214k expression by 
55%, furthermore, Myostatin treatment resulted in a dramatic up-regulation of 
Atrogin-1 expression (Figure 5.3C).  To assess the effect of myostatin on the level 
of ubiquitinated proteins a Western Blot using an anti-ubiquitin-specific antibody 
was performed and as shown in Figure 5.3D, Myostatin treatment resulted in a 
60% increase in the level of ubiquitin-conjugated proteins.  This increased 
ubiquitin-conjugation is particularly prevalent in proteins ~70 kDa or smaller.  
These observations confirm that Myostatin up-regulates several genes involved 
with ubiquitination of muscle proteins and indeed Myostatin treatment enhances 
the level of ubiquitin-conjugated proteins.   
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Figure 5.3  Proteolytic gene expression is altered during myostatin-induced 
cachexia in vitro and in vivo   
A) The proteolytic gene expression differences for C2C12 cells treated with Mstn 
were measured by Northern Blot analyses.  Cells were seeded at a density of 
25,000 cells/cm2.  Following a 24 hr attachment period cells were switched to 
Differentiation Medium for 72 hr.  The cells were treated for an additional 48 hr 
of differentiation with either 0 µg/mL (-) or 3 µg/mL (+) of Mstn.  The in vitro 
Northern Blots demonstrate the effect of Mstn on E214k, atrogin-1 and MuRF-1, 
all members of the ubiquitin-proteasome pathway, with the 28S and 18S RNA 
bands demonstrating equal loading of RNA.  B) The proteolytic gene expression 
differences for immune-deficient mice injected intra-muscularly with either 
control CHO cells (-) or Myostatin-expressing CHO cells (+) were measured by 
Q-RT-PCR.  The in vivo Southern Blots demonstrate the effect of Mstn on E214k, 
atrogin-1 and MuRF-1, with GAPDH expression was analysed as a measure of 
RNA amounts used in Q-RT-PCR.  All Northern and Southern Blots pictured 
represent three independent experiments.  C) Western Blot to demonstrate the 
effect of Mstn on the protein levels of the proteolytic genes E214k and Atrogin-1.  
Cells were seeded at a density of 25,000 cells/cm2 and after a 24 hr attachment 
period cells were switched to Differentiation Medium for 72 hr. To study E214k the 
cells were treated for 1 hr with either 0 µg/mL (-) or 1 µg/mL (+) of Mstn, and to 
study Atrogin-1 the cells were treated for an additional 24 hr in Differentiation 
Medium with either 0 µg/mL (-) or 10 µg/mL (+) of Mstn.  Tubulin levels were 
measured to ensure equal loadings.  The graph represents relative densitometry 
analysis of each E214k band normalised to Tubulin.  D)  Western Blot analysis of 
the effect of Mstn on protein ubiquitination.  Cells were seeded at a density of 
25,000 cells/cm2 and after a 24 hr attachment period cells were switched to 
Differentiation Medium for 72 hr. The cells were treated for 3 hr with either 0 
µg/mL (-) or 3 µg/mL (+) of Mstn.  Tubulin levels were measured to ensure equal 
loadings.  The graph represents relative densitometry analysis of each band 
normalised to Tubulin.   
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5.3.4  Myostatin signals independently of NF-κB to regulate cachexia 
NF-κB is activated by TNF-α, a cytokine that is believed to be an inducer of 
cachexia (Guttridge et al. 2000).  In fact, the down-regulation of myoD during 
cachexia has been shown to occur via a mechanism involving TNF-α, IFN-γ and 
NF-κB (Guttridge et al. 2000).  Therefore, it is conceivable that myostatin acts via 
NF-κB to cause a down-regulation of myoD expression during cachexia.  
However, despite previous evidence linking NF-κB with atrophic conditions, NF-
κB (p65) expression was not altered in both in vitro and in vivo models of 
myostatin-induced cachexia (Figure 5.4A and Figure 5.4B).  In addition, there 
was no change in the nuclear localisation of p65 following Myostatin treatment 
(Figure 5.4C).  To further confirm that myostatin signalling to induce cachexia is 
independent of NF-κB, the ability of myostatin to up-regulate Atrogin-1 was 
assessed in a stable C2C12 cell line expressing the IκBα SR protein.  The IκBα SR 
protein acts as a potent and specific inhibitor of NF-κB activity (Guttridge et al. 
1999).  As shown in Figure 4D, myostatin is still able to increase the expression 
of Atrogin-1 by 110% in the absence of NF-κB activity.  Thus myostatin may 
signal independently of NF-κB to mediate the induction of cachexia.   
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Figure 5.4  Myostatin signals independently of NF-κB p65 to regulate cachexia 
A)  The expression of p65 in vitro with Mstn treatment.  Cells were seeded at a 
density of 25,000 cells/cm2 and after a 24 hr attachment period cells were 
switched to Differentiation Medium for 72 hr. The cells were treated for 48 hr 
with either 0 µg/mL (-) or 10 µg/mL (+) of Mstn.  Tubulin levels were measured 
to ensure equal loadings.  B)  The p65 gene expression differences for nude mice 
injected intra-muscularly with either control CHO cells (-) or Myostatin-
expressing CHO cells (+) were measured by Q-RT-PCR.  GAPDH expression was 
analysed as a measure of RNA amounts used in Q-RT-PCR.  All Northern and 
Southern Blots pictured represent three independent experiments.  C)  Western 
Blot demonstrating the effect of Mstn treatment on the nuclear localisation of p65.  
Cells were seeded at a density of 25,000 cells/cm2 and after a 24 hr attachment 
period cells were switched to Differentiation Medium for 72 hr. The cells were 
treated for an additional 24 hr with either 0 µg/mL (-) or 5 µg/mL (+) of Mstn.  
Ponceau S staining was shown as a measure of equal loading and SP1 protein 
expression shows nuclear enrichment of the protein samples. D)  Analysis of 
atrogin-1 gene expression in C2C12 cells which express the IκBα SR protein.  
The IκBα SR cells were differentiated for 72 hr followed by a further 24 hr with 
either 0 µg/mL (-) or 10 µg/mL (+) of Mstn.  The Northern Blot shows the effect 
of Mstn on atrogin-1 expression in the IκBα SR cell line, with 28S and 18S RNA 
bands shown as a measure of RNA loading.  The graph represents relative 
densitometry analysis of each band normalised to 28S and 18S RNA.  All 
Northern Blots pictured represent three independent experiments. 
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5.3.5  Microarray analysis of myostatin-induced cachexia 
In addition to the candidate gene approach outlined above, global gene expression 
changes were analysed during a model of myostatin-induced cachexia via 
microarray technology.  Microarray analysis was performed using an in vitro 
model of myostatin-induced muscle atrophy.  As identified by microarray analysis 
several myofibrillar structural proteins including Myosin Heavy Chain, Troponin 
C, Tropomyosin 3 (gamma) and Titin-cap were significantly down-regulated 
during myostatin-induced cachexia (Table 5.1).  In agreement with additional in 
vitro and in vivo data presented in this Chapter, microarray analysis has identified 
several members of the ubiquitin-proteasome pathway significantly up-regulated 
by myostatin (Table 5.1).  Recent publications have demonstrated that the 
ubiquitin E3 ligases Atrogin-1 and MuRF-1 are significantly up-regulated in many 
forms of muscle atrophy (Bodine et al. 2001; Gomes et al. 2001).  Consistent with 
this published data, myostatin-mediated myotube atrophy also induces the E3 
ligase Atrogin-1 (Table 5.1).   
 
 
Function Sequence Name Accession No.
Atrogin-1 (fbxo32) NM_026346 1.7
Ubiquitin c (ubc) NM_019639 1.5
Ubiquitin-specific protease 2 (USP2) NM_016808 2.3
Ubiquitin-conjugating enzyme (mhr6bn AF299059 1.5
Ring finger protein 31 (Rnf31) NM_194346 2.5
Myosin heavy chain 2A (myh2) NM_144961 2.7
Troponin c (tcns) NM_009394 2.2
Tropomyosin 3 (Gamma) (tprn3) NM_022314 1.7
Titin-cap (tcap) NM_011540 2
Protein 
degradation
Myofibrilla
r proteins
Fold change
 
 
Table 5.1  Microarray identification of genes altered in a model of myostatin-
induced cachexia   
C2C12 cells were grown in Differentiation Medium for 72 hr followed by a 
further 24 hr in Differentiation Medium without or with 10 µg/mL Mstn.  Genes 
are separated into structural or proteolytic function and were at least 1.5 fold up-
regulated (     ) or down-regulated (     ). 
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In addition, several other genes critically involved during different stages of the 
ubiquitin-proteasome pathway are up-regulated during myostatin-induced 
myotube atrophy.  These include the polyubiquitin gene c (UBC), ubiquitin-
specific protease 2, ubiquitin-conjugating enzyme (mhr6bn) and Ring finger 
protein 31 (Rnf31), a gene sharing characteristics with many E3 ligases (Table 
5.1).  This indicates that myostatin induces atrophy through the up-regulation of 
specific components of the ubiquitin-proteasome pathway, concomitant with a 
significant down-regulation of several myofibrillar proteins. 
 
5.3.6  Myostatin signals atrophy through a FoxO1-dependent pathway 
Microarray analysis of myostatin treated myotube cultures identified an ~85% 
increase in the expression of foxO1 (data not shown). FoxO transcription factors 
have been shown to induce skeletal muscle wasting via the regulation of atrophy-
related genes, including the ubiquitin ligase Atrogin-1 (Sandri et al. 2004; Stitt et 
al. 2004).  In addition, hypertrophy-inducing factors such as IGF-1 function by 
down-regulating the activity of FoxO1 through a PI3-K/AKT dependent pathway 
(Stitt et al. 2004).  Since lack of myostatin induces hypertrophy, and high levels of 
it induce muscle wasting, it was hypothesised that myostatin may induce atrophy 
by reversing canonical hypertrophy signalling pathways, including the IGF/PI3-
K/AKT pathway.  Hence, to further elucidate the role of FoxO1 signalling in 
myostatin-induced cachexia, the levels and the phosphorylation status of FoxO1 
were monitored following myostatin treatment.  Initial Q-RT-PCR analysis of 
foxO1 demonstrated a ~100% increase in foxO1 expression with Myostatin 
treatment (Figure 5.5A).  Subsequent Western Blot analysis demonstrated that 
FoxO1 protein expression is directly up-regulated upon addition of recombinant 
Myostatin protein to C2C12 myotubes (Figure 5.5B).  A ~650% increase in 
FoxO1 expression was also detected in M. Biceps femoris excised from Myostatin 
CHO injected mice as compared to controls (Figure 5.5C).  In addition, it appears 
that Myostatin treatment reduces the levels of phosphorylated FoxO1 in a dose-
dependent manner, thus resulting in an accumulation of active FoxO1 (Figure 
5.5D).   
 
 
 216
 
 
 
 
 
 
 
 
 
Figure 5.5  Myostatin-induced cachexia occurs via a FoxO-dependent pathway   
A) Q-RT-PCR demonstrating the effect of Mstn on foxO1 mRNA expression.  
C2C12 cells were grown in Differentiation Medium for 72 hr followed by a 
further 24 hr in Differentiation Medium without (-) or with 10 µg/mL (+) Mstn.  
RNA was subsequently extracted, reverse transcribed and subjected to PCR 
specific for foxO1 and GAPDH.  The Southern Blot was hybridised with probes 
specific for murine foxO1 and GAPDH.  FoxO1 expression was normalised to 
total GAPDH levels.  B) Western Blot demonstrating the effect of Mstn on FoxO1 
expression.  C2C12 cells were grown in Differentiation Medium for 72 hr 
followed by a further 24 hr in Differentiation Medium without (0) or with 4 
µg/mL (4.0) or 6 µg/mL (6.0) Mstn.  Tubulin levels were measured to ensure 
equal loadings.  The graph represents relative densitometry analysis of each band 
normalised to Tubulin.  C) Western Blot analysis of FoxO1 gene expression 
differences between immune-deficient mice injected intra-muscularly with either 
control CHO cells (-) or Myostatin-expressing CHO cells (+).  Tubulin levels 
were measured to ensure equal loadings.  The graph represents relative 
densitometry analysis of each band normalised to Tubulin.  D) Western Blot 
demonstrating the effect of Mstn on the levels of phosphorylated FoxO1 (p-
FoxO1 Ser 256).  C2C12 cells were grown in Differentiation Medium for 72 hr 
followed by a further 24 hr in Differentiation Medium without (0) or with 4 
µg/mL (4.0), 6 µg/mL (6.0) or 10 µg/mL (10.0) Mstn.  Tubulin levels were 
measured to ensure equal loadings.  The graph represents relative densitometry 
analysis of each band normalised to Tubulin.  E) Western Blot showing the effect 
of Mstn on FoxO1 nuclear localisation.  C2C12 cells were grown in 
Differentiation Medium for 72 hr followed by a further 24 hr in Differentiation 
Medium without (0) or with 10 µg/mL (10.0) Mstn.  C2C12 samples were 
enriched for cytoplasmic (c) or nuclear (n) content with FoxO1 expression in both 
fractions analysed.  Ponceau S staining was shown as a measure of equal loading 
and SP1 was used as a control to verify the purity of nuclear enrichment.  The 
graph represents relative densitometry analysis of each band.  F) Western Blot 
demonstrating the effect of Mstn on the levels of phosphorylated AKT (p-AKT 
Ser 473).  C2C12 cells were grown in Differentiation Medium for 72 hr followed 
by a further 24 hr in Differentiation Medium without (0) or with 4 µg/mL (4.0) or 
6 µg/mL (6.0) Mstn.  Tubulin levels were analysed to ensure equal loadings.  The 
graph represents relative densitometry analysis of each band normalised to 
Tubulin.  All Western and Southern Blots pictured represent three independent 
experiments. 
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Dephosphorylated, and thus active, FoxO1 readily translocates to the nucleus.  
Therefore, nuclear accumulation of FoxO1 was analysed following Myostatin 
treatment.  As shown in Figure 5.5E, Myostatin treatment resulted in an 83% 
increase in nuclear FoxO1 expression when compared to untreated controls 
(Figure 5.5E).  To determine if the myostatin-mediated reduction in 
phosphorylated FoxO1 was in some manner due to an interference with the PI3-
K/AKT pathway, the levels of phosphorylated AKT were measured, and as shown 
in Figure 5.5F, Myostatin treatment resulted in diminished levels of 
phosphorylated AKT in a dose-dependent manner.  Therefore myostatin appears 
to induce cachexia by antagonising IGF-1 hypertrophy signalling through 
targeting and inactivating AKT, leading to activated FoxO1 and increased 
Atrogin-1 expression. 
 
5.3.7  Myostatin signals through FoxO1 to regulate Atrogin-1 expression 
To confirm that myostatin signals through both FoxO1 and Atrogin-1 during the 
induction of cachexia, the ability of myostatin to regulate atrogin-1 expression in 
the presence of siRNA specific for FoxO1 was analysed.  As shown in Figure 
5.6A, Myostatin is able to induce atrogin-1 expression by ~250% in the presence 
of non-silencing siRNA.  However, induction of atrogin-1 by Myostatin is 
impaired in the presence of FoxO1 specific siRNA, when compared to non-
silencing controls (Figure 5.6A).  The expression of FoxO1 was also analysed to 
measure the efficiency of siRNA silencing.  As shown in Figure 5.6B, the levels 
of FoxO1 were reduced by ~70% in the presence of the FoxO1-specific siRNA.  
Thus myostatin may signal through FoxO1 to regulate Atrogin-1 expression and 
the induction of cachexia.   
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Figure 5.6  Myostatin regulation of Atrogin-1 is dependent on FoxO1   
C2C12 cells were grown in Differentiation Medium for 72 hr followed by a 
further 24 hr in Differentiation Medium without (0) or with 10 µg/mL (10.0) 
Mstn.  A) Northern Blot showing the effect of Mstn on atrogin-1 expression in the 
presence of non-silencing control siRNA (-) or FoxO1-specific siRNA (+).  The 
level of RNA loading was determined by 28S and 18S RNA bands.  The graph 
represents relative densitometry analysis of each band normalised to 28S and 18S 
RNA.  B) Western Blot analysing the expression of FoxO1 in the absence (-) or 
presence (+) of a FoxO1-specific siRNA.  Tubulin levels were measured to ensure 
equal loadings.  The graph represents relative densitometry analysis of each band 
normalised to Tubulin.  Both Western and Northern Blots pictured represent three 
independent experiments. 
 220
5.4  Discussion 
 
The role of myostatin as a negative regulator of muscle growth is now well 
established.  Indeed, myostatin has been implicated in atrophic conditions such as 
AIDS (Gonzalez-Cadavid et al. 1998) and disuse atrophy (Carlson et al. 1999; 
Lalani et al. 2000; Wehling et al. 2000).  Furthermore, systemic administration of 
Myostatin protein has been shown to induce skeletal muscle atrophy (Zimmers et 
al. 2002).  Although it is reported that myostatin plays a role in muscle atrophy 
little is known about the mechanism behind this process.  Therefore, in this 
Chapter the molecular mechanism behind myostatin-induced cachexia is defined. 
Both in vitro and in vivo models were used to delineate the mechanism behind 
myostatin-induced cachexia.  Differentiated C2C12 myotubes when treated with 
Myostatin, showed signs of atrophy (Figure 5.1A and 5.1B).  Specifically, 
Myostatin treatment resulted in a dramatic dose-dependent reduction in C2C12 
myotube diameter (Figure 5.1B), indicating that treatment of C2C12 myotubes 
with Myostatin protein could be used to establish an in vitro model to delineate 
the molecular mechanism(s) behind myostatin-induced cachexia.  In addition to 
the in vitro model, an in vivo model of myostatin-induced cachexia was generated 
based upon the previously published protocol by Zimmers et al.  In this report 
Zimmers et al demonstrated that CHO cells which over-express Myostatin were 
very effective in inducing cachexia, as a dramatic body weight loss of ~33% was 
observed with only 16 days of treatment (Zimmers et al. 2002).  However in this 
Chapter an 18% drop in mean body mass after 30 days of treatment was observed.  
The reduced atrophic response presented in this Chapter compared to that of 
Zimmers et al. could be due to lowered Myostatin secretion as a result of a higher 
passage number for the CHO cells used in this study.  Consistent with this theory, 
the tumours excised from mice injected with Myostatin-CHO cells were 
consistently smaller (data not shown) than those reported by Zimmers et al. 
(Zimmers et al. 2002).  However, due to the observed reduction in mean body 
mass this approach was deemed suitable to investigate myostatin-induced 
cachexia in vivo.   
Molecular analysis clearly indicates that Myostatin down-regulates myoD 
expression in both in vitro and in vivo models of cachexia (Figure 5.2A and 5.2B).   
In addition, promoter analysis confirmed that Myostatin inhibits the myoD 
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promoter (Figure 5.2D).  Thus, myostatin functions to prevent muscle growth and 
regeneration through the regulation of myoD expression, ultimately resulting in a 
loss of muscle mass.  Previous results indicate that MyoD is a direct down-stream 
target of the transcription factor NF-κB which is activated during cachexia by 
TNF-α (Guttridge et al. 2000).  NF-κB is a potent inhibitor of MyoD expression, 
therefore it was hypothesised that myostatin may signal through NF-κB to 
regulate myoD expression.  However, the results presented here clearly indicate 
that Myostatin treatment did not alter the expression or cellular localisation of NF-
κB (p65) (Figure 5.4A, Figure 5.4B and Figure 5.4C).  This data is in agreement 
with previously published results showing that Myostatin signalling does not 
activate NF-κB in C2C12 cells (Bakkar et al. 2005).  Thus myostatin appears to 
function independently of NF-κB to regulate cachectic events.  One gene of 
particular importance with respect to myogenesis is Pax3.  Interestingly, Pax3 lies 
genetically upstream of MyoD (Tajbakhsh et al. 1997) and ectopic expression of 
Pax3 has been shown to activate MyoD (Maroto et al. 1997).  Furthermore, an in 
vivo gain of function mutation in pax3, through the insertion of a Pax3-FKHR 
fusion sequence, also results in activation of myoD (Relaix et al. 2003).  Current 
gene expression (Figure 5.2A and Figure 5.2B) and promoter analysis (Figure 
5.2C) indicates that myostatin inhibits pax3 expression.  Together these data 
suggest that myostatin may regulate myoD expression through a preceding 
inhibition of pax3, thus contributing towards the observed cachectic phenotype 
following Myostatin treatment.  Myostatin-induced loss of MyoD has serious 
repercussions on skeletal muscle tissue, as without MyoD the transcription of 
several muscle specific genes is inhibited, leading to reduced myogenesis 
(Bergstrom et al. 2002; Bean et al. 2005). During atrophy, an attempt is made to 
repair the loss of muscle fibres by activating satellite cells which in turn migrate 
to the site of injury and either replace lost muscle cells, or self-renew to refurnish 
the quiescent satellite cell pool (Hawke and Garry 2001).  Myostatin has 
previously been shown to inhibit the activation and self-renewal of satellite cells 
(McCroskery et al. 2003). MyoD is also essential for the activation of satellite 
cells (Megeney et al. 1996), therefore the down-regulation of myoD that is evident 
in myostatin-induced cachexia may also result in an inhibition of satellite cell 
activation.  This would further prevent the regeneration of skeletal muscle, thus 
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contributing greatly to the maintenance of muscle wasting due to increased 
myostatin expression.   
One of the salient features of cachexia is the increased degradation of muscle 
proteins; this is due to activation of the ubiquitin-proteasome pathway and other 
proteolytic systems by various cachexia-inducing factors. Although myostatin has 
been previously shown to induce cachexia in vivo (Zimmers et al. 2002), there is 
no prior documentation demonstrating the ability of myostatin to regulate genes 
involved with proteolytic degradation.  Both candidate gene expression analysis 
(Figure 5.3) and microarray analysis (Table 5.1) presented in this Chapter indicate 
that proteolytic genes are indeed significantly up-regulated following Myostatin 
treatment, including the recently characterised E3 ligase Atrogin-1.  In addition 
Myostatin treatment results in an increase in the levels of ubiquitin-conjugated 
proteins.  This result is consistent with previous publications highlighting the role 
of the ubiquitin-proteasome pathway in muscle atrophy.  Indeed, increased 
Atrogin-1 expression is detected following starvation and dexamethasone 
treatment of C2C12 myotubes (Sandri et al. 2004).  Furthermore, Atrogin-1 levels 
are elevated in rats experiencing muscle wasting induced by diabetes, uraemia, 
tumour growth and fasting (Lecker et al. 2004).  In contrast, MuRF-1, an E3 
ligase that has also been associated with many forms of muscle wasting, was only 
marginally up-regulated during myostatin-induced cachexia in vivo (Figure 5.3B).  
This selective gene regulation may form the underlying basis for myostatin-
induced cachexia.   
IκBα is a potent and specific inhibitor of NF-κB activity, which functions by 
binding to an inhibiting NF-κB nuclear import (Chen 2005).  In the canonical NF-
κB signalling pathway, IκB proteins are phosphorylated at amino-terminal serine 
residues (DiDonato et al. 1997; Regnier et al. 1997; Zandi et al. 1997).  The 
resulting phosphorylated IκB proteins are targeted for polyubiquitination, with 
subsequent degradation by the proteasome (Chen et al. 1995), thus relieving NF-
κB repression.  As described above, stable cell lines expressing a mutated IκBα 
protein, whereby the serine residues have been replaced with alanines, were 
utilised in this Chapter (Guttridge et al. 1999).  The resulting IκBα protein is no 
longer phosphorylated or targeted for degradation, thus proving to be a very 
potent inhibitor of NF-κB activity.  Therefore the ability of myostatin to regulate 
Atrogin-1 in these cells was analysed.  As shown in Figure 5.4D Myostatin 
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treatment resulted in a ~110% increase in atrogin-1 expression as determined by 
Northern Blot analysis.  These data provide further evidence that myostatin 
signals independently of NF-κB to induce cachexia, as shown by the ability of 
Myostatin to induce atrogin-1 expression in the absence of NF-κB activity.  As 
stated, myostatin appears to induce cachectic conditions through an NF-κB 
independent pathway.  Interestingly TNF-α has recently been shown to induce the 
expression of Atrogin-1 through a p38-dependent, NF-κB-independent pathway 
(Li et al. 2005).  Indeed, myostatin has been shown to signal through the p38 
MAPK pathway to mediate growth inhibition and up-regulation of the cyclin-
dependent kinase inhibitor p21 (Philip et al. 2005).  Thus it is feasible that 
myostatin may signal through the p38 MAPK pathway to induce factors 
associated with muscle degradation such as Atrogin-1.   
FoxO transcription factors have recently been shown to induce skeletal muscle 
atrophy through the up-regulation of Atrogin-1 (Sandri et al. 2004).  Therefore, 
myostatin may up-regulate genes involved in ubiquitin-mediated proteolysis 
through a FoxO1-dependent pathway.  Consistent with this, myostatin signalling 
appears to up-regulate FoxO1 expression (Figure 5.5A, 5.5B, 5.5C) and reduce 
the amount of phosphorylated FoxO1 (Figure 5.5D).  Furthermore, Myostatin 
treatment induces nuclear accumulation of FoxO1 thus leading to increased levels 
of active FoxO1 (Figure 5.5E).  This is in contrast with factors that induce 
hypertrophy, such as IGF-1 which has been shown to signal through the PI3-
K/AKT pathway to increase the levels of phosphorylated FoxO1, thus maintaining 
FoxO1 cytoplasmic localisation away from target genes (Stitt et al. 2004). 
Therefore, myostatin may function by targeting and inactivating AKT (Figure 
5.5F), leading to active FoxO1 and increased Atrogin-1 expression.  Furthermore, 
siRNA-mediated knockdown of FoxO1 impaired the ability of Myostatin to 
induce atrogin-1 expression (Figure 5.6A); thus, providing further evidence for a 
FoxO1-dependent pathway during myostatin-induced cachexia.  As seen in Figure 
5.6A Myostatin was still able to increase the expression of atrogin-1 in the 
presence of the FoxO1 siRNA when compared to non-silencing controls, albeit to 
a lesser degree.  One possible explanation for this observation is that although a 
~70% decrease in FoxO1 expression was observed with siRNA transfection 
(Figure 5.6B); FoxO1 was not completely silenced, thus allowing Myostatin to 
partially induce atrogin-1 expression.  Therefore myostatin appears to antagonise 
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the IGF-1/PI3-K/AKT hypertrophy signalling pathway during the induction of 
cachectic conditions. 
Interestingly, microarray analysis suggests that several genes encoding specific 
structural proteins including Myosin Heavy Chain, Troponin C, Tropomyosin 3 
and Titin-cap were down-regulated during myostatin-mediated cachexia (Table 
5.1).  The calcium-dependent Calpain system has previously been shown to 
degrade several myofibrillar proteins such as Troponin and Tropomyosin (Goll et 
al. 2003) therefore myostatin may regulate Calpain dependent degradation of 
primary muscle structure.  However, no significant changes in Calpain expression 
were detected as a result of the microarray (data not shown).  Calpain-mediated 
degradation is thought to occur early during muscle atrophy (Costelli et al. 2002; 
Jagoe et al. 2002), therefore any changes in Calpain expression as a result of 
Myostatin treatment may be undetectable using the current in vitro model of 
myostatin-mediated myotube atrophy.  Alternatively myostatin may directly 
down-regulate the expression of the identified myofibrillar proteins thus directly 
affecting primary muscle structure.   
Like other cachexia-inducing factors, myostatin appears to induce cachexia by 
blocking protein synthesis and activating protein degradation (Figure 5.7).  
However, it was discovered in this study that myostatin acts independently of the 
classical TNF-α and NF-κB pathway to inhibit myoD expression and signal 
cachexia (Figure 5.7).   Functional blockade of Myostatin in mdx mice, a model of 
Duchenne Muscular Dystrophy, appears to ameliorate the muscle loss observed in 
this model (Bogdanovich et al. 2002).  Therefore targeting myostatin or the 
mechanisms through which myostatin functions may provide new therapeutic 
strategies to combat the symptoms of cachexia. 
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Figure 5.7  Proposed mechanism behind myostatin-induced cachexia   
Unlike TNF-α, myostatin appears to induce cachexia independent of the NF-κB 
pathway.  Increased levels of Myostatin blocks myogenesis by down-regulating 
pax3 and myoD expression.  In addition, myostatin appears to up-regulate the 
ubiquitin proteolysis system by hypo-phosphorylating FoxO1 through the 
inhibition of the PI3-K/AKT signalling pathway. Broken lines represent nuclear 
translocation.  Arrows represent activation while blunt-ended lines represent 
inhibition. 
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Chapter 6  Global gene expression analysis during 
myostatin-mediated cachexia 
 
6.1  Introduction 
 
The results presented in Chapter 5 outline the candidate gene approach used to 
identify the molecular mechanism behind myostatin-induced cachexia.  To 
support the candidate approach, global gene expression changes were analysed in 
an in vitro model of myostatin-mediated cachexia.  The widely used C2C12 
myoblast cell line provides a convenient means to analyse gene expression 
patterns in response to a plethora of stimuli.  Therefore, the C2C12 myotube 
model system was used to study myostatin-induced gene expression changes.  In 
this Chapter results of the microarray analysis are described.  In addition, the 
novel CXXC zinc finger motif-containing gene, CXXC5, was identified as one of 
the molecules that mediate myostatin signalling during muscle wasting.   
The CXXC (Cys-X-X-Cys) zinc finger domain has eight conserved cysteine 
residues that bind to zinc.  The CXXC domain is found in proteins that methylate 
cytosine and in proteins that bind to the methyl cytosine (Lee et al. 2001; 
Jorgensen et al. 2004; Allen et al. 2006).  Methylation is used by mammals to 
prevent transcriptional initiation and to ensure the silencing of some genes 
(Wolffe et al. 1999); therefore genes that contain the CXXC domain appear to 
function as transcriptional regulators.  CXXC5, initially characterised in 2004 
(Katoh and Katoh 2004b), belongs to a family of CXXC motif-containing proteins 
consisting of eleven members: CXXC1, CXXC2 (FBXL10), CXXC3 (MBD1), 
CXXC4 (IDAX), CXXC5, CXXC6, CXXC7 (MLL), CXXC8 (FBXL11), 
CXXC9 (DNMT1) CXXC10 and CXXC11 (FBXL19) (Katoh and Katoh 2004a; 
Katoh and Katoh 2004b).  CXXC5, a homolog of CXXC4, shares 45% homology 
with CXXC4.  CXXC4, also known as Idax (inhibition of Dvl and Axin complex), 
has been shown to inhibit Wnt signalling through direct binding to the protein 
Dishevelled (Hino et al. 2001).  Like Idax, CXXC5 has been linked with 
regulation of the Wnt signalling pathway (Kim et al. 2005); however, to date little 
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is known about the function of CXXC5.  One recent paper gives a role for 
CXXC5 as a positive regulator of the NF-κB signalling cascade (Matsuda et al. 
2003).  Interestingly, NF-κB signalling has been found to have a role in the 
induction of muscle wasting (Li and Reid 2000; Cai et al. 2004).  Furthermore, 
CXXC5 has been identified as a downstream target of both the TGF-β and BMP 
signalling cascades, and in fact is up-regulated in response to treatment of C2C12 
cells with both BMP-2 and TGF-β1 (de Jong et al. 2002).   
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6.2  Materials and Methods 
 
6.2.1  Cell cultures 
For in vitro studies of myostatin-induced muscle wasting, C2C12 myoblasts 
(American Type Culture Collection; ATCC, Manassas, VA) were used (Yaffe and 
Saxel 1977).  Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen, Carlsbad, CA), buffered with 17 mM of NaHCO3 (Sigma, St 
Louis, MO) and 5% gaseous CO2.  2.93 nM of Phenol Red (Sigma) was used as a 
pH indicator and antibiotics 1 x 105 IU/L penicillin (Sigma) and 100 mg/L 
streptomycin (Sigma) were added.  Foetal Bovine Serum (FBS, Invitrogen) was 
added to the DMEM at 10% of the total volume for culturing cells under growth 
conditions.  The recombinant Myostatin protein (Mstn) used in these in vitro 
experiments was generated and purified in our laboratory (Sharma et al. 1999).  
To assess the ability of myostatin to induce cachexia in vitro, C2C12 cells were 
grown as above, on Thermanox coverslips (Nalge Nunc International, Rochester, 
NY).  The C2C12 cells were differentiated for 72 hr in Differentiation Medium 
(DMEM + 2% Horse Serum; HS) followed by a further 24 hr in Differentiation 
Medium with or without 10 µg/mL Mstn.   
 
6.2.2  Stable transfection and generation of clonal cell lines 
CXXC5 over-expressing C2C12 cells were generated by stable transfection of a 
pcDNA3-CXXC5 construct, which encodes full-length murine CXXC5 driven by 
a CMV promoter and includes both neomycin and ampicillin resistance cassettes.  
The pcDNA3-CXXC5 construct was generated by Bridgette Wilson, Functional 
Muscle Genomics, AgResearch, Hamilton, New Zealand (Wilson 2006).  These 
stable cell lines were generated by transfection with 12.5 µg of pcDNA3-CXXC5 
or pcDNA3 in 0.8 mL DMEM (no serum) mixed with 40 µL of Lipofectamine 
2000 (Invitrogen) in 0.8 mL DMEM (no serum).  After 20 min at room 
temperature the transfection mixture was added to the appropriate plates and 
incubated for 24 hr at 37˚C. Cells were then subjected to neomycin treatment at a 
concentration of 0.6 mg/mL and selected based on their ability to grow in the 
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presence of neomycin.  After 21 days, neomycin-resistant cells were taken for 
further analysis or frozen in liquid nitrogen for later use.  Clonal cell lines were 
generated by plating CXXC5 transfected cells at a clonal density of 25 cells/cm2; 
individual neomycin-resistant colonies were isolated and further expanded to 
allow for analysis of CXXC5 expression.  Three CXXC5 over-expressing clonal 
cell lines were selected for further study (CXXC5 clones 1, 2 and 3). 
 
6.2.3  Microarray analysis  
C2C12 cells were cultured in Differentiation Medium for 72 hr as outlined above 
followed by a further 24 hr in Differentiation Medium with or without 10 µg/mL 
Mstn.  RNA was then isolated using TRIZOL reagent (Invitrogen) according to 
manufacturer’s guidelines (see Section 2.2.10).  Contaminating DNA was 
removed by DNase1 (Invitrogen) treatment.  The RNA was then column purified 
using the RNeasy Midi Kit (Qiagen) following the manufacturer’s guidelines (see 
Section 2.2.11), ethanol precipitated overnight at -20°C and resuspended in 
RNase-free water.  Microarray analysis was performed by MWG, Ebersberg, 
Germany as per their standardised techniques, using the MWG mouse 30k array.  
Briefly, the Myostatin-untreated and -treated RNA samples were reverse 
transcribed and directly labelled with Cy3 or Cy5, respectively, or conversely 
Cy5/Cy3 as a control.  Following co-hybridisation spots were scanned numerous 
times and signal intensities determined using Imagene software (BioDiscovery).  
The MWG proprietary software MAVI was then used for combining the data from 
multiple scans, normalisation and background correction.  The ratio between 
signal intensity for both Cy3 to Cy5 and Cy5 to Cy3 were used to generate mean 
values for intensity of each gene, corresponding to fold up- or down-regulation.  
Gene expression changes were deemed significant if expression was up-regulated 
or down-regulated by ≥ 1.5-fold. 
 
6.2.4  Western Blot analysis 
Total protein was isolated as per the described method (see Section 2.2.13).  Total 
protein (15 µg) was separated by 4-12% SDS-PAGE (Invitrogen) and transferred 
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to nitrocellulose membrane by electroblotting.  The membranes were blocked in 
0.3% BSA, 1% PEG (polyethylene glycol 4,000; Sigma), 1% PVP 
(polyvinylpyrrolidone 10,000; Sigma) for 1 hr at room temperature, then 
incubated with specific primary antibodies overnight at 4°C.  Alternatively, the 
membranes were blocked overnight at 4ºC using a solution of TBST/5% milk, 
then incubated with specific primary antibodies for 3 hr at room temperature.  The 
following primary antibodies were used for immunoblotting; 1:10,000 dilution of 
purified mouse monoclonal anti-ubiquitin antibody (sc-8017; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA); 1:1,000 dilution of purified rabbit 
polyclonal anti-FKHR (FoxO1) antibody (sc-11350; Santa Cruz Biotechnology 
Inc.); 1:3,000 dilution of purified rabbit polyclonal anti-p-FKHR (p-FoxO1; 
Ser256) antibody (sc-22158-R; Santa Cruz Biotechnology Inc.); 1:400 dilution of 
rabbit polyclonal anti-MyoD antibody (sc-304; Santa Cruz Biotechnology Inc.); 
1:400 dilution of purified rabbit polyclonal anti-myogenin antibody (sc-576; Santa 
Cruz Biotechnology Inc.); 1:400 dilution of purified mouse monoclonal anti-p21 
antibody (556430; BD Pharmingen, San Diego, CA) or 1:10,000 dilution of 
purified mouse monoclonal anti-GAPDH antibody (RDI-TRK5G4-6C5, Research 
Diagnostics, Concord, MA).  The membranes were washed (5 x 5 min) with 
TBST and further incubated with anti-rabbit IgG Horseradish Peroxidase (HRP) 
conjugate, 1:5,000 dilution (P0448; Dako, Glostrup, Denmark), or anti-mouse IgG 
HRP conjugate, 1:5,000 dilution (P0447; Dako) secondary antibodies for 1 hr at 
room temperature.  The membranes were washed as above, and HRP activity was 
detected using Western Lightning Chemiluminescence Reagent Plus (NEL104; 
PerkinElmer Life And Analytical Sciences, Inc., Wellesley, MA). 
 
6.2.5  Cloning of atrogin-1 and FoxO1 upstream promoter elements 
The promoter fragments were PCR amplified using purified DNA from Bacterial 
Artificial Chromosome (BAC) clones, which contained regions of chromosome 
specific to murine atrogin-1 (RP23-48C24, BACPAC resources) and murine 
FoxO1 (RP24-337A16, BACPAC resources).  Following PCR amplification, 
promoter regions were cloned into the pGEM-T easy vector, briefly, PCR purified 
PCR products were ligated into the pGEM-T easy vector, transformed into the 
DH5-α E.coli strain (Invitrogen) followed by DNA prurification using the 
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QIAprep Spin miniprep kit (27104; QIAGEN Inc. Valencia, CA).  Positive 
transformants were selected and subjected to double restriction digestion using 
KpnI/BglII and KpnI/NheI for atrogin-1 and FoxO1 respectively.  The now 
purified promoter regions were further subcloned into the pGL3b luciferase vector 
(Promega Corporation, Madison, WI).  Clones positive for atrogin-1 and FoxO1 
promoter regions were sequenced and subjected to restriction mapping using 
HindIII to confirm correct cloning of the promoter insert.  One positive 
transformant for atrogin-1 and FoxO1 was selected and subjected to plasmid 
DNA isolation and purification using the QIAGEN Maxiprep plasmid DNA kit 
(12163; QIAGEN Inc.).  The purified plasmids were subsequently transfected (see 
Section 6.2.6), and promoter-luciferase activity measured (see Section 2.2.9).  
PCR was performed with 1 µL of the purified BAC clone DNA at 98°C for 30 s, 
60°C for 30 s, and 72°C for 4 min 30 s for 30 cycles using ThermalAce DNA 
polymerase (Invitrogen).  This was followed by a single 72°C extension step for 
10 min.  The following murine-specific primers were used to PCR amplify the 
promoter fragments.  atrogin-1 promoter Fwd, 5’-GGG GTA CCC TTC TCC 
AGG CCA GTA GGT G-3’; atrogin-1 promoter Rev, 5’-GGA AGA TCT TGG 
TAC AGA GCG CGG ACG CG-3’; FoxO1 promoter Fwd, 5’-GGT ACC AGT 
GCC CAT GAA GTT TGG AG-3’; FoxO1 promoter Rev, 5’-GCT AGC CCC 
ACC AGC AGA GAA GTA CC-3’.   
 
6.2.6  Transient co-transfections 
Transfections were performed on stably transfected CXXC5 clones to test the 
effect of CXXC5 on either the atrogin-1 promoter or the FoxO1 promoter 
enhancer region.  Clones were seeded in 6 well plates at a density of 15,000 
cells/cm2.  Following a 24 hr attachment period, the cells were transfected with 2 
µg of each plasmid DNA using Lipofectamine 2000 (Invitrogen) reagent as per 
the manufacturer’s guidelines (see Section 2.2.8.9).  The myoblasts were then 
incubated overnight at 37oC in 5% CO2.  Proliferation Medium (DMEM + 10% 
FBS) was then removed and replaced with Differentiation Medium for a further 
72 hr for FoxO1 transfections and 48 hr and 72 hr for atrogin-1 transfections.  
Clones were transfected with either atrogin-1 or FoxO1 promoter constructs in 
conjunction with the β-galactosidase (β-gal) expression plasmid pCH110 (GE 
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Healthcare Bio-Sciences Corp. Piscataway, NJ).  Following treatment the medium 
was removed and cells were washed twice with 5 mL PBS per well and lysed in 
300 µL of Reporter Lysis Buffer (Promega).  Lysates were analysed for luciferase 
reporter gene activity (Promega) in a Turner Designs luminometer (Model TD-
20/20).  β-gal expression levels were also detected in each supernatant using the 
β-gal Enzyme Assay System (Promega) as per the manufacturer’s guidelines 
(Promega) (see Section 2.2.9).  The luciferase values for each sample were 
normalised to the corresponding β-gal value as a measure of transfection 
efficiency. 
 
6.2.7  Gene expression analysis by semi-quantitative RT-PCR   
RNA was isolated from C2C12 cells using TRIZOL reagent (Invitrogen) as per the 
manufacturer’s protocol (See Section 2.2.10).  RNA was reverse-transcribed into 
cDNA for use in semi-quantitative RT-PCR (Q-RT-PCR) analysis of gene 
expression.  First-strand cDNA was synthesised in a 20 µL reverse transcriptase 
(RT) reaction from 5 µg of total RNA using a SuperScript II First-Strand Synthesis 
System (Invitrogen), according to the manufacturer's protocol (See Section 
2.2.6.1).  PCR was performed with Taq DNA polymerase (Roche Diagnostics 
Corporation, Indianapolis, IN) using 1 µL of the RT reaction at 94°C for 2 min, 
followed by 94°C for 20 s, a gene-specific annealing temperature for 30 s (see 
Table 2.7), then 72°C for 2 min.  This process was repeated for 30 cycles for 
atrogin-1, MuRF-1, E214k, and E220k, 27 cycles for RC2 and 20 cycles for 
GAPDH.  This was followed by a single 72°C extension step for 5 min. These 
PCR conditions were used for Q-RT-PCR expression analysis 
The following murine specific primers were used for performing the Q-RT-PCR:  
CXXC5 Fwd, 5’-AAG CTT ATG TCG AGC CTC GGC GGT-3’; CXXC5 Rev, 
5’-GGA TCC TCA CTG AAA CCA CCG GAA-3’; E214k Fwd, 5’-ATG TCG 
CCC CGG CCC GGA GGC TCA TG-3’; E214k Rev, 5’-ATG AAT CAT TCC 
AGC TTT GTT CAA C-3’; atrogin-1 Fwd, 5’-AAC ATG TGG GTG TAT CGG-
3’; atrogin-1 Rev, 5’-TCT TGA GGG GAA AGT GAG-3’; MuRF-1 Fwd, 5’-
GTT AAA CCA GAG GTT CGA G-3’; MuRF-1 Rev, 5’-ATG GTT CGC AAC 
ATT TCG G-3’; E220k Fwd, 5’- GGC GAC ACC ATG TCA TC -3’; E220k Rev, 
5’- ATG TCC TGG GCC TCA TC -3’; RC2 Fwd, 5’- TCC AAA CCT GCC CAT 
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CTG CTA ACT -3’; RC2 Rev, 5’- AGG CTG TGC TTT TCT CTG TGG TCT -
3’; GAPDH Fwd, 5’-GTG GCA AAG TGG AGA TTG TTG GCC-3’; GAPDH 
Rev, 5’-GAT GAT GAC CCG TTT GGC TCC-3’. 
 
6.2.8  Proliferation assay 
Myoblast proliferation was assessed as described previously (Thomas et al. 2000).  
Briefly, C2C12 cultures were seeded on 96 well plates (Nalge Nunc) at a density 
of 1,000 cells per well in Proliferation Medium.  After an overnight attachment 
period, cells were supplemented with fresh Proliferation Medium (DMEM 10% 
FBS). Cultures were subsequently fixed at 24 hr intervals.  Cells were fixed in 100 
µL of 10% formal saline (0.17% saline, 10% formaldehyde).  Following the 
incubation periods, proliferation was assessed using the methylene blue 
photometric end-point assay, as previously described (Oliver et al. 1989).  Briefly, 
the fixative was removed, 100 µL of stain (1% methylene blue, 0.01 M Borate 
buffer, pH 8.5) was added to each well and the cells were incubated for 30 min at 
room temperature.  The stain solution was removed and the cells washed four 
times with 200 µL Borate buffer, followed by the addition of 200 µL 0.1 N 
HCl:70% ethanol, (1:1).  The absorbance of the cells was read on a microplate 
reader (model 3550; Bio-Rad), at 655 nm.  In this assay absorbance at 655 nm is 
directly proportional to final cell number. Samples were run in replicates of eight 
with the results representing two independent experiments.   
 
6.2.9  DNA fragmentation assay 
Genomic DNA isolation and fragmentation assay were based on the protocol from 
(Jiang et al. 2005).  Following removal of the medium, cells were washed twice 
with PBS then lysed by addition of 200 µL of apoptosis lysis buffer [10 mM Tris-
HCL (pH 8.0), 10 mM EDTA, 0.5% Triton X-100 and 0.1 mg/mL RNase A] with 
cells collected by scraping.  Following 1 hr incubation at 37°C the lysates were 
treated with Proteinase K (0.2 mg/mL) at 54°C for 30 min.  Genomic DNA was 
isolated by one separation with phenol/chloroform followed by two additional 
choloroform steps.  Genomic DNA was precipitated with 100% ethanol and 
 242
sodium acetate for 1 hr at -20°C, washed with 70% ethanol and resuspended in 
100 µL of 10 mM Tris-HCL, 1 mM EDTA (TE) buffer.  Aliquots of genomic 
DNA from control and CXXC5 over-expressing clones were subjected to DNA 
electrophoresis on a 1.0% agarose gel and visualised with ethidium bromide using 
the Gel Doc imaging system (Bio-Rad Laboratories, Hercules, CA). 
 
6.2.10  Detection of Tubulin by immunocytochemistry 
Myotube cultures grown on Permanox chamber slides (Nalge Nunc) were fixed 
with 70% ethanol:formaldehyde:glacial acetic acid (20:2:1) for 30 s, then rinsed 
three times with PBS.  Cells were permeabilised with 0.1% triton X-100 in PBS 
for 10 min at room temperature then washed with PBS. Cells were then blocked in 
5% NGS in 0.35% Carrageenen λ (Sigma) in PBS for 1 hr at room temperature; 
the same solution was used for subsequent antibody and fluorophore dilutions. 
Cells were incubated with mouse monoclonal anti-α-Tubulin antibody (T-9026; 
Sigma) overnight at 4˚C.  The next day, slides were washed 3 times for 5 min in 
TBST before secondary incubation with biotinylated sheep anti-mouse IgG 
(RPN1001; GE Healthcare Bio-Sciences) at 1:300 for 1 hr at room temperature.  
Following another 3 washes in TBST, fluorescent complex Alexa Fluor 488 
(S11223; Invitrogen) was added at 1:400 and incubated for 1 hr at room 
temperature.  After a further 3 washes in TBST, slides were incubated with DAPI 
(1:1000 in PBS, Invitrogen) for 5 min at room temperature, rinsed with PBS, and 
mounted using fluorescent mounting medium (Dako, Glostrup, Denmark).  Cells 
were visualised using an Olympus BX50 microscope (Olympus Optical Co, 
Germany) with a SPOT RT camera (Diagnostic Instruments Inc, Sterling Heights, 
MI) and the Windows Version 4.0.1 SPOT Basic software program (Diagnostic 
Instruments Inc). 
 
6.2.11  Cell staining 
To assess CXXC5 clone myotube formation during differentiation, cultures were 
grown on Thermanox coverslips (Nalge Nunc) in Differentiation Medium 
(DMEM + 2% HS), fixed with 20:2:1 and stained with Gill’s haematoxylin 
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followed by 1% eosin (see Section 2.2.17).  Cells were then photographed as 
above with myotube number counted.   
 
6.2.12  Statistics 
For CXXC5 over-expressing clone and control myotube assessment, average 
myotube number (±SEM) over 3 coverslips per timepoint was calculated.  Total 
myotubes were counted in 5 random images per coverslip.  For the transfection 
experiments, the mean luciferase values were calculated per well and the three 
means averaged over three independent experiments.  To determine the 
significance level of differences between two groups, comparisons were made 
using Student’s-T test.  Statistical analysis was performed in Excel.  A P value of 
<0.05 was deemed significant for all experiments. 
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6.3  Results 
 
6.3.1  Microarray identification of myostatin downstream target genes 
Microarray analysis was performed to compare the in vitro gene expression 
changes which occur in a model of myostatin-induced muscle wasting.  
Alterations in gene expression were quantified for 30,000 mouse genes in 
response to treatment with Myostatin.  Table 6.1 summarises the global gene 
changes that were identified by microarray, with genes separated on the basis of 
function.  The number given in the fold-change column represents the difference 
in gene expression when comparing cells treated with Myostatin to untreated 
controls (Table 6.1).  For the purpose of substantiating the candidate gene 
approach, microarray-identified changes in mRNA levels of genes involved in 
protein degradation and myofibrillar structure were integrated into the 
communicated paper described in Chapter 5 (see Section 5.3.5 and Table 5.1).   
The mRNA expression of genes involved in several cellular processes was altered 
in response to treatment with Myostatin.  Treatment with recombinant Myostatin 
protein enhanced the expression of the extracellular matrix protein collagen.  In 
particular, mRNA levels for type-III and type-VI collagen and type-III and type-IX 
procollagen were up-regulated following Myostatin treatment (Table 6.1).   
The mRNA levels of two fundamental genes involved in energy production were 
altered following addition of Myostatin.  The expression of the gene encoding 
lactate dehydrogenease a (LDH-A), an enzyme responsible for converting lactate 
to pyruvate during glycolysis (Lehninger et al. 1993), was down-regulated 
following Myostatin treatment.  Conversely, the gene encoding glutamine 
synthetase (glns) was significantly up-regulated following addition of Myostatin 
(Table 6.1).  Glutamine synthetase is an enzyme that catalyses the conversion of 
glutamate and ammonia into glutamine (Lehninger et al. 1993).   
Several additional genes of interest were differentially regulated in response to 
increased levels of Myostatin.  In particular, gene expression of the metal-binding 
metallothionein proteins 1 and 2 (mt1 and mt2) was down-regulated following 
treatment with Myostatin; while the mRNA expression of stress-induced protein 
18 (sip18) was up-regulated in response to increased Myostatin (Table 6.1).  
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Furthermore, genes encoding the proteolytic enzymes matrix metalloproteinase-2 
and -23 (mmp-2 and mmp-23) were up-regulated following Myostatin treatment, 
while in contrast, expression of tissue inhibitor of matrix metalloproteinase-1 
(timp-1) was down-regulated (Table 6.1).  The gene lipin-1 which encodes for 
Lipin protein was also significantly induced following addition of Myostatin.  In 
addition, genes encoding the transcription factors, myocyte enhancer factor 2b 
(mef2b), forkhead box O 1 (FoxO1), and the CXXC finger 5 (CXXC5) zinc finger 
protein were all up-regulated in response to myostatin treatment (Table 6.1).  The 
mRNA expression of the gene encoding CXXC5 was dramatically up-regulated, 
demonstrating an almost 9.5-fold induction in response to Myostatin treatment 
(Table 6.1).  As shown in Figure 6.1, Q-RT-PCR analysis has subsequently 
confirmed Myostatin up-regulation of CXXC5, albeit to a lesser degree than that 
seen in the microarray data.  Despite the variation, the putative zinc finger 
transcription factor CXXC5 has potential as a myostatin downstream target gene 
and therefore was selected to be studied further.   
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Function Sequence Name Accession No.
collagen, type VI, alpha 2 chain Z18272 2.2
collagen, type III, alpha 1; (col3a1) X52046 3.6
procollagen, type IX, alpha 1 X57984 3.2
procollagen, type III, alpha 1 AK019448 2.2
Metabolism glutamine synthetase (glns) NM_008131 2.3
lactate dehydrogenase 1, a chain (ldh1) NM_010699 2.2
myocyte enhancer factor 2b (mef2b) NM_008578 2.1
forkhead box O1a  (foxO1) NM_019739 1.9
CXXC5 NM_133687 9.5
Miscellaneous Metallothionein 1 (mt1) NM_013602 3.1
Metallothionein 2 (mt2) AK002567 3.9
Stress-induced protein 18 (sip18) AY034611 2.8
Matrix metalloproteinase 2 (mmp2) NM_008610 1.7
Matrix metalloproteinase 23 (mmp23) NM_011985 1.9
Tissue inhibitor of matrix 
metalloproteinase 1 (timp1) NM_011593 2.1
Lipin-1 NM_015763 3.0
Fold change
Extracellular 
matrix
Transcription 
factors
 
 
 
 
 
 
 
Table 6.1  Microarray identification of genes altered in a model of myostatin-
induced cachexia   
C2C12 cells were grown in Differentiation Medium for 72 hr followed by a 
further 24 hr in Differentiation Medium without or with 10 µg/mL Mstn.  Genes 
are separated into structural or proteolytic function and were at least 1.5 fold up-
regulated (     ) or down-regulated (     ). 
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Figure 6.1  Myostatin up-regulates the expression of CXXC5 
Semi-quantitative RT-PCR analysis of CXXC5 expression following treatment of 
C2C12 cells with recombinant Myostatin protein (Mstn).  C2C12 cells were 
grown in Differentiation Medium for 72 hr followed by a further 24 hr or 48 hr in 
Differentiation Medium without (-) or with 10 µg/mL (+) Mstn.  GAPDH levels 
were measured to ensure equal loadings.  The graph represents fold change in 
CXXC5 expression normalised to GAPDH levels.   
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6.3.2  Stable over-expression of CXXC5 in the C2C12 myoblast cell line 
To further characterise the function of CXXC5 a set of CXXC5 over-expressing 
stable clonal cell lines were generated.  Briefly, the murine CXXC5 coding 
sequence was cloned into the pcDNA3 expression vector (Invitrogen) (see Section 
6.2.2).  The pcDNA3 expression vector contains a neomycin cassette, which 
allows for antibiotic-mediated selection of C2C12 cells which have stably 
integrated the CXXC5/pcDNA3 construct.  Following transfection, the CMV 
promoter contained within pcDNA3 constitutively drives the expression of the 
gene of interest, in this case CXXC5.  C2C12 cells were subjected to several 
rounds of antibiotic selection followed by quantification of CXXC5 expression.  
Q-RT-PCR identified that clones 1, 2, and 3 significantly up-regulated the mRNA 
expression of CXXC5, and thus were utilised to aid in the identification of putative 
functions for CXXC5 in skeletal muscle (Figure 6.2A).   
A proliferation assay was performed to compare the proliferative potential of the 
CXXC5 clones compared to the control C2C12 cell line.  As shown in Figure 
6.2B, the growth rate of the CXXC5 clones (CXXC5 clone 1 and CXXC5 clone 
3) was reduced to a statistically significant level when compared to that of control 
(C2C12) through the periods of 48 hr, 72 hr and 96 hr proliferation (Figure 6.2B).  
However, the difference between CXXC5 clones and control was not dramatic.   
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Figure 6.2  CXXC5 alters C2C12 myoblast proliferation 
A) Q-RT-PCR showing mRNA expression of CXXC5 during actively growing 
conditions in CXXC5 over-expressing (CXXC5 clone 1, CXXC5 clone 2 and 
CXXC5 clone 3) lysates compared to control (C2C12) lysates.  GAPDH 
expression was analysed to ensure equal loading of samples.  B) Methylene blue 
assay showing proliferation of control (C2C12) cells compared to CXXC5 over-
expressing clones (CXXC5 clone 1 and clone 3) over a 96 hr period.  Statistical 
differences determined by Student’s-T test are indicated, P< 0.001 (***) for clone 
3 compared to C2C12 and P< 0.001 (###), P< 0.01 (##), P< 0.05 (#) for clone 1 
compared to C2C12.   
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Upon serum withdrawal, C2C12 myotubes rapidly exit the cell cycle, fuse and 
form multinucleated myotubes.  The differentiation capacity of the CXXC5 clones 
was thus examined and compared to that of the control C2C12 cell line.  Myotube 
populations were stained with Gill’s haematoxylin and eosin and total myotube 
number was counted.  As shown in Figure 6.3A and 6.3B, a dramatic reduction in 
myotube formation during the progression of myogenic differentiation was 
observed in the CXXC5 clones when compared with the control (C2C12).  
Indeed, the CXXC5 clones exhibited a dramatic 10-100-fold reduction in myotube 
number at 48 hr differentiation (Figure 6.3B).  CXXC5 clone 1 had a ~10-fold 
reduction in myotube number at 72 hr and a ~8-fold reduction in myotube number 
at 96 hr differentiation as compared to C2C12 control.  In addition, CXXC5 clone 
3 had a ~2.6-fold reduction in myotube number at 72 hr and a ~3-fold reduction in 
myotube number at 96 hr differentiation as compared to C2C12 control (Figure 
6.3B).  The CXXC5 clones also demonstrated several morphological 
characteristics distinctive from control cells.  As can be seen in Figure 6.3A, very 
few myotubes were observed at 48 hr differentiation; however, by 72 hr, large 
myotubes began to appear in CXXC5 clones 1 and 3, although, compared to the 
densely populated control cell line the CXXC5 clone myotube cultures were 
relatively sparse (Figure 6.3A).  By 96 hr differentiation the typical elongated 
myotube morphology was radically altered in the CXXC5 clones, whereby 
characteristic myotubes were progressively replaced with circular “myosac-like” 
formations, which appeared to be primarily comprised of large numbers of nuclei 
(Figure 6.3A).  Therefore, in addition to a delay in myogenic differentiation, over-
expression of CXXC5 appears to alter the typical myotube phenotype associated 
with the C2C12 myogenic cell line. 
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Figure 6.3  CXXC5 alters myotube formation and physiology in C2C12 myoblasts 
A)  Representative images of differentiating cells for CXXC5 over-expressing 
clones (CXXC5 clone 1 and 3) compared to control (C2C12) cells at 48 hr, 72 hr 
and 96 hr differentiation; cells were stained with Gill’s haematoxylin and eosin.  
Scale bar represents 5 µm.  B)  The graph shows the average myotube number 
±SEM over 3 coverslips per timepoint for CXXC5 over-expressing clones 
(CXXC5 clone 1 and 3) and control (C2C12) cells; total myotubes were counted 
in 5 random images per coverslip.  Statistical differences determined by 
Student’s-T test are indicated, P<0.001 (***) compared to C2C12. 
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6.3.3  Time-lapse microscopy of CXXC5 over-expressing clones during 
differentiation 
To further characterise the “myosac” phenomenon, time-lapse microscopy was 
employed.  CXXC5 clones were differentiated for 72 hr prior to time-lapse 
microscopy.  During microscopy, cells were maintained under optimal conditions 
(37°C/5% CO2), with images collected every minute over a 24 hr period spanning 
72 hr-96 hr differentiation.  Figure 6.4, Figure 6.5 and Figure 6.6 display still 
images of representative timepoints from C2C12 control, CXXC5 clone 1 and 
CXXC5 clone 3 respectively.  As shown in Figure 6.4, the size of the indicated 
myotube appeared to increase with time, a phenomenon consistent with the 
progression of myogenic differentiation.  Furthermore, no observed myosac 
formation was detected in the control cell line cultures (Figure 6.4).  In contrast 
however, over-expression of CXXC5 resulted in a dramatic change in myotube 
morphology with what appeared to be gradual myotube collapse (Figure 6.5 and 
Figure 6.6).  Interestingly, the myotube nuclei appeared to coalesce at one end of 
the myotube, followed by the eventual collapse of the remaining cytoplasm to that 
same general area.  The resulting myotube disintegration resulted in the formation 
of the myosac-like phenotype characterised in Section 6.3.2 (Figure 6.5 and 
Figure 6.6).  The 1441 time-lapse images taken at 1 min intervals were combined 
into movies and are included on the DVD attached to the back cover of this thesis 
(Appendix 2).   
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Figure 6.4  Time-lapse microscopy of normal myotube growth in control C2C12 
cells 
Time-lapse phase contrast microscopy covering a 24 hr period of differentiation 
between 72 hr and 96 hr in the control C2C12 cell line.  Box i-viii show 
representative timepoints through the course of the time-lapse experiment with the 
corresponding minutes (min) indicated in the top left of each box.  Dotted lines 
indicate the myotube of interest.   
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Figure 6.5  Time-lapse microscopy of myosac formation in CXXC5 clone 1 
Time-lapse phase contrast microscopy covering a 24 hr period of differentiation 
between 72 hr and 96 hr in CXXC5 Clone 1.  Box i-viii show representative 
timepoints through the course of the time-lapse experiment with the 
corresponding minutes (min) indicated in the top left of each box.  Dotted lines 
indicate the myotube of interest.   
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Figure 6.6  Time-lapse microscopy of myosac formation in CXXC5 clone 3 
Time-lapse phase contrast microscopy covering a 24 hr period of differentiation 
between 72 hr and 96 hr in CXXC5 Clone 3.  Box i-viii show representative 
timepoints through the course of the time-lapse experiment with the 
corresponding minutes (min) indicated in the top left of each box.  Dotted lines 
indicate the myotube of interest.   
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6.3.4  Gene expression analysis of CXXC5 over-expressing clones 
Gene expression analysis was undertaken to gain further insights into the effect of 
CXXC5 on C2C12 myoblast growth and differentiation.  The Myogenic 
Regulatory Factors (MRFs), MyoD and myogenin play a critical role in the ability 
of myogenic cells to exit the cell cycle and adopt a differentiated phenotype.  
Furthermore, the cyclin-dependent kinase inhibitor (CKI) p21 is a target of 
MyoD, and in fact plays a critical role in MyoD-mediated myoblast cell cycle exit 
and commitment to differentiation (Guo et al. 1995; Halevy et al. 1995; Megeney 
and Rudnicki 1995).  Therefore the expression patterns of these critical genes 
were analysed in the stable CXXC5 over-expressing clones during the progression 
of myogenic differentiation.  MyoD expression was up-regulated in all cell lines 
following the induction of differentiation (Figure 6.7 and Figure 6.8).  As 
expected the expression pattern of p21 closely followed that of MyoD and was 
up-regulated following the switch to differentiation, with peak p21 expression 
detected at 48 hr differentiation (Figure 6.7 and Figure 6.8).  In addition, 
myogenin peak expression was detected at 48 hr differentiation in both the 
CXXC5 clones and C2C12 control, however, the peak expression of myogenin, 
and for that matter MyoD and p21, appeared to be higher in the CXXC5 clones as 
compared to the control (C2C12) cell line (Figure 6.7 and Figure 6.8).  Thus as 
shown in Figure 6.7 and Figure 6.8, although peak gene expression was elevated 
in the CXXC5 over-expressing clones, the general pattern of MRF expression was 
similar to that observed in the control (C2C12) cells through the process of 
myogenic differentiation (Figure 6.7 and Figure 6.8).   
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Figure 6.7  Over-expression of CXXC5 alters myogenic gene expression during 
differentiation   
A)  Western Blots showing protein expression of MyoD, p21 and myogenin at 
Time 0 and after 24, 48, 72 and 96 hr of differentiation in CXXC5 over-
expressing (CXXC5 clone 1) lysates compared to control (C2C12) lysates.  
GAPDH expression was analysed to ensure equal loading of samples.  B)  
Densitometry analysis of protein expression for Western Blots (MyoD, p21, 
myogenin), normalised to GAPDH expression, for CXXC5 over-expressing 
clones (CXXC5 clone 1) compared to control (C2C12) cells. 
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Figure 6.8  Over-expression of CXXC5 alters myogenic gene expression during 
differentiation   
A)  Western Blots showing protein expression of MyoD, p21 and myogenin at 
Time 0 and after 24, 48, 72 and 96 hr of differentiation in CXXC5 over-
expressing (CXXC5 clone 3) lysates compared to control (C2C12) lysates.  
GAPDH expression was analysed to ensure equal loading of samples.  B)  
Densitometry analysis of protein expression for Western Blots (MyoD, p21, 
myogenin), normalised to GAPDH expression, for CXXC5 over-expressing 
clones (CXXC5 clone 3) compared to control (C2C12) cells. 
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As outlined in Chapter 5, myostatin is capable of promoting muscle wasting 
through regulation of the ubiquitin-proteasome pathway; thus gene expression 
patterns in the CXXC5 over-expressing clonal cell lines were analysed, to 
determine if CXXC5 is capable of regulating components of the ubiquitin-
proteasome pathway.  Semi-quantitative RT-PCR (Q-RT-PCR) was used to 
measure the expression of several genes involved with ubiquitin-mediated 
degradation.  As shown in Figure 6.9, Q-RT-PCR analysis of the CXXC5 clones 
demonstrated an up-regulation in the expression of the ubiquitin E3 ligase 
atrogin-1, however, no significant change was observed in the E3 ligase MuRF-1 
in response to increased expression of CXXC5 (Figure 6.9).  Furthermore, 
expression levels of the ubiquitin-conjugating enzymes E214k and E220k as well as 
the proteasome sub-unit RC2 were also significantly up-regulated in the CXXC5 
over-expressing clones as compared with the control (C2C12) cell line (Figure 
6.9).  To further confirm CXXC5 regulation of atrogin-1 an atrogin-1 promoter-
luciferase construct was generated.  Specific primers were synthesised based on 
the published sequences from Sandri et al 2004 (Sandri et al. 2004).  The resulting 
3.5 Kb PCR product (Figure 6.10Ai) was purified and ligated into the pGEM-T 
easy cloning vector.  The pGEM-T easy construct was transformed into the DH5α 
strain of E.coli.  Following plasmid DNA purification the 3.5 kb promoter 
fragment was mobilised through Kpn1 and BglII restriction enzyme digestion, 
purified, and subcloned into the pGL3b luciferase vector.  Restriction digestion 
using HindIII was performed to confirm the presence of the atrogin-1 promoter in 
the pGL3b vector (Figure 6.10Aii).  The atrogin-1 promoter-luciferase construct 
was subsequently transfected into the CXXC5 over-expressing clones.  As shown 
in Figure 6.10B, Over-expression of CXXC5 resulted in a significant increase in 
atrogin-1-dependent luciferase activity (Figure 6.10B).  Specifically, atrogin-1 
promoter activity was up-regulated by ~2.5 and ~3.7 fold in CXXC5 clone 1 and 
3 respectively at both 48 hr and 72 hr differentiation.  Moreover, a dramatic ~40 
fold up-regulation in atrogin-1 promoter activity was observed following 
transfection into CXXC5 clone 2 at both 48 hr and 72 hr differentiation timepoints 
(Figure 6.10B).  Thus CXXC5 appears to induce the expression of several 
components of the ubiquitin-proteasome pathway and therefore may contribute to 
ubiquitin-mediated muscle proteolysis.  In support, over-expression of CXXC5 
results in an increase in the levels of ubiquitin-conjugated proteins as determined 
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by Western Blot analysis (Figure 6.11).  Moreover, the increase in ubiquitinated 
proteins was particularly prevalent during later differentiation timepoints (Figure 
6.11).  Conjugation of ubiquitin to proteins is a critical step in ubiquitin-mediated 
proteolysis; in fact ubiquitin-conjugation targets proteins for degradation through 
the proteasome.  Therefore increased ubiquitin-conjugation is indicative of 
enhanced ubiquitin-proteasome pathway activity and thus increased protein 
degradation. 
 
 
 
 
 
 
 
Figure 6.9  Over-expression of CXXC5 up-regulates the expression of atrophy-
related genes   
Q-RT-PCR showing the expression of atrogin-1, MuRF-1, E214k, E220k and RC2 
during proliferating conditions in CXXC5 over-expressing (CXXC5 clone 1, 
clone 2 and clone 3) lysates compared to control (C2C12) lysates.  GAPDH 
expression was analysed to ensure equal loading of samples.   
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Figure 6.10  Over-expression of CXXC5 up-regulates atrogin-1 promoter activity   
Ai) Agarose gel visualisation of the ~3.5 kb atrogin-1 promoter PCR product.  
Aii) Agarose gel visualisation of the ~7 kb and ~2 kb products from the 
pGL3b/atrogin-1 promoter HindIII restriction digest.  A 1kb plus DNA ladder 
(Invitrogen) was run with each sample with representative band sizes indicated.  
B)  Graph demonstrating the activity of the atrogin-1 promoter in the CXXC5 
over-expressing clones (CXXC5 clone 1, clone 2 and clone 3) compared to 
control (C2C12) cells.  Relative luciferase activity is represented as values 
normalised to β-gal activity.  Statistical differences determined by Student’s-T test 
are indicated, P<0.001 (***) compared to C2C12. 
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Figure 6.11  CXXC5 over-expression increases the levels of ubiquitin-conjugated 
proteins.   
Western Blots showing the level of ubiquitin-conjugated proteins at Time 0 and 
after 12, 24, 48 and 72 hr of differentiation in CXXC5 over-expressing (CXXC5 
clone) lysates compared to control (C2C12) lysates.  The level of ubiquitin-
conjugated proteins was assessed in CXXC5 clone 1 (A), CXXC5 clone 2 (B) and 
CXXC5 clone 3 (C).  GAPDH expression was analysed to ensure equal loading of 
samples.   
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As previously described, myostatin induces muscle wasting through antagonising 
IGF-1 signalling, allowing for up-regulation of FoxO1 expression and activity, 
thereby increasing the expression of the Ubiquitin E3 Ligase Atrogin-1 (see 
Chapter 5).  Therefore, the ability of CXXC5 to regulate FoxO1 was assessed.  
Initially a FoxO1 promoter-luciferase construct was generated.  Specific primers 
were synthesised based on the upstream sequence of the murine FoxO1 gene.  The 
resulting 4 kb PCR product (Figure 6.12Ai) was purified and ligated into the 
pGEM-T easy cloning vector.  The pGEM-T easy construct was transformed into 
the DH5α strain of E.coli.  Following plasmid DNA purification the 4 kb 
promoter fragment was mobilised through Kpn1 and Nhe1 restriction enzyme 
digestion, purified, and subcloned into the pGL3b luciferase vector.  Restriction 
digestion using HindIII was performed to confirm the presence of the FoxO1 
promoter in the pGL3b vector (Figure 6.12Aii).  The FoxO1 promoter-luciferase 
construct was subsequently transfected into the stable CXXC5 over-expressing 
cell lines, with luciferase activity analysed as a measure of FoxO1 promoter 
activity (Figure 6.12B).  As shown in Figure 6.12B, Over-expression of CXXC5 
resulted in a significant increase in FoxO1-dependent luciferase activity; 
indicating that CXXC5 is capable of regulating transcriptional activity of the 
FoxO1 gene.  Furthermore, the protein levels of FoxO1 were measured in the 
CXXC5 over-expressing clones.  The expression of FoxO1 was markedly 
increased in the three CXXC5 over-expressing clones when compared to C2C12 
control, as measured by Western Blot analysis (Figure 6.13A, Figure 6.13B, 
Figure 6.13C and Figure 6.13D).  In addition, the CXXC5-stimulated increase in 
FoxO1 expression was more apparent at later timepoints during the progression of 
myogenic differentiation (Figure 6.13A, Figure 6.13B, Figure 6.13C and Figure 
6.13D).  To become active FoxO1 must first be de-phosphorylated (Sandri et al. 
2004), therefore the levels of phosphorylated FoxO1 (p-FoxO1) were measured in 
the CXXC5 over-expressing clones.  As shown in Figure 6.13D, the level of p-
FoxO1, expressed as a proportion of total FoxO1, was reduced in the CXXC5 
over-expressing cell lines compared with control.  Specifically, reduced levels of 
p-FoxO1 were evident in all three CXXC5 over-expressing clones from 48 hr 
differentiation onwards (Figure 6.13D).  Therefore, increased expression of 
CXXC5 appears to up-regulate the expression of FoxO1 as well as promote the 
accumulation of active FoxO1. 
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Figure 6.12  Over-expression of CXXC5 up-regulates FoxO1 promoter activity.   
Ai) Agarose gel visualisation of the ~4 kb FoxO1 promoter PCR product.  Aii) 
Agarose gel visualisation of the ~7 kb and ~2.4 kb products from the 
pGL3b/FoxO1 promoter HindIII restriction digest.  A 1kb plus DNA ladder 
(Invitrogen) was run with each sample with representative band sizes indicated.  
B)  Graph demonstrating the activity of the FoxO1 promoter in the CXXC5 over-
expressing clones (CXXC5 clone 1, clone 2 and clone 3) compared to control 
(C2C12) cells.  Relative luciferase activity is represented as values normalised to 
β-gal activity.  Statistical differences determined by Student’s-T test are indicated, 
P<0.001 (***), compared to C2C12.   
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Figure 6.13  CXXC5 regulates the Forkhead box O transcription factor FoxO1.   
A), B), C)  Western Blots showing the expression of FoxO1 and p-FoxO1 at Time 
0 and after 12, 24, 48 and 72 hr of differentiation in CXXC5 over-expressing 
(CXXC5 clone) lysates compared to control (C2C12) lysates.  The expression of 
FoxO1 and p-FoxO1 was assessed in CXXC5 clone 1 (A), CXXC5 clone 2 (B) 
and CXXC5 clone 3 (C).  GAPDH expression was analysed to ensure equal 
loading of samples.  D)  Densitometry analysis of protein expression for Western 
Blots (FoxO1 and p-FoxO1), normalised to GAPDH expression, for CXXC5 
over-expressing clones (CXXC5 clone 1, clone 2 and clone 3) compared to 
control (C2C12) cells. The level of p-FoxO1 is expressed as a proportion of total 
FoxO1.   
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6.3.5  Over-expression of CXXC5 does not promote aberrant apoptosis in the 
C2C12 cell line 
The level of cell apoptosis was assessed in the CXXC5 over-expressing clones 
compared with control (C2C12) cells.  The extent of DNA fragmentation, or DNA 
laddering, is used as a measure of apoptosis.  Thus, genomic DNA was extracted 
from proliferating CXXC5 clones and control (C2C12) cells, subjected to gel 
electrophoresis and visualised using ethidium bromide.  As shown in Figure 6.14, 
control (C2C12) cells and the CXXC5 over-expressing clones had similar low 
levels of DNA fragmentation, thus CXXC5 may not induce aberrant apoptosis in 
the C2C12 cell line.   
 
 
 
 
 
Figure 6.14  CXXC5 over-expression does not alter the level of apoptosis.   
DNA fragmentation assay showing the levels of apoptosis in the CXXC5 over-
expressing clones (CXXC5 clone 1, clone 2 and clone 3) and control (C2C12) 
cells.  Genomic DNA was isolated and subjected to electrophoresis.  1 kb plus 
ladder (Invitrogen) is shown with representative marker sizes indicated. 
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6.3.6  Over-expression of CXXC5 alters microtubule structure 
Myotube “myosac” formation is a phenomenon that has been previously reported.  
Indeed, treatment of myotube cultures with several inhibitors of microtubule 
polymerisation, including the drugs colchicine, colcemid and nocodazole, result in 
myotube disassembly and the formation of multinucleated myosacs (Bischoff 
1968; Saitoh et al. 1988).  Microtubules are filamentous cytoskeletal structures 
which are involved in maintaining cell shape and strength, controlling cell 
movement and the formation of the spindle apparatus during cell division (Martini 
2001).  Therefore, over-expression of CXXC5 may alter microtubule structure 
during differentiation, to promote the formation of the distinctive myosac 
phenotype (see Figure 6.3A).  Microtubules are composed of repeating units of 
dimerised Tubulin molecules, thus to study microtubule morphology alpha-
Tubulin localisation was assessed in the CXXC5 over-expressing clones by 
immunofluorescence.  As shown in Figure 6.15A, control (C2C12) myotubes 
differentiated for 72 hr and stained with alpha-Tubulin show a typical microtubule 
phenotype, with parallel bundles of microtubules running along the length of the 
myotube structure.  In addition, CXXC5 clone 1 and CXXC5 clone 3 demonstrate 
a similar microtubule pattern to that seen in controls, although the presence of 
myosac-like myotubes was becoming more apparent at this stage of differentiation 
(Figure 6.15B and Figure 6.15C).  By 96 hr differentiation the typical microtubule 
morphology is dramatically altered in CXXC5 clone 1 and CXXC5 clone 3 
(Figure 6.16B and Figure 6.16C), as compared with the control (C2C12) cell line 
(Figure 6.16A).  Microtubules appear to be severely degraded, with only minimal 
microtubule content remaining, following over-expression of CXXC5.  The 
residual microtubules are localised in an irregular pattern surrounding the 
resulting myosac that encloses the myotube nuclei (Figure 6.16B and Figure 
6.16C).   
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Figure 6.15  Over-expression of CXXC5 alters microtubule structure at 72 hr 
differentiation 
Tubulin immunocytochemistry (green) for control (C2C12) cells (A), CXXC5 
over-expressing clone 1 (B) and CXXC5 over-expressing clone 3 (C) after 72 hr 
differentiation.  Corresponding nuclei are stained with DAPI (blue).  Scale bar 
represents 5 µm.   
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Figure 6.16  Over-expression of CXXC5 disrupts microtubule structure at 96 hr 
differentiation 
Tubulin immunocytochemistry (green) for control (C2C12) cells (A), CXXC5 
over-expressing clone 1 (B) and CXXC5 over-expressing clone 3 (C) after 96 hr 
differentiation.  Corresponding nuclei are stained with DAPI (blue).  Scale bar 
represents 5 µm.   
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6.4  Discussion 
 
Myostatin is a potent inhibitor of skeletal muscle growth; furthermore, over-
expression of Myostatin has been shown to induce skeletal muscle degradation, 
resulting in symptoms common with a severe form of muscle wasting, cachexia 
(Zimmers et al. 2002).  As outlined in Chapter 5 of this thesis, myostatin-
mediated cachexia was shown to induce the up-regulation of components of the 
ubiquitin-proteasome pathway as well as enhance ubiquitin-conjugation of 
cellular proteins.  This Chapter describes research undertaken to extend on the 
observations outlined in Chapter 5, and thus describes the global gene changes 
that occur in a model of myostatin-mediated cachexia via microarray.  
Furthermore, this Chapter provides an initial characterisation of a novel myostatin 
downstream target gene during skeletal muscle wasting.   
As previously discussed (see Chapter 5), microarray analysis has identified that 
myostatin-induced myotube atrophy was associated with an up-regulation in the 
expression of genes encoding several components of the ubiquitin-proteasome 
pathway; with concomitant down-regulation of genes encoding for critical 
myofibrillar proteins.  These data highlighted a possible mode of action for 
myostatin in the regulation of skeletal muscle catabolism.  In addition, microarray 
analysis has identified several further genes regulated by myostatin during the 
induction of skeletal muscle wasting.  Importantly, increased levels of Myostatin 
resulted in the enhanced expression of genes encoding collagen and procollagen 
isoforms.  Recently it has been demonstrated that in myostatin-null mice skeletal 
muscle regeneration is enhanced, while scar tissue formation and collagen 
deposition are dramatically reduced in response to notexin-stimulated muscle 
injury (McCroskery et al. 2005).  Therefore, elevated levels of Myostatin may 
promote collagen formation during muscle wasting.  In support, unpublished 
results from our laboratory demonstrate that myostatin acts as a chemo-attractant 
for fibroblast cells, which are responsible for the production and deposition of 
collagen (Asakura et al. 2004). 
Myostatin-mediated myotube atrophy also resulted in the inhibition of the gene 
encoding lactate dehydrogenease A (LDH-A).  Conversely, increased mRNA 
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expression of glutamine synthetase (glns) was observed following Myostatin 
treatment (Table 6.1).  Interestingly, similar changes in the mRNA expression of 
LDH-A and glns are observed in several models of muscle wasting (Lecker et al. 
2004).  Lactate dehydrogenase-A catalyses the formation of pyruvate from lactate 
(Lehninger et al. 1993).  Therefore, inhibition of LDH-A may reduce the available 
pool of pyruvate for subsequent conversion into glucose or oxidation to acetyl-
CoA for energy production.  In skeletal muscle, glutamine is formed from 
glutamate and ammonia through the action of glutamine synthetase (Lehninger et 
al. 1993).  During skeletal muscle wasting conditions including cachexia and 
sepsis, glutamine is exported from muscle and taken up by organs such as the 
liver (Karinch et al. 2001; Argiles et al. 2006).  Glutamine influx to the liver 
appears to assist in Acute-Phase Protein (APP) synthesis and gluconeogenesis 
(Argiles et al. 2006).   
Metallothionein-1 and -2 were down-regulated during myostatin-mediated 
myotube atrophy (Table 6.1).  Metallothionein proteins are induced in response to 
conditions such as oxidative stress, and can function to protect cells from the 
effects of Reactive Oxygen Species (ROS) (Nath and Norby 2000).  ROS have 
been associated with increased skeletal muscle protein degradation; indeed, ROS-
mediated modification targets muscle proteins for rapid removal during burn-
injury associated muscle proteolysis (Fagan et al. 1999).  Therefore Myostatin 
treatment may result in enhanced susceptibility to oxidative stress and increased 
ROS-mediated protein modification.  Interestingly, the stress-induced protein 
SIP18, was up-regulated during myostatin-induced muscle wasting.  As the name 
suggests, SIP18 is induced in response to various conditions of stress, including 
UV exposure, heat shock and oxidative stress (Tomasini et al. 2001).  Over-
expression of SIP18 has been shown to promote cellular apoptosis in vitro 
(Tomasini et al. 2001); therefore myostatin-mediated myotube atrophy may also 
be associated with an increase in the level of apoptosis. 
Matrix metalloproteinases-2 and -23 (MMP-2 and MMP-23) were also up-
regulated during myostatin-mediated myotube atrophy, while the expression of 
Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) was dramatically down-
regulated following treatment with Myostatin (Table 6.1).  MMPs are zinc-
dependent proteolytic enzymes which are responsible for degrading several 
components of the extracellular matrix (ECM) (Carmeli et al. 2004).  
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Furthermore, MMPs have been shown to play a role in skeletal muscle 
remodelling in response to muscle wasting.  Certainly, increased MMP activity is 
detected in skeletal muscle tissue following prolonged periods of hindlimb 
unloading, as a result of congestive heart failure, and in response to nerve crush 
induced muscle denervation (Reznick et al. 2003; Demestre et al. 2005; Schiotz 
Thorud et al. 2005).  Therefore myostatin-mediated up-regulation of MMP 
expression may promote degradation of the extracellular matrix, thus supporting 
the formation of the myostatin atrophic phenotype as previously described (Figure 
5.1).   
The expression of Lipin-1 was shown to be up-regulated during myostatin-
mediated myotube atrophy (Table 6.1).  Indeed, Lipin-1 has been previously 
shown to be up-regulated in muscle atrophy associated with diabetes, starvation, 
uraemia and tumour growth (Lecker et al. 2004).  Lipin-1 is required for the 
induction of adipocyte differentiation (Phan et al. 2005).  Furthermore, muscle 
specific over-expression of Lipin-1 results in increased adipose tissue content 
coupled with insulin resistance and obesity (Phan and Reue 2005)  Interestingly, 
over-expression of myostatin has previously been shown to result in adipocyte 
conversion, while lack of myostatin results in decreased adipose tissue formation 
(McPherron and Lee 2002; Artaza et al. 2005; Feldman et al. 2006). In addition, 
Mcpherron and Lee demonstrated that crossing myostatin-null mice with the 
Agouti Lethal Yellow mouse model of obesity and diabetes, reduced the levels of 
fed glucose and insulin to normal (McPherron and Lee 2002).  Therefore 
myostatin-mediated up-regulation of Lipin-1 may induce adipocyte formation 
resulting in alterations in glucose homeostasis. 
These data outlined in this Chapter identify the putative zinc finger binding 
transcription factor, CXXC5, as a novel downstream target of myostatin during 
the progression of myotube atrophy.  CXXC5, like Idax (CXXC4), has previously 
been linked with inhibition of Wnt signalling (Kim et al. 2005).  In addition, 
CXXC5 was identified as a positive regulator of the NF-κB signalling cascade, 
through a large-scale screening process (Matsuda et al. 2003).  However, little is 
known about the function of CXXC5, therefore this research endeavoured to 
characterise the role of CXXC5 in skeletal muscle.  Initial studies were performed 
using the well characterised C2C12 mouse myoblast cell line through the 
generation of a set of clonally selected cell lines over-expressing CXXC5.  One of 
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the defining features of the CXXC5 over-expressing clones was the observed 
gradual myotube collapse and subsequent development of the myosac phenotype 
(Figure 6.3A, Figure 6.5 and Figure 6.6).  The myosac phenotype has been 
previously described and is associated with disintegration of cytoplasmic 
microtubule structure (Bischoff 1968; Saitoh et al. 1988).  Consistent with this 
previous data, between 72 hr and 96 hr differentiation the Tubulin microtubule 
structure is dramatically altered in the CXXC5 clones, whereby the typical 
parallel microtubule structure is degraded resulting in generalised myotube 
collapse and myosac formation (Figure 6.15 and Figure 6.16).  Thus over-
expression of MM1 may induce microtubule de-polymerisation, resulting in 
reduced myotube structural integrity and subsequent myotube collapse.  Indeed 
one of the critical functions of microtubules is to provide strength and rigidity to 
cells (Martini 2001).   
The mode of action of CXXC5 in regulating microtubule structure remains 
undefined, however, CXXC5, as a putative transcription factor, could signal to 
downstream effectors which may then regulate microtubule structure.  Indeed, 
several factors have been shown to result in microtubule destabilisation and 
depolymerisation.  The AAA ATPases, katanin and spastin, appear to destabilise 
microtubule structure by severing microtubules (Quarmby 2000; Evans et al. 
2005).  Furthermore, the kinesins XKCM1 and MCAK also result in microtubule 
depolymerisation (Walczak et al. 1996; Helenius et al. 2006).  In addition, over-
expression of a novel Tubulin-destabilising protein, termed E-like protein (El), 
results in microtubule depolymerisation and targeted degradation of Tubulin 
through the ubiquitin-proteasome pathway (Bartolini et al. 2005).  Therefore the 
ubiquitin-proteasome pathway may play a role in CXXC5-mediated microtubule 
disruption.  In fact, over-expression of CXXC5 resulted in the up-regulation of 
components of the ubiquitin-proteasome pathway.  The well-characterised E3 
ligase atrogin-1, the ubiquitin-conjugating enzymes E214k and E220k and the 
proteasome sub-unit RC2 were all up-regulated in response to over-expression of 
CXXC5 (Figure 6.9).  Furthermore, a dramatic increase in the levels of 
ubiquitinated proteins was observed following over-expression of CXXC5 (Figure 
6.11).  Therefore, CXXC5 over-expression may induce skeletal muscle 
proteolysis and microtubule depolymerisation through mediation of the ATP-
dependent ubiquitin-proteasome pathway.   
 274
Over-expression of CXXC5 appeared to affect the normal progression of 
myogenesis in the C2C12 myoblast cell line.  Over-expression of CXXC5 reduced 
the growth rate of the C2C12 cell lines, without inducing cellular apoptosis 
(Figure 6.2B and Figure 6.14).  While the reduction in growth rate was 
statistically significant, the differences between CXXC5 clones and C2C12 
control were not dramatic and thus may not be physiologically significant (Figure 
6.2B).  Microtubules play an important role in cell division and form the spindle 
apparatus during mitosis (Martini 2001), thus it is interesting to surmise that 
CXXC5-mediated microtubule depolymerisation may result in disruption of 
normal cell cycle progression.  In support, treatment of cells with a low dose of 
the microtubule-stabilising chemical taxol results in mitotic delay (Ikui et al. 
2005).  However, taxol-mediated cell cycle delay, unlike CXXC5, eventually 
induces cellular apoptosis (Ikui et al. 2005).  Over-expression of CXXC5 resulted 
in a significant reduction in myotube number as compared to the control C2C12 
cell line at all timepoints analysed (Figure 6.3B).  However, expression of the 
myogenic genes MyoD and myogenin as well as the cell cycle regulator p21, 
appeared to follow a similar expression pattern to that observed in the control 
C2C12 cell line (Figure 6.7 and Figure 6.8).  Therefore, it is unlikely that the 
dramatic reduction in myotube number observed in the CXXC5 over-expressing 
clones was due to insufficiencies in the expression of key regulators of myogenic 
differentiation; in fact, a characteristic feature of the CXXC5 clones was the up-
regulation of MyoD, myogenin and p21, to levels greater than those observed in 
the control C2C12 cell line during differentiation (Figure 6.7 and Figure 6.8).  The 
enhanced up-regulation of MyoD and myogenin may be a compensatory 
mechanism, to counteract the CXXC5-mediated myotube wasting and protein 
degradation during differentiation.  During denervation-induced muscle atrophy, 
the levels of MyoD and myogenin are rapidly up-regulated (Hyatt et al. 2003; 
Raffaello et al. 2006).  This mechanism may involve activation of the C2C12 
quiescent reserve cell pool, which are cells analogous to quiescent satellite cells, 
and are able to activate, proliferate and differentiate to form new myotubes 
(Kitzmann et al. 1998; Yoshida et al. 1998).  Indeed, MyoD expression is 
detected during myoblast growth and initiates differentiation, whereas myogenin 
is expressed during early stages of myotube formation to execute the 
differentiation program (Guo et al. 1995; Halevy et al. 1995; Megeney and 
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Rudnicki 1995).  Further support for this proposed mechanism is the sparse nature 
of the differentiated CXXC5 clone cultures (Figure 6.3A), presumably due to an 
enhanced contribution of the reserve cell pool to myogenesis. 
Due to the dramatic effect of CXXC5 on C2C12 myotube morphology and gene 
expression, CXXC5 has tentatively been renamed to “Menos músculo 1” (MM1), 
simply meaning “less muscle”.  As outlined in Chapter 5, myostatin appears to 
regulate protein degradation through a decrease in the activity of AKT, resulting 
in enhanced FoxO1 activity and subsequent up-regulation of components of the 
ubiquitin-proteasome pathway.  Results in this Chapter indicate that MM1 may 
play a role in myostatin-mediated myotube atrophy.  In support, over-expression 
of MM1 results in enhanced FoxO1 expression as well as increased FoxO1 
activation (Figure 6.12 and Figure 6.13).  Therefore myostatin may signal through 
MM1 to regulate FoxO1 expression and activity, resulting in an increase in the 
expression of Atrogin-1 and enhanced ubiquitin-mediated proteolysis.  An 
adapted model for the tentative involvement of MM1 in myostatin-mediated 
muscle wasting is shown in Figure 6.17.  However, it is noteworthy to mention 
that treatment of C2C12 myotubes with recombinant Myostatin protein does not 
induce the formation of the myosac phenotype (see Figure 5.1).  Therefore, it is 
plausible that Myostatin treatment failed to up-regulate MM1 expression to levels 
comparable to those detected in the over-expressing clones; or more importantly, 
MM1 may trigger responses independent of myostatin stimulation to promote 
protein degradation and myotube collapse (Figure 6.17).  Nevertheless, MM1 
over-expression has yielded some exciting results and warrants further 
investigation.  
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Figure 6.17  Proposed model of MM1 (CXXC5) function during muscle wasting 
Myostatin appears to up-regulate the ubiquitin-proteolysis system by hypo-
phosphorylating FoxO1 through the inhibition of the PI3-K/AKT signalling 
pathway.  Results presented in this Chapter identify a role for MM1 in enhancing 
FoxO1 activity and promoting the expression of downstream target atrophy-
related genes.  MM1 may therefore be a downstream mediator of myostatin-
induced skeletal muscle wasting.  In addition to myostatin, currently 
undetermined signals may also promote MM1 expression and subsequent protein 
degradation.  Broken lines represent nuclear translocation.  Arrows represent 
activation while blunt-ended lines represent inhibition. 
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Chapter 7  Final discussion 
 
The majority of research undertaken in the Functional Muscle Genomics 
Laboratory, AgResearch, Hamilton, New Zealand has been focussed on 
understanding myostatin function during the progression of embryonic and foetal 
myogenesis.  However, recent publications from our laboratory and others have 
highlighted a role for myostatin in the regulation of post-natal myogenesis.  
Specifically, in myostatin-null mice there is increased satellite cell activation and 
self-renewal as well as enhanced skeletal muscle regeneration in response to 
injury (McCroskery et al. 2003; McCroskery et al. 2005).  Conversely, increased 
levels of myostatin are associated with numerous skeletal muscle wasting 
conditions (Gonzalez-Cadavid et al. 1998; Reardon et al. 2001; Schulte and 
Yarasheski 2001; Ma et al. 2003) and exogenous over-expression of Myostatin 
has been shown to promote the progression of the cachexia syndrome (Zimmers et 
al. 2002).  While evidence suggests a role for myostatin in skeletal muscle 
wasting, little is known about the mechanism of action for myostatin in this 
process of muscle degeneration.  Thus the overall aim of this thesis is to further 
clarify the role of myostatin in post-natal skeletal muscle growth and repair and 
delineate mechanisms through which myostatin acts to regulate skeletal muscle 
wasting.   
The major site of synthesis for myostatin is skeletal muscle, with expression of 
myostatin detected in satellite cell, myoblast and myotube populations.  The 
presence of myostatin in satellite cells may form the basis of an autocrine 
signalling mechanism, through which myostatin negatively regulates the 
activation of satellite cells.  However, the paracrine and/or endocrine mode of 
action for myostatin cannot be ruled out, given that subcutaneous injection of 
Myostatin results in muscle wasting.  Thus further work needs to be performed to 
clarify this mechanism.   
Like other members of the TGF-β superfamily, myostatin is synthesised, 
proteolytically processed and secreted into circulation as a latent complex to elicit 
biological responses (Lee and McPherron 2001).  Thus myostatin acts as a 
circulatory factor in an endocrine or perhaps paracrine manner to regulate 
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downstream targets.  The rate-limiting step in the activation of myostatin appears 
to be the proteolytic processing or cleaving of the full length Myostatin peptide 
into LAP and mature Myostatin portions.  Myostatin processing was thus 
examined, and interestingly the level of Myostatin processing appears to be 
developmentally regulated, with reduced processing observed during foetal stages 
of growth.  In addition, I have characterised a mechanism through which 
myostatin negatively auto-regulates its own processing through targeted down-
regulation of the proprotein convertase furin.  This level of regulation may 
provide a mechanism through which myostatin is effectively removed, thus 
allowing for successive rounds of primary and secondary myogenesis to occur 
during foetal growth.  Future work will be performed creating dominant-negative 
furin cell lines; wherein myostatin expression and processing will be assessed, 
thus allowing us to confirm the requirement of furin in the regulation of myostatin 
activity.  In addition, techniques designed to target and inactivate furin may be 
useful as possible therapies to counteract myostatin-induced skeletal muscle 
atrophy.  However myostatin is not the only target of furin, in fact, furin is 
responsible for processing other members of the TGF-β superfamily including 
TGF-β1 and BMP-4 (Cui et al. 1998; Dubois et al. 2001).  Furthermore, furin-null 
mice are lethal around embryonic day 10.5 (Zhou et al. 1999), therefore total 
inactivation of furin as a means to disrupt myostatin function is not a viable 
approach.  Perhaps an approach to impart furin inhibitors in a muscle specific 
manner, during post-natal muscle repair, may become a viable option for 
inactivating myostatin. 
Skeletal muscle stem cells, or satellite cells, form a distinct population of 
myogenic precursor cells responsible for post-natal skeletal muscle growth and 
repair (Seale and Rudnicki 2000).  Myostatin has been implicated in the 
regulation of satellite cell activation, proliferation and self-renewal.  Indeed, 
McCroskery et al. demonstrated that in the absence of myostatin, satellite cell 
number is significantly increased; moreover it was shown that satellite cells 
isolated from myostatin-null mice are more active and have an enhanced rate of 
proliferation (McCroskery et al. 2003).  The significantly increased satellite cell 
number in myostatin-null mice may arise through enhanced satellite cell self-
renewal, increased specification of somitic precursor cells or enhanced 
contribution of non-muscle derived cells to the satellite cell pool.  Firstly, satellite 
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cell self-renewal may provide a means through which satellite cell number is 
enhanced in myostatin-null mice.  In this thesis I have addressed the role of 
myostatin in satellite cell self-renewal.  Specifically, I have identified a 
mechanism behind myostatin-mediated inhibition of satellite cell self-renewal, 
whereby myostatin regulates the pool of self-renewed satellite cells through 
inhibition of Pax7.  A mechanism involving regulation of Pax7 is consistent with 
current evidence supporting a role for Pax7 in satellite cell self-renewal (Olguin 
and Olwin 2004; Zammit et al. 2004).  However, further work will be performed 
to characterise the signalling mechanism behind myostatin regulation of Pax7 
during satellite cell self-renewal.  Candidate pathways that will be studied are the 
Smad signalling pathway, which is the typical signalling pathway of TGF-β 
superfamily members.  Furthermore, the p38 MAPK signalling pathway, which 
has been shown to play a role in myostatin-mediated inhibition of cell 
proliferation will be studied (Philip et al. 2005).  In addition the notch signalling 
cascade will be analysed, indeed the notch signalling cascade has previously been 
identified as playing a role in satellite cell fate determination and self-renewal 
(Conboy and Rando 2002).  Future studies will also be performed based on the 
elegant experiments of Collins et al. (Collins et al. 2005), specifically transgenic 
mice will be generated by crossing myostatin-null (mstn-/-) mice with Myf5nLacZ/+ 
mice, wherein β-gal activity represents Myf5 expression in both satellite cell 
nuclei and newly formed muscle fibres.  Single muscle fibres will be isolated from 
the mstn-/-/ Myf5nLacZ/+ mice and injected into injured immune-deficient nude 
mice, with the resulting β-gal+ (blue) cells identified and quantified.  Satellite cell 
self-renewal will be assessed through quantification of the β-gal+/Pax7+ cells that 
progressively associate with the satellite cell niche beneath the basal lamina.  The 
effect of myostatin on satellite cell self-renewal will be analysed through 
quantification of β-gal+/Pax7+ satellite cells in mice injected with mstn-/-/ 
Myf5nLacZ/+ fibres compared with mice injected with Myf5nLacZ/+ fibres.   
The widely accepted theory is that satellite cells are derived from myogenic 
precursor cells in the somite.  Indeed, recently identified populations of 
Pax7+/Pax3+ cells present in the somite have been shown to give rise to adult 
skeletal muscle satellite cells (Kassar-Duchossoy et al. 2005; Relaix et al. 2005; 
Schienda et al. 2006).  Therefore, these populations of Pax7+/Pax3+ cells will be 
assessed by immunofluorescence and quantified to determine if the increased 
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satellite cell number detected in myostatin-null mice is due to enhanced 
specification of myogenic precursor cells during embryonic myogenesis.   
Lastly, cells derived from other sources such as bone marrow may contribute to 
the increased satellite cell pool present in myostatin-null mice.  To determine the 
contribution of non-muscle-derived cells, myostatin-null mice will be subjected to 
injury and injected with GFP-expressing bone marrow-derived cells from the 
B6TgGFP transgenic mouse line.  This experiment is based on the published paper 
of Dreyfus et al. (Dreyfus et al. 2004).  The pool of GFP-labelled, Pax7-positive 
(GFP+/Pax7+) cells aligning to the satellite cell niche will be quantified to 
determine the contribution of non-muscle satellite cell sources to the enhanced 
satellite cell number observed in the myostatin-null transgenic mouse line.  The 
populations of GFP+/Pax7+ cells will be analysed in both myostatin-null and wild-
type mice injected with GFP-labelled, bone marrow-derived cells.   
The role of myostatin as a growth factor which negatively regulates skeletal 
muscle growth is now well established.  However, questions remain as to whether 
or not myostatin acts as a cachexia-inducing factor which functions in the 
regulation of skeletal muscle wasting.  Enhanced myostatin expression is 
associated with many forms of skeletal muscle wasting including disuse atrophy, 
sarcopenia, AIDS and glucocorticoid-induced muscle wasting (Gonzalez-Cadavid 
et al. 1998; Reardon et al. 2001; Yarasheski et al. 2002; Ma et al. 2003).  
Moreover, exogenous addition of Myostatin has been shown to induce severe 
muscle wasting consistent with the phenotype observed during cachexia (Zimmers 
et al. 2002).  Although research has been performed studying the role of 
myostatin in various other muscle wasting conditions, and despite the severity of 
cancer-related muscle loss, evidence for the role of myostatin in cancer-cachexia 
is currently lacking.  Therefore future studies will be performed, whereby the 
levels of circulating and thus potentially active myostatin will be assessed in 
human patients suffering from various forms of cancers.  This data would 
highlight whether or not myostatin expression correlates with cancer-related 
muscle loss.  In addition, myostatin-null mice will be tested for resistance to 
cancer-associated cachexia through injection of colon-26 adenocarcinoma and 
Lewis lung carcinoma cells.  These model systems of tumour associated muscle 
wasting will be used to assess the efficacy of myostatin disruption in reducing the 
severity of cancer-associated cachexia.  As outlined in this thesis, myostatin 
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appears to induce skeletal muscle degradation though regulation of the ubiquitin-
proteasome pathway.  In fact, in vitro and in vivo models of myostatin-induced 
cachexia have highlighted the ability of myostatin to antagonise IGF-1/PI3-
K/AKT hypertrophy signalling, resulting in enhanced FoxO1 transcriptional 
activity and subsequent up-regulation of ubiquitin-related genes including the 
widely studied E3 ligase Atrogin-1.  However, further work needs to be 
performed to confirm myostatin regulation of ubiquitin-proteasome mediated 
protein degradation.  Thus atrogin-1-null (atrogin-1-/-) transgenic mice will be 
obtained (Bodine et al. 2001) and tested for resistance to myostatin-mediated 
muscle wasting through injection of Myostatin-expressing CHO cells (see Section 
5.2.3).  Furthermore, primary myoblast cultures will be isolated from atrogin-1-/- 
mice and treated with recombinant Myostatin protein.  These experiments will 
allow us to test whether Atrogin-1 is mandatorily required for the progression of 
myostatin-mediated muscle wasting.  Interestingly, myostatin has recently been 
shown to be a downstream target of FoxO1 (Allen and Unterman 2006).  In 
particular, over-expression of FoxO1 was shown to up-regulate the mRNA 
expression of myostatin as well as enhance myostatin promoter activity (Allen and 
Unterman 2006).  It is thus interesting to surmise that FoxO1-mediated up-
regulation of myostatin may enhance the process of skeletal muscle wasting.  
Alternatively, myostatin has been shown to negatively auto-regulate its expression 
through the action of Smad7.  Therefore FoxO1 up-regulation of myostatin may 
be a mechanism through which myostatin negatively auto-regulates its own 
expression during muscle wasting, however, further work will need to be 
performed to ascertain the validity of this mechanism.  The recent study by Allen 
and Unterman employed in vitro techniques to identify myostatin as a 
downstream target of FoxO1 (Allen and Unterman 2006).  To expand on this 
research I will undertake a set of experiments characterising this mechanism in 
vivo, by obtaining FoxO1 over-expressing transgenic mice (Kamei et al. 2004).  
Furthermore, FoxO1 over-expressing mice will be crossed with myostatin-null 
mice.  The resulting double mutant will be tested for resistance to skeletal muscle 
wasting enabling clarification of the role of FoxO1-mediated up-regulation of 
myostatin during muscle wasting conditions.   
The evidence to date associates increased myostatin expression with many forms 
skeletal muscle atrophy.  Furthermore, the candidate gene approach utilised in this 
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thesis has highlighted a possible mechanism through which myostatin signals 
muscle atrophy, however, more comprehensive approaches should be undertaken 
to enhance our understanding of myostatin as a cachexia-inducing factor.  To that 
end I employed a microarray approach to analyse the global gene expression 
changes that occurred in a model of myostatin-mediated cachexia.  Microarray 
analysis identified that expression of the gene CXXC5 (MM1) was significantly 
up-regulated during myostatin-mediated myotube atrophy.  MM1 was 
subsequently characterised as a muscle wasting-inducing gene through a series of 
in vitro experiments.  Specifically, MM1 was shown to up-regulate components of 
the ubiquitin-proteasome pathway.  Moreover, MM1 over-expression resulted in 
the progressive collapse of the myotube population during differentiation, 
resulting in the formation of multinucleated myosacs.  However, the data 
presented in this thesis focuses on characterising the function of MM1 in vitro, 
thus future work will be performed to clarify the role of this gene during muscle 
wasting in vivo.  As such, muscle-specific MM1 over-expressing transgenic mice 
are currently being generated.  In addition, muscle specific MM1 knockout 
transgenic mice will be generated.  The MM1 knockout mice (MM1-/-) will prove 
useful in analysing the role of MM1 in myostatin-mediated muscle wasting.  
Indeed treatment of MM1-/- mice with Myostatin-expressing CHO cells will allow 
us to confirm the link between myostatin, MM1, Atrogin-1 and subsequent 
protein degradation.   
In conclusion, I believe that myostatin is a cachexia-inducing factor which is 
capable of signalling through established systems to regulate ubiquitin-mediated 
protein degradation.  With this in mind, methods should be employed to target and 
potentially inactivate myostatin, especially in patients suffering from muscle 
wasting diseases.  If successful, these gene-based therapies may ameliorate the 
severe symptoms associated with devastating diseases such as cancer and AIDS, 
and may improve the quality and longevity of life in these patients. 
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